Document:

EX-4.2

 Exhibit 4.2 

CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 24b-2 UNDER THE EXCHANGE ACT OF 1934, AS AMENDED. [*****] INDICATES OMITTED MATERIAL THAT IS THE
SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION 

AMENDED AND RESTATED LICENSE AGREEMENT 

BETWEEN 
 THE BRITISH
COLUMBIA CANCER AGENCY BRANCH 
 AND 

THE UNIVERSITY OF BRITISH COLUMBIA 

AND 
 ESSA PHARMA INC.

 TABLE OF CONTENTS 

 

							
	 1.0
		 DEFINITIONS
		 	2	  
	 2.0
		 PROPERTY RIGHTS IN AND TO THE TECHNOLOGY
		 	6	  
	 3.0
		 GRANT OF LICENSE
		 	7	  
	 4.0
		 SUBLICENSING
		 	10	  
	 5.0
		 ROYALTIES AND MILESTONE PAYMENTS
		 	11	  
	 6.0
		 ANNUAL PAYMENTS AND EQUITY
		 	13	  
	 7.0
		 PATENTS
		 	14	  
	 8.0
		 DISCLAIMER OF WARRANTY
		 	16	  
	 9.0
		 INDEMNITY AND LIMITATION OF LIABILITY
		 	18	  
	 10.0
		 PUBLICATION AND CONFIDENTIALITY
		 	18	  
	 11.0
		 PRODUCTION AND MARKETING
		 	21	  
	 12.0
		 ACCOUNTING RECORDS AND REPORTS
		 	23	  
	 13.0
		 INSURANCE
		 	24	  
	 14.0
		 ASSIGNMENT
		 	25	  
	 15.0
		 GOVERNING LAW
		 	25	  
	 16.0
		 NOTICES
		 	25	  
	 17.0
		 TERM
		 	26	  
	 18.0
		 TERMINATION OF AGREEMENT
		 	26	  
	 19.0
		 MISCELLANEOUS COVENANTS OF THE LICENSEE
		 	29	  
	 20.0
		 GENERAL
		 	30	  

  

					
	SCHEDULES:		
			
	 Schedule “A”
		-		Description of “Technology”
	 Schedule “B”
		-		Payment Report
	 Schedule “C”
		-		BCCA License Agreement Annual Report
	 Schedule “D”
		-		Address for Notices and Payment Instructions
	 Schedule “E”
		-		Confidential Information
	 Schedule “F”
		-		Restrictions on Transfer and Drag-Along/Tag-Along Rights
	 Schedule “G”
		-		New Licensee Shareholders
	 Schedule “H”
		-		Material Transfer Agreement between UBC and University of Washington dated November 16, 2010
	 Schedule “I”
		-		Patent Client and Billing Agreement

  

  
 i 

 AMENDED AND RESTATED LICENSE AGREEMENT 

BETWEEN: 
 THE BRITISH
COLUMBIA CANCER AGENCY BRANCH, a branch society of the Provincial Health Services Authority amalgamated under the Society Act (British Columbia), having an office at Suite 600, West 10th Avenue, Vancouver, British Columbia,
Canada, V5Z 4E6 
 (“BCCA”) 

AND: 
 THE UNIVERSITY
OF BRITISH COLUMBIA, a corporation continued under the University Act (British Columbia), having its registered office at 103 – 6190 Agronomy Road, Vancouver, British Columbia, V6T 1Z3 

(“UBC”, and together with BCCA, the “Licensor”) 

AND: 
 ESSA PHARMA
INC., a corporation incorporated under the laws of the Province of British Columbia, having its registered office at 1500 – 1040 West Georgia Street, Vancouver, British Columbia, V6E 4H8 

(the “Licensee”) 

WHEREAS: 
 A. The Licensor has been engaged in
research during the course of which it has invented, developed and/or acquired certain technology relating to compounds that modulate androgen receptor activity, which research was undertaken by Marianne Sadar, Raymond Andersen, NR Mawji, Jun
(Jean) Wang, David Williams, Mike LeBlanc, Lu-Ping Yan, Carmen Banuelos, Javier Garcia Fernandez, Hsing Chen (Amy) Tien, Yusuke Imamura and Jian Kunzhong; 

B. It is the objective of each of BCCA and UBC to exploit their technology for the public benefit, and to generate further research in a
manner consistent with their respective status as a non-profit, tax exempt: educational with respect to UBC, and research and clinical: with respect to BCCA, institution; and 

C. The Licensor and the Licensee entered into a License Agreement dated December 22, 2010, (BCCA AGR#11-411), as amended by an
Amendment to License Agreement dated February 10, 2011 (collectively, the “Prior Agreement”); 
 D. The Parties
have agreed to amend and restate their relationship set forth in the Prior Agreement effective as of the Amendment Date (except as set out herein) as more fully set forth in this license agreement granting the Licensee the exclusive worldwide right
to use or cause to be used such technology to manufacture, distribute, market, sell and/or license or sublicense products derived or developed from such technology and to sell the same to the general public on the terms and conditions set out in
this Agreement. 

 NOW THEREFORE THIS AGREEMENT WITNESSETH that in consideration of the premises and the mutual
covenants and agreements herein set forth, the parties hereto have covenanted and agreed as follows: 
  

	1.0	 DEFINITIONS 

1.1 In this Agreement: 
  

	 	(a)	 “$” means Canadian dollars. 

  

	 	(b)	 “Affiliated Company” or “Affiliated Companies” means two or more corporations where the relationship between them
is one in which one of them is a subsidiary of the other, or both are subsidiaries of the same corporation, or 50% or more of the voting shares of each of them is owned or controlled by the same person, corporation or other legal entity;

  

	 	(c)	 “Agreement” means this License Agreement and any appendixes and schedules attached hereto, as the same may be amended or
supplemented from time to time; 

  

	 	(d)	 “Amendment Date” means May [•], 2014; 

 

	 	(e)	 “BADGE Patents” means collectively: 

  

	 	(i)	 the patents and patent applications listed in Schedule “A - BADGE” hereto, and any foreign counterparts thereof;

  

	 	(ii)	 any and all other patents and patent applications filed after the Start Date that, when filed, claim or cover any invention within the definition
of “Improvements” set out in this Section 1.1 that relate directly to the molecular structures described in the Patents listed in Schedule “A - BADGE” hereto; and 

 

	 	(iii)	 any related patent applications, issued patents, provisionals, non-provisionals, divisionals,
continuations, continuations-in-part, reissues, re-examinations, substitutions, extensions, term restorations, renewals, and any foreign counterparts applied for or issued therefrom; 

 

	 	(f)	 “Confidential Information” means all information, regardless of its form designated by the Licensee or the Licensor as
confidential, whether orally (as long as identified in writing as confidential or proprietary within 30 days from the time of disclosure) or in writing, including without limitation all information related to the Technology (including all
derived analyses and conclusions) and the terms and conditions of this Agreement, except that “Confidential Information” does not include information: 

 

	 	(i)	 possessed by the recipient (in this Section 1.1(f), the “Recipient”) prior to receipt from the disclosing party (in this
Section 1.1(f), the “Discloser”), other than through prior disclosure by the Discloser, as evidenced by the Recipient’s business records; 

  
  2 

	 	(ii)	 published or available to the general public otherwise than through a breach of this Agreement; 

 

	 	(iii)	 obtained by the Recipient from a Third Party with a valid right to disclose it, provided that the Third Party is not under a confidentiality
obligation to the Discloser; or 

  

	 	(iv)	 independently developed by employees, agents or consultants of the Recipient who had no knowledge of or access to the Discloser’s information
as evidenced by the Recipient’s business records; 

  

	 	(g)	 “Cost-Based Price” shall mean all out-of-pocket expenses and/or costs incurred directly in connection with the manufacturing of a
Product, and the subsequent distribution of a Product to a central warehouse in PNG or IND, plus a 65% overhead charge and a 25% return on capital charge. The Cost-Based Price of a Product shall be calculated according to the following formula:
Cost-Based Price = A + (A 0.65) + (A 0.25), where A is the total of all out-of-pocket expenses and/or costs incurred directly in connection with the manufacturing of the Product and the subsequent distribution of the Product
to a central warehouse in PNG or IND, (A x 0.65) represents overhead, and (A x 0.25) represents return on capital; 

  

	 	(h)	 “Direct Costs” means all costs that have been incurred by Licensee directly in connection with the manufacturing of Products;

  

	 	(i)	 “Dispute” has the meaning ascribed thereto in Section 11.4; 

 

	 	(j)	 “Effective Termination Date” means the date on which this Agreement is terminated pursuant to Section 11.0 or 18.0;

  

	 	(k)	 “Gross Revenue” means all revenues, receipts, money, and the fair market value of any shares, securities or other consideration,
other than Sublicensing Revenue, directly or indirectly collected or received, whether by way of cash, credit or other value, by the Licensee from the marketing, manufacturing, sale or distribution of the Technology, any Improvements and/or any
Products; 

  

	 	(l)	 “Improvements” means collectively the Licensor Improvements and the Licensee Improvements; 

 

	 	(m)	 “IND” means the Republic of Indonesia; 

  

	 	(n)	 “IND Agency” has the meaning ascribed thereto in Section 3.4(a); 

 

	 	(o)	 “Interested Party” has the meaning ascribed thereto in Section 10.1; 

 

	 	(p)	 “Licensee Improvements” means improvements, variations, updates, modifications and enhancements made or acquired at any time after
the Start Date by the Licensee that relate directly to the molecular structures described in the Patents listed in Schedule “A” hereto; 

  
  3 

	 	(q)	 “Licensor Improvements” means the interests of both UBC and BCCA in improvements, variations, updates, modifications and
enhancements made or acquired at any time after the Start Date by: 

  

	 	(i)	 Marianne Sadar and/or Raymond Andersen, in the course of their employment by either BCCA or UBC, and faculty members, employees or graduate
students of the Licensor that are under their supervision in their respective laboratories at BCCA or UBC (such persons, together with Marianne Sadar and Raymond Andersen, referred to as “Sadar/Andersen Research Group Members”); or

  

	 	(ii)	 jointly by Marianne Sadar and/or Raymond Andersen and any person (including any Third Party(ies)) who is not a Sadar/Andersen Research Group
Member, subject to Section 2.3); or 

  

	 	(iii)	 made by a Sadar/Andersen Research Group Member, including those which do not name Marianne Sadar or Raymond Andersen as an inventor; or

  

	 	(iv)	 a Sadar/Andersen Research Group Member at UBC, BCCA or both of them and the Licensee jointly; or 

 

	 	(v)	 a Sadar/Andersen Research Group Member at UBC, BCCA or both of them pursuant to a written and executed joint development agreement with the
Licensee regarding the subject matter of this Agreement which, among other things, defines the joint development and the responsibilities of each of the Licensor and the Licensee; 

that relate directly to the molecular structures described in the Patents listed in Schedule “A” hereto.

  

	 	(r)	 “Licensor Trade-Marks” means any mark, trade-mark, service mark, logo, insignia, seal, design, symbol or device owned or licensed
by either of the parties comprising the Licensor in any manner at all; 

  

	 	(s)	 “Licensor’s Shares” has the meaning ascribed thereto in Section 6.4; 

 

	 	(t)	 “Manuscript” has the meaning ascribed thereto in Section 10.4; 

 

	 	(u)	 “Mediator” has the meaning ascribed thereto in Section 11.5; 

 

	 	(v)	 “MTA” means the Material Transfer Agreement between UBC and University of Washington dated November 16, 2010, a copy of which
is attached hereto as Schedule “H”; 

  

	 	(w)	 “Net Revenue” means Gross Revenue less applicable sales, transfer, excise import, export and other taxes (including any tax such
as value added or similar tax or government charge); 

  

	 	(x)	 “New Licensee Shareholder” has the meaning ascribed thereto in Section 6.4; 

 

	 	(y)	 “Objectionable Material” has the meaning ascribed thereto in Section 10.5; 

  
 4 

	 	(z)	 “Other Patents” means collectively: 

  

	 	(i)	 the patents and patent applications listed in Schedule “A - Other” hereto, and any foreign counterparts thereof;

  

	 	(ii)	 any and all other patents and patent applications filed after the Start Date that, when filed, claim or cover any invention within the definition
of “Improvements” set out in this Section 1.1 that relate directly to the molecular structures described in the Patents listed in Schedule “A - Other” hereto; and 

 

	 	(iii)	 any related patent applications, issued patents, provisionals, non-provisionals, divisionals,
continuations, continuations-in-part, reissues, re-examinations, substitutions, extensions, term restorations, renewals, and any foreign counterparts applied for or issued therefrom; 

 

	 	(aa)	 “Parties” means the Licensor and the Licensee; 

 

	 	(bb)	 “Patents” means collectively the BADGE Patents and the Other Patents; 

 

	 	(cc)	 “Payment Report” means a report in the form referred to in Section 12.0 setting out in detail how the amount of Net Revenue
and Sublicensing Revenue for the relevant period was determined; 

  

	 	(dd)	 “PNG” means Papua New Guinea; 

  

	 	(ee)	 “Product” or “Products” means BADGE Product(s) or Other Product(s); 

 

	 	(ff)	 “BADGE Product” means goods or services manufactured or provided in connection with the use of all or some of the BADGE Patents
and/or related Technology and/or any related Improvements; 

  

	 	(gg)	 “Other Product” means goods or services manufactured or provided in connection with the use of all or some of the Other Patents
and/or related Technology and/or any related Improvements; 

  

	 	(hh)	 “Royalties” has the meaning ascribed thereto in Section 5.1; 

 

	 	(ii)	 “Royalty Due Date” means the last day of each of March, June, September and December of each year during the Term;

  

	 	(jj)	 “Royalty Stream Recipient” has the meaning ascribed thereto in Section 14.2; 

 

	 	(kk)	 “Start Date” means December 22, 2010; 

 

	 	(ll)	 “Sublicensee” means any individual or entity, other than an Affiliated Company, who has obtained directly or indirectly from or
through the Licensee any rights to the Technology, any Improvements or any Products, and shall include all sub-sublicensees or other third parties that have entered into agreements with the Licensee for the
use, development, co-development, partnered development, manufacture, distribution, marketing or sale of Products. Notwithstanding the foregoing, a Third Party Contractor is not a Sublicensee for the purposes hereof; 

  
  5 

	 	(mm)	 “Sublicensing Revenue” means all initial or periodic revenues, receipts, royalties, option fees, license fees, development or
commercialization fees, milestone payments or other payments, directly or indirectly collected or received by the Licensee from a Sublicensee pursuant to any sublicense agreement, whether received in cash or other form, and which, for greater
certainty, will include the fair market value of any shares, securities and other consideration received by the Licensee in respect of the foregoing. For greater clarity, Sublicensing Revenue will include all research or development fees received by
the Licensee in connection with the Technology, any Improvements or any Products that are in excess of the direct reimbursement for the actual costs of such research and development; 

 

	 	(nn)	 “Technology” means the Patents and all knowledge, know-how and technique or techniques invented, developed and/or acquired by the
Licensor prior to the Start Date relating directly to, and including, the molecular structures described in the Patents listed in Schedule “A” hereto, including without limitation all research, data, test results, specifications,
instructions, manuals, papers or other related materials of any nature at all, whether written or otherwise, relating directly thereto; 

  

	 	(oo)	 “Term” has the meaning ascribed thereto in Section 17.1; 

 

	 	(pp)	 “Third Party” means any entity or person that is not a party to this Agreement; 

 

	 	(qq)	 “Third Party Contractor” has the meaning ascribed thereto in Section 3.1; 

 

	 	(rr)	 “Third Party Agreements” has the meaning ascribed thereto in Section 3.4(a). 

 

	 	(ss)	 “Third Party Licenses” has the meaning ascribed thereto in Section 5.2. 

 

	 	(tt)	 “UPNG” has the meaning ascribed thereto in Section 3.4(a). 

 

	 	(uu)	 “US Federal Government Interest” shall mean the rights of the United States Government under Public Laws 96-517 (the
Bayh–Dole Act), 97-256 and 98-620, codified at 35 U.S.C. 200-212, and any regulations issued thereunder, as statute or regulations may be amended from time to time hereafter. 

 

	2.0	 PROPERTY RIGHTS IN AND TO THE TECHNOLOGY 

2.1 As between the Parties, the Licensee acknowledges and agrees that the Licensor owns all right, title and interest in and to the Technology
and any Licensor Improvements. The Licensor acknowledges and agrees that the Licensee owns all right, title and interest in and to the Licensee Improvements. Notwithstanding the ownership of Licensee Improvements by Licensee, the obligations of
Licensee under Article 5.0, Article 12.0 and 18.9 with respect to Licensee Improvements shall survive any termination of this Agreement. The obligations of Licensee to pay a minimum annual royalty to the Licensor under Sections 6.1 to 6.3 inclusive
shall continue and survive any termination of this Agreement, during any period that that the Licensee continues to file, prosecute, maintain and defend any intellectual property relating to the Licensee Improvements, until the date of expiry of the
last patent relating to the Licensee Improvements. The Licensee may terminate its obligations under the preceding two sentences by assigning without consideration the intellectual property relating to the Licensee Improvements to the Licensor. 

  
  6 

 2.2 The Licensee will, at the reasonable request of the Licensor, sign all documents that may be
required to ensure that ownership of the Technology and any Improvements (other than the Licensee Improvements referred to in Section 2.1) remain with the Licensor. 

2.3 If the Licensor requires a Third Party consent to the grant of rights to a Licensor Improvement under this Agreement, the grant of rights
is made subject to such consent. The Licensee shall have the opportunity to obtain such consent, and the Licensor will cooperate with the Licensee for such purpose. If requested by the Licensee, the Licensor will make reasonable efforts to obtain
such consent. The Licensee will pay all reasonable legal expenses and costs incurred by the Licensor regarding the obtaining of any such consent, including without limitation expenses and costs regarding the Licensor’s review of any consent
obtained by the Licensee. 
 2.4 On the last business day of June and December of each year during the Term, the Licensee will give notice
to the Licensor of the details of any and all Improvements of which the Licensee is then aware and that have been developed and/or acquired by the Licensee or its Sublicensees during the previous six-month
period. 
  

	3.0	 GRANT OF LICENSE 

3.1 In consideration of the Licensor’s Shares and the royalty and milestone payments provided for herein, the Licensor hereby
grants to the Licensee a worldwide, royalty bearing, exclusive license to use and sublicense (subject to the provisions of Section 4.0) the Technology, any and all Licensor Improvements, and all Confidential Information of the Licensor relating
to the Technology, for the purpose of developing, manufacturing, distributing, using, offering for sale and selling Products (and having any of these activities performed by a Third Party (each a “Third Party Contractor”)) for all
commercial purposes during the Term. 
 3.2 The license granted under this Agreement is personal to the Licensee and is not granted
to any of its Affiliated Companies. 
 3.3 Notwithstanding Section 3.1, the Parties acknowledge and agree that the Licensor may (and
where applicable, has a non-exclusive license to) use the Technology, any Improvements, and all Confidential Information of the Licensor relating to the Technology, without charge, for the following
non-commercial purposes: academic research, scholarly publication and educational purposes. 
 3.4
Rights Granted to Third Parties. 
  

	 	(a)	 The Licensee acknowledges that certain third-party rights related to the Technology exist through: 

 

	 	(i)	 an Inter-Institutional Memorandum of Understanding between UBC and the University of Papua New Guinea (“UPNG”); and

  

	 	(ii)	 a Memorandum of Understanding between the Agency for Marine and Fisheries Research of the Ministry of Marine Affairs and Fisheries of the Republic
of Indonesia (“IND Agency”) and UBC 

 (in this Section 3.4, collectively the
“Third Party Agreements”). 
  

	 	(b)	 In the Third Party Agreements, among other rights, both UPNG and IND Agency are entitled to have UBC make reasonable efforts to ensure that
agreements provide for at-cost access to products that result from the commercialization of certain of the Technology and a share of the consideration received by the Licensor under this Agreement, including the Licensor’s Shares.

  
  7 

	 	(c)	 UBC shall be fully responsible for any and all payments required to be made to UPNG and IND Agency under the Third Party Agreements.

  

	 	(d)	 Each of UBC and BCCA hereby represents and warrants that it has the corporate power and authority to grant the license to the Technology and the
other rights under this Agreement. Except as disclosed by UBC under this Agreement, UBC represents and warrants that there are no terms and/or conditions under the Third Party Agreements which would prevent or restrict it from granting the rights
granted to the Licensee under this Agreement. 

 3.5 Sales to Papua New Guinea and Indonesia. 

 

	 	(a)	 The Licensee agrees to use reasonable commercial efforts: itself, or to cause a Sublicensee or distributor; to sell: 

 

	 	(i)	 BADGE Products in the geographical territory of PNG. If the Licensee appoints a Sublicensee or distributor to sell the BADGE Products, the price to
such Sublicensee or distributor shall not exceed the Cost-Based Price, provided that: 

  

	 	(A)	 the BADGE Products have received all required regulatory approvals in PNG; and 

 

	 	(B)	 the distribution of the BADGE Products in PNG is governed by a reasonable monitoring and reporting system designed to prevent recurrent re-export
of the BADGE Products outside the territory of PNG. 

  

	 	(ii)	 Other Products in the geographical territory of IND. If the Licensee appoints a Sublicensee or distributor to sell the Other Product, the price to
such Sublicensee or distributor shall not exceed the Cost-Based Price, provided that: 

  

	 	(A)	 the Other Products have received all required regulatory approvals in IND; and 

 

	 	(B)	 the distribution of the Other Products in IND are governed by a reasonable monitoring and reporting system designed to prevent recurrent re-export
of the Other Products outside the territory of IND. 

  

	 	(b)	 The Licensee agrees that it will use reasonable commercial efforts to provide supporting documentation, data, or other information in its
possession necessary for the regulatory approval of: 

  

	 	(i)	 the BADGE Products in PNG; and 

  

	 	(ii)	 the Other Products in IND. 

  
  8 

	 	(c)	 The Licensee shall have no obligation under: 

  

	 	(i)	 Section 3.5(b)(i) until regulatory approvals have been obtained and sales of the BADGE Product have commenced in all of: North America, the
countries of the European Union, and Japan. 

  

	 	(ii)	 Section 3.5(b)(ii) until regulatory approvals have been obtained and sales of the Other Product have commenced in all of: North America, the
countries of the European Union, and Japan. 

  

	 	(d)	 If the Licensee or a Sublicensee determines in good faith that it cannot perform the obligations set out in this Section 3.5 with respect to
BADGE Product and/or Other Product without adversely impacting the value of the rest of the Product business, or causing unacceptable commercial risk to such business, then the Licensee may seek relief for UBC from UBC’s obligations to UPNG
and/or IND Agency as appropriate to use reasonable efforts to ensure that agreements for the commercialization of the relevant Technology provide at-cost access to products under Sections 4.11 and/or 5.11 of the relevant Third Party
Agreement(s). UBC will cooperate with the Licensee in such efforts. If such Third Party(ies) are amenable to relieving UBC of such obligations, then UBC shall, at the Licensee’s request, accept a waiver of such obligations or an amendment to
one or more of the Third Party Agreements to such effect, provided that in either case UBC will not be bound by any duties and obligations that extend beyond the other duties and obligations assumed by UBC under such Third Party Agreement(s), and
any remuneration payable by UBC under such Third Party Agreement(s) shall not be increased by such waiver or amendment. In the event of any such waiver or amendment by one or more of the parties to the Third Party Agreements, UBC shall so waive or
amend the Licensee’s obligations under this Section 3.5 that correspond to obligations of UBC so waived or amended. The Licensee will pay all reasonable legal expenses and costs incurred by the Licensor regarding the obtaining of any such
waiver or amendment, including without limitation expenses and costs regarding the Licensor’s review of any such waiver or amendment obtained by the Licensee. 

 

	 	(e)	 The Licensee indemnifies, holds harmless and defends UBC against any and all claims (including all associated legal fees and disbursements actually
incurred) arising out of any alleged failure, breach or default of UBC under the Third Party Agreements to provide IND and/or UPNG the opportunity to consult with UBC, or review the terms of this Agreement prior to execution of this Agreement by
UBC. The Licensor shall comply with Section 9.2 in respect of any such indemnification. 

  
  9 

 3.6 In addition to Third Party rights outlined in Section 3.4, Licensee acknowledges that in
accordance with the US Federal Government Interest, the United States government retains certain rights to intellectual property that arises from any contract, grant or similar agreement that is funded in whole or in part by a US Federal agency. As
of the Start Date, the BADGE Patents and the Other Patents and any applicable national patent filings, including continuation, divisional, or continuation-in-part applications of such intellectual property and the license grant of this Agreement is
expressly subject to the US Federal Government Interest, including the Bayh-Dole Act. 
  

	4.0	 SUBLICENSING 

4.1 The Licensee will not grant sublicenses (including cross-licenses) of the Technology and any Improvements, without the prior written
consent of the Licensor, not to be unreasonably withheld, subject to: 
  

	 	(a)	 the Licensee providing the Licensor with a fully executed copy of such sublicense agreement within 14 days of execution;

  

	 	(b)	 the Sublicensee agreeing to indemnify the Licensor, UPNG and IND Agency in accordance with the indemnification provision set forth in
Section 9.0 (except that each reference to this Agreement in Section 9.0 shall be amended to refer to the sublicense agreement for the purposes of such indemnity from the Sublicensee); 

 

	 	(c)	 the sublicense agreement not interfering with the Licensee’s performance of its obligations under this Agreement; and 

 

	 	(d)	 the sublicense agreement not materially conflicting with any terms in this Agreement. 

4.2 Notwithstanding Section 4.1, the Licensor’s consent will not be required if: 

 

	 	(a)	 the proposed Sublicensee has a market capitalization, or in the case of a private company, shareholders equity, of $1 billion (Canadian funds)
or more; or 

  

	 	(b)	 the Licensee has, prior to or at the time of granting such sublicense, conducted financing or other activities that have resulted in the receipt by
the Licensee of at least $10 million (Canadian funds). 

 4.3 With respect to any sublicense agreement requiring the
Licensor’s consent under Section 4.1, the Licensee will provide the Licensor with a fully executed copy of such sublicense agreement within 14 days of it being signed by the Licensee and Sublicensee. 

4.4 Any sublicense granted by the Licensee will be personal to the Sublicensee, and will not be assigned or sublicensed without the prior
written consent of the Licensor, not to be unreasonably withheld, provided however that such sublicensed rights may be sub-sublicensed by the Sublicensee without the prior consent of the Licensor if such
sub-sublicense and the parties thereto comply with the provisions of Sections 4.1 and 4.3 (except that, for the purposes of this Section 4.4, each reference therein to a “sublicense” or “Sublicensee” shall be deemed to
be a reference to a “sub-sublicense” or a “sub-sublicensee”, respectively). 

4.5 Prior to the execution of any sublicense agreement and sub-sublicense agreement under this Article 4.0, the Licensee shall demonstrate to
the Licensor that such sublicense and sub-sublicense, as the case may be, complies with the requirements set out in Section 4.1(b) (except that, in respect of a sublicense, the indemnity will be by the “sublicensee” and in respect of
a sub-sublicense, the indemnity will be by the “sub-sublicensee”, respectively) by providing a copy of such sublicense agreement and sub-sublicense agreement to Licensor prior to execution. 

  
 10 

	5.0	 ROYALTIES AND MILESTONE PAYMENTS 

5.1 As part of the consideration for the rights granted by the Licensor to the Licensee under this Agreement, the Licensee will pay to
the Licensor, on a quarterly basis, an annual royalty of *****% of annual Net Revenue and *****% of annual Sublicensing Revenue (collectively, the “Royalties”). 

5.2 Third Party Licenses. 
  

	 	(a)	 The Parties acknowledge that the Licensee may from time to time enter into additional royalty bearing technology licenses with Third Parties (in
this Section 5.2, the “Third Party Licenses”) on a Product-by-Product basis which are essential in order to commercialize the Technology, any Improvements and/or the Products. If the Licensee enters into one or more Third Party
Licenses with respect to a particular Product, the royalty payable under this Agreement will be reduced by *****% for such Product if the combined royalty rates of the Third Party Licenses for such Product and this Agreement would otherwise exceed
*****%, provided that such Third Party Licenses for such Product include substantially the same royalty-stacking provisions as set out in this Section 5.2(a). 

 

	 	(b)	 The Parties acknowledge and agree, notwithstanding anything in Section 5.2(a), that: 

 

	 	(i)	 Third Party Licenses shall be limited to licenses of patents for formulations, and shall specifically exclude any technology and/or patents
relating to research tools, technology platforms and assays; 

  

	 	(ii)	 Third Party Licenses shall be limited to licenses which include substantially the same royalty-stacking provisions as set out in
Section 5.2(a); 

  

	 	(iii)	 the Licensee shall notify the Licensor as soon as it enters into any Third Party License that triggers Section 5.2(a); 

 

	 	(iv)	 royalty-stacking will be on a Product-by-Product basis, and for greater certainty, the royalty stacking provisions under Section 5.2(a) shall
not apply to any Products which are commercialized without Third Party Licenses; 

  

	 	(v)	 the final royalty rate payable by the Licensee to the Licensor on Net Revenue will never be reduced to less than *****%; 

 

	 	(vi)	 there will be no reduction of the royalty rates on Sublicensing Revenue under Section 5.1; and 

  
 11 

	 	(vii)	 there will be no reduction of the *****% royalty rate set out in Section 5.1 with respect to any royalty paid: 

 

	 	(A)	 by the Licensee to an Affiliated Company of the Licensee; or 

 

	 	(B)	 by the Licensee to any Sublicensee or any Affiliated Company of any Sublicensee. 

5.3 The Licensee shall use commercially reasonable efforts to collect any and all Gross Revenues and Sublicensing Revenues. The royalties
payable hereunder are due and payable within 45 days after each respective Royalty Due Date and are to be calculated with respect to the Net Revenue and the Sublicensing Revenue for the three-month period
ending on the applicable Royalty Due Date. 
 5.4 All royalties paid by the Licensee to the Licensor under this Agreement will be in
Canadian dollars, without any reduction or deduction of any nature or kind at all. If the Licensee receives any Gross Revenue or Sublicensing Revenue in a currency other than Canadian dollars, the currency will be converted to the equivalent in
Canadian dollars on the date that any amount is payable to the Licensor, at the rate of exchange set by the Bank of Montreal for buying Canadian dollars with such currency. The amount of Canadian dollars resulting from the conversion will be
included in Gross Revenue or Sublicensing Revenue. Any payment to made by the Licensee to the Licensor may be made by the Licensee to BCCA, who will receive such payment on behalf of both Licensors. UBC shall not make a claim against the Licensee
for UBC’s share of any payment made by the Licensee to BCCA. 
 5.5 Any transaction, disposition or other dealing involving all or any
part of the Technology, any Improvements or any Products between the Licensee and any of its Affiliated Companies that is not made at fair market value shall be deemed to have been made at fair market value, and the fair market value of such
transaction, disposition or other dealing will be added to and deemed to be part of the Gross Revenue or Sublicensing Revenue, as the case may be. 

5.6 In addition to all other payments provided for in this Section 5.0, the Licensee shall, within 30 days after the achievement of
any of the milestones set out below, pay to the Licensor the amount specified below in respect of such milestone: 
  

									
	 Description of Milestones
	  	Payment for
First Compound	 	 	Payment for
Second and
Every Subsequent
Compound	 
			
	 Filing of an Investigational New Drug Application or equivalent for any Product
	  	$	*	**** 	 	$	*	**** 
			
	 First enrolment of a patient in a Phase II clinical trial using any Product
	  	$	*	**** 	 	$	*	**** 
			
	 First enrolment of a patient in a Phase III clinical trial using any Product
	  	$	*	**** 	 	$	*	**** 
			
	 Upon filing of an application for marketing approval of any Product in the United States of America, Europe or Japan
	  	$	*	**** 	 	$	*	**** 

  
 12 

	6.0	 ANNUAL PAYMENTS AND EQUITY 

6.1 The Licensee will pay to the Licensor a minimum annual royalty for each calendar year of the Term commencing on or after January 1,
2013 in the amount specified in the table below: 
  

					
	 Year Commencing on January 1
	  	Minimum Annual Royalty (CAD)	 
	 2013
	  	$	40,000	  
	 2014
	  	$	40,000	  
	 2015
	  	$	65,000	  
	 2016
	  	$	65,000	  
	 2017 and successive years
	  	$	85,000	  

 6.2 If the Royalties payable by the Licensee to the Licensor pursuant to Section 5.0 for any calendar
year of the Term commencing on or after January 1, 2013 are less than the minimum annual royalty for such year specified in the table set out in Section 6.1, the Licensee shall, within 45 days after the end of such calendar year, pay
to the Licensor the difference between such minimum annual royalty and such Royalties. 
 6.3 The minimum annual royalties paid to the
Licensee pursuant to Section 6.1 will not be refunded to the Licensee (in whole or in part) under any circumstances. 
 6.4 As
part of the consideration for the rights granted by the Licensor to the Licensee hereunder, the Licensee agrees to issue to the Licensor and the individuals and entities identified in Schedule “G” hereto (in this
Section 6.0, each a “New Licensee Shareholder”), on the Start Date, and in lieu of an initial licensing fee, the number of common shares in the capital of the Licensee set forth opposite their respective names in such schedule
for a total of 1,000,000 shares (the “Licensor’s Shares”), representing *****% of the shares of the Licensee issued and outstanding as of the Start Date. 

6.5 Each New Licensee Shareholder shall, on or before the Start Date, execute and deliver to the Licensee a subscription agreement in form and
substance acceptable to the Licensee, acting reasonably. 
 6.6 The Licensor’s Shares shall have the same rights and restrictions as
the equity issued to the Licensee’s founders, including the rights and restrictions set out in Schedule “F” hereto. 

6.7 The Licensor, the Licensee and each of the Licensee’s founders shall, on or before the Start Date, enter into a shareholders’
agreement in a form and substance acceptable to each of them. 
 6.8 The Licensee will use commercially reasonable efforts to cause the
Licensor’s Shares to be issued free from any pooling, escrow or other trading restrictions placed on such shares by the Licensee or any regulatory authority having jurisdiction over the Licensee. 

6.9 The Licensee acknowledges and agrees that it will comply with all applicable laws with respect to the issuance of the Licensor’s
Shares. 

  
 13 

 6.10 The Licensor agrees that it will comply with all applicable laws with respect to the resale
or transfer of the Licensor’s Shares and with the restrictions on transfer and drag-along and tag-along rights contained in the Licensee’s Articles. 

6.11 The Licensor’s Shares shall be deemed to be fully paid for by the Licensor as of the date of issuance and shall be the absolute
property of UBC, BCCA and each New Licensee Shareholder, as applicable, and shall not be refundable to the Licensee under any circumstances. 
  

	7.0	 PATENTS 

7.1 The Licensee shall be responsible for the preparation, filing, prosecution, maintenance and defence of any intellectual property directly
relating to the Technology and any Improvements. Notwithstanding the foregoing, Licensee agrees it will not unduly limit the scope or claims of the Patents without the prior consent of the Licensors, and Licensee further agrees: 

 

	 	(a)	 that all Improvements shall be disclosed to the BCCA Technology Development Office, and further agrees to supply BCCA Technology Office with a copy
of any and all documentation received and filed in connection with the Technology and Improvements; and 

  

	 	(b)	 to provide Licensor with a summary of activities related to the filing, prosecution, maintenance and defence of any intellectual property related
to the Technology and Improvements upon reasonable request of Licensor; and 

  

	 	(c)	 for each PCT or provisional application related to the Technology and any Improvement, that Licensee with provide BCCA Technology Development
Office with a list of Licensee’s intended jurisdictions for national filings at least 2 months prior to each 30 month deadline, and that BCCA shall have the right at its sole discretion and expense to prepare, file, prosecute, maintain and
defend any intellectual property related to the Technology and any Improvement in jurisdictions not covered in the list by Licensee; and 

  

	 	(d)	 in the event it becomes apparent to Licensee that Licensee is unable or unwilling to cover expenses related to the preparation, prosecution,
maintenance and defence of any intellectual property national filings related to the Technology and any Improvement in any jurisdiction, that Licensee shall immediately inform the BCCA Technology Development Office, which may in the BCCA’s sole
discretion take on the responsibility and expense for the prosecution, maintenance and defence of any such intellectual property (the “Excluded Intellectual Property”). If BCCA exercises its rights to proceed with patent prosecution
of any Excluded Intellectual Property, such Excluded Intellectual Property will be automatically deemed to be excluded and removed from the Technology and Improvements being licensed to the Licensee under this Agreement. The parties shall execute
any documents required to evidence the foregoing. 

 7.2 The Licensee shall have the sole and total responsibility for,
and shall pay, any and all out-of-pocket non-administrative costs incurred after November 10, 2010 in relation to drafting,
filing, prosecution, maintenance and defence of the intellectual property directly relating to the Technology and any Improvements. 
  

	7.3	 This Section 7.3 was purposely left blank. 

  
  14 

 7.4 This Section 7.4 was purposely left blank. 

7.5 If the Licensee fails to pay any cost as required pursuant to Section 7.2, the Licensee shall reimburse the Licensor for such cost
within 30 days after its receipt of a request for such reimbursement from the Licensor, together with the invoice and payment receipt in respect of such cost. 

7.6 On the filing of any patent application or the issuance of any Patent as contemplated in this Section 7.0, the Licensee will
automatically become the licensee of such patent application or Patent (if and when granted), respectively, on the terms and conditions set out in this Agreement, and such patent application and Patent (if and when granted) will be deemed to be part
of the Technology and/or Improvements, as the case may be. 
 7.7 The Licensee will not contest the validity of any Patents relating to the
Technology and any Improvements licensed under this Agreement. 
 7.8 The Licensee will ensure proper patent marking of the Products claimed
by a Patent to the extent required by applicable law or as reasonably customary in the industry. 
 7.9 Upon notice from the Licensee to
Licensor and payment by the Licensee of $***** to the Licensor, the Licensor will, at the Licensee’s request and expense, assign the Licensor’s interest in the Technology and Licensor Improvements to the Licensee and provide reasonable
assistance to the Licensee to facilitate the filing and prosecution and maintenance of applications or registrations for same, and the Licensor will execute all documents reasonably deemed necessary or desirable by the Licensee therefor. Upon and
after such notice and payment: 
  

	 	(a)	 the Licensee may prosecute litigation against infringers and potential infringers of the Technology or any Improvements without the consent of the
Licensor, notwithstanding the terms of Section 8.5; 

  

	 	(b)	 the Licensee will have full control over the conduct of complaints referred to in Section 8.6, and notwithstanding Sections 8.6(c), may take
decisions and actions concerning or governing any final disposition of complaints referred to in Section 8.6 without consultation with or approval by the Licensor; 

 

	 	(c)	 the Licensee shall have the rights set out in Section 14.3; and 

 

	 	(d)	 the termination rights set out in Sections 18.2(a) and 18.2(c) and Sections 3.1, 3.2 and 7.6 shall be of no further force or effect.

 For clarity, no assignment pursuant to this Section shall relieve the Licensee from any of its obligations to pay
milestones and royalties, indemnify the Licensor, or any other terms and conditions of this Agreement, except as specifically modified under Sections 7.9(a) to (d) inclusive. Upon the notice and payment referred to in this Section 7.9, the
parties shall use good faith efforts to enter into an assignment agreement with the equivalent of the rights and obligations of this Agreement as modified by this Section and any other modifications as may be agreed between the parties to reflect
the changed circumstances as set out in the Section, but in the absence of such agreement, the Licensor will comply with its obligations set out in this Section and this Agreement as modified by this Section 7.9 shall survive such assignment.
The Licensee will pay all reasonable legal expenses and costs incurred by the Licensor regarding the preparation and negotiation of such assignment agreement. 

  
 15 

	8.0	 DISCLAIMER OF WARRANTY 

8.1 Except for the express representations and warranties made in Section 8.4, none of the Licensor, UPNG and IND Agency makes any
representations, conditions or warranties, either express or implied, with respect to the Technology, any Improvements or the Products. Without limitation, the Licensor, UPNG and IND Agency specifically disclaims any implied warranty, condition
or representation that the Technology, any Improvements or the Products: 
  

	 	(a)	 correspond with a particular description; 

  

	 	(b)	 are of merchantable quality; 

  

	 	(c)	 are fit for a particular purpose; or 

  

	 	(d)	 are durable for a reasonable period of time. 

8.2 None of the Licensor, UPNG and IND Agency will be liable for any loss, whether direct, consequential, incidental or special, which
the Licensee or other third parties may suffer arising from any defect, error or fault of the Technology, any Improvements or the Products or their failure to perform, even if the Licensor, UPNG or IND Agency is aware of the possibility of the
defect, error, fault or failure. The Licensee acknowledges that it has been advised by the Licensor, UPNG and IND Agency to undertake its own due diligence regarding the Technology and any Improvements. 

8.3 Except for the express representations and warranties made in Section 8.4, nothing in this Agreement: 

 

	 	(a)	 constitutes a warranty or representation by the Licensor, UPNG or IND Agency as to title to the Technology or any Improvements or that
anything made, used, sold or otherwise disposed of under the license granted in this Agreement is or will not infringe the patents, copyrights, trade-marks, industrial design or other intellectual property rights owned, in whole or in part, by the
Licensor, UPNG or IND Agency or licensed by the Licensor, UPNG or IND Agency to any third parties; 

  

	 	(b)	 constitutes a warranty or representation by the Licensor, UPNG or IND Agency that the Licensee will, on execution of this Agreement, have the
freedom to operate or practice the Technology or any Improvements, or to make, have made, use, sell or otherwise dispose of products made using the Technology or any Improvements; or 

 

	 	(c)	 imposes an obligation on the Licensor, UPNG or IND Agency to bring, prosecute or defend actions or suits against third parties for
infringement of patents, copyrights, trade-marks, industrial designs or other intellectual property or contractual rights. 

8.4 The Licensor hereby represents and warrants to the Licensee that to the best of the knowledge of the Technology Transfer Offices of each
of UBC and BCCA, without making any enquiries, the Licensor: 
  

	 	(a)	 has exclusive ownership of the Technology; and 

  
 16 

	 	(b)	 has not sold, given, hypothecated, assigned or otherwise transferred, licensed or encumbered any right, title or interest in or to the Technology
to any Third Party other than the Licensee, and shall not do so during the term of this Agreement. 

 8.5 Notwithstanding
Section 8.3, if there is an alleged infringement of the Technology or any Improvements or any right with respect to the Technology or any Improvements, the Licensee may, on receiving the prior written consent of the Licensor, such consent not
to be unreasonably withheld, prosecute litigation designed to enjoin and obtain damages from infringers of the Technology or any Improvements. Provided that: (i) Licensor has first granted its prior written consent; or the Licensee has given
the notice and made the payment referred to in Section 7.9; the Licensor agrees to reasonably co-operate to the extent of signing all necessary documents and to vest in the Licensee the right to institute the litigation, provided that all the
direct and indirect costs and expenses of bringing and conducting the litigation or settlement are paid by the Licensee and in this case all recoveries are for the benefit of the Licensee. 

8.6 If any complaint alleging infringement of any patent or other proprietary rights is made against the Licensee or a Sublicensee regarding
the use of the Technology or any Improvements or the manufacture, use or sale of the Products, the following procedure will be adopted: 
  

	 	(a)	 the Licensee will promptly notify the Licensor on receipt of the complaint and will keep the Licensor fully informed of the actions and positions
taken by the complainant and taken or proposed to be taken by the Licensee on behalf of itself or a Sublicensee; 

  

	 	(b)	 except as provided in Section 8.6(d), all costs and expenses incurred by the Licensee or any Sublicensee in investigating, resisting,
litigating and settling the complaint, including the payment of any award of damages and/or costs to any Third Party, will be paid by the Licensee or the Sublicensee, as the case may be; 

 

	 	(c)	 no decision or action concerning or governing any final disposition of the complaint will be taken without full consultation with, and approval by,
the Licensor, such approval not to be unreasonably withheld; 

  

	 	(d)	 the Licensor may elect to participate as a party in any litigation involving the complaint to the extent that the court may permit, but any
additional expenses generated by such participation will be paid by the Licensor (subject to the possibility of recovery of some or all of the additional expenses from the complainant); and 

 

	 	(e)	 the Licensee will pay all royalties payable under this Agreement to the Licensor in trust from the date the Licensor receives notice of the
complaint and until a resolution of the complaint has been finalized. If the complainant is successful, then the royalties paid to the Licensor in trust under this Section 8.6(e) will be returned to the Licensee, provided that the amount being
returned to the Licensee is no more than the amount paid by the Licensee to the complainant in the settlement or other disposition of the complaint. If the complainant does not succeed, then the Licensor retains all royalties paid to it under this
Section 8.6(e). 

  
 17 

	9.0	 INDEMNITY AND LIMITATION OF LIABILITY 

9.1 The Licensee indemnifies, holds harmless and defends each of BCCA, UBC and the Provincial Heath Services Authority and their respective
Board of Governors, Board of Directors, officers, employees, faculty, students, invitees and agents, and UPNG and IND Agency, against any and all claims (including all associated legal fees and disbursements actually incurred) arising out of
the exercise of any rights under this Agreement, including without limitation against any damages or losses, consequential or otherwise, arising in any manner at all from or out of the use of the Technology or any Improvements or Products licensed
under this Agreement by the Licensee or any of its Third Party Contractors, Sublicensees or their respective customers or end-users. 
 9.2
The Licensor shall provide to the Licensee: 
  

	 	(a)	 prompt written notice of any claim under Section 9.1; 

 

	 	(b)	 the exclusive right to control and direct the investigation, defence, or settlement (if applicable) of such claim, provided that the Licensee shall
not admit any fault or liability on behalf of either of the parties comprising the Licensor without full consultation with and written approval from the Licensor; and 

 

	 	(c)	 all reasonable necessary cooperation of the Licensor. 

9.3 The Licensor’s total liability, whether under the express or implied terms of this Agreement, in tort (including negligence) or at
common law, for any loss or damage suffered by the Licensee, whether direct, indirect or special, or any other similar damage that may arise or does arise from any breaches of this Agreement by BCCA, UBC and the Provincial Heath Services Authority
and their respective Board of Governors, Board of Directors, the Provincial Health Service Authority, officers, employees, faculty, students or agents is limited to $10,000 (Canadian funds). 

9.4 The Licensee acknowledges and agrees that neither of the parties comprising the Licensor nor UPNG nor IND Agency will be liable for
consequential or incidental damages arising from any breach or breaches of this Agreement. 
 9.5 Notwithstanding any other provision of
this Agreement, each Party acknowledges that an irreparable injury would be suffered by the non-breaching Party as a result of a breach of the provisions of this Agreement by the breaching Party and that an
award of monetary damages alone would not be an adequate remedy. Notwithstanding any provision hereof to the contrary, the non-breaching Party will have the right, in addition to any other rights it may have,
to obtain injunctive relief to restrain any breach or threatened breach by the breaching Party or otherwise to specifically enforce any provision of this Agreement, and the non-breaching Party will not be
obligated to post bond or other security in seeking such relief. 
 9.6 Notwithstanding the termination or expiration of this Agreement, the
rights and obligations provided for in Section 9.0 will survive and continue to bind and enure to the benefit of the Parties and their respective successors and permitted assigns. 

  
 18 

	10.0	 PUBLICATION AND CONFIDENTIALITY 

10.1 Each Party will keep and use the other Party’s Confidential Information in confidence and will not, without the other Party’s
prior written consent, disclose the other Party’s Confidential Information to any person or entity, except to the Party’s directors, officers, employees, faculty, graduate students and professional advisors who require the Confidential
Information to assist such Party in performing its obligations under this Agreement. The Licensee shall be entitled to disclose the Licensor’s Confidential Information, on a confidential basis, to potential investors or financiers and their
professional advisors (in this Section 10.0, each an “Interested Party”), for the sole purpose of examining and assessing the Technology and its commercialization value. The Licensee will use reasonable efforts to
obtain a written confidentiality undertaking from the Interested Party, failing which the Licensee shall, if it discloses the Licensor’s Confidential Information to the Interested Party, be responsible for any breach by the Interested Party of
the confidentiality obligations contained in this Agreement. The Licensee shall notify the Licensor of the identity of any Interested Party to whom the Licensee has disclosed the Licensor Confidential Information without a written confidentiality
agreement. The identity of an Interested Party shall be regarded and treated by the parties as the Licensee’s Confidential Information. The Licensee will maintain reasonable internal program limiting the distribution of the Licensor’s
Confidential Information to only those officers, employees and professional advisors who require such Confidential Information in performing the Licensee’s obligations under this Agreement and who have signed appropriate non-disclosure agreements. 
 10.2 Any Party required by judicial or administrative process to disclose
the other Party’s Confidential Information, will promptly notify the other Party and allow it reasonable time to oppose the process before disclosing the Confidential Information. 

10.3 A list of all Confidential Information that has been exchanged between the Parties prior to the date of execution of this Agreement is
attached as Schedule “E” hereto. For greater certainty, the Parties hereto acknowledge and agree that they make no representations or warranties in this Agreement as to the completeness of the list of Confidential Information
attached hereto as Schedule “E”, and that such list will not in any manner restrict or limit the definition of “Confidential Information” set out in Section 1.1. 

10.4 The Licensor will not be restricted from presenting at symposia, national or regional professional meetings, or from publishing in
journals or other publications, accounts of their research with respect to the Technology and any Improvements, provided that: 
  

	 	(a)	 the Licensor provides the Licensee with copies of the proposed presentation or publication (in this Section 10.0, each a
“Manuscript”) at least 60 days before the presentation or publication date; and 

  

	 	(b)	 the Licensee has not, within 30 days after receipt of the Manuscript, objected in writing to such Manuscript. 

10.5 The Licensee may object to a Manuscript on the grounds that it contains material the Licensee considers objectionable on the basis that:

  

	 	(a)	 it discloses patentable subject matter which needs protection; or 

 

	 	(b)	 it discloses a Licensee Improvement or Confidential Information of the Licensee (in this Section 10.0, the “Objectionable
Material”). 

  
 19 

 In the event that the Licensee makes such objection, the researchers, the Licensor and the
Licensee shall work together to revise the Manuscript to remove or alter the Objectionable Material as follows: 
  

	 	(i)	 if the Objectionable Material discloses a Licensee Improvement or other Confidential Information of the Licensee, such Objectionable Material will
be removed from any Manuscript prior to disclosure of the same; and 

  

	 	(ii)	 if the Manuscript contains other patentable subject matter which needs protection, it shall be dealt with in accordance with Section 10.6.

 10.6 The Licensor and its researchers shall co-operate in all reasonable
respects in making revisions to any Manuscripts considered by the Licensee to contain Objectionable Material. Once a Manuscript has been revised to remove or alter the Objectionable Material in a manner reasonably acceptable to the Licensee, the
Licensee shall withdraw its objection and the researchers and the Licensor shall not be restricted from publishing or presenting the Manuscript. In the event that the Licensee makes such an objection on the grounds that the Manuscript contains
patentable subject matter that constitutes Technology or any Improvement, Licensee may file a patent application pursuant to Section 7.1, and the Licensor shall ensure that its researchers refrain from disclosing the Objectionable Material
until the Licensee has filed one or more patent applications with one or more patent offices directed to such patentable subject matter, provided that such patents are filed within 90 days of the date of Licensee’s objection. 

10.7 The Licensor is not restricted from publishing or presenting any Manuscript as long as any Objectionable Material has been removed. After
six months from the date the Licensor delivers the Manuscript to the Licensee, the Licensor is free to present and/or publish the Manuscript whether or not it contains Objectionable Material. 

10.8 With respect to any Manuscript that contains the results of research conducted using any Material or Information (as such terms are
defined under the MTA) pursuant to the terms of the MTA, such Manuscript shall be excluded from the application of Sections 10.4, 10.5, 10.6 and 10.7 of this Agreement and shall be governed by the publication provisions of Section 10.1 of
the MTA. UBC shall promptly provide the Licensee with copies of any proposed Manuscript that it receives from the University of Washington pursuant to the MTA to allow the Licensee to review and identify any Objectionable Material within the
Manuscript. 
 10.9 The Licensee requires of the Licensor and, to the extent permitted by law, the Licensor agrees, that this Agreement (and
each part of it) is confidential and will not be disclosed to third parties, as the Licensee claims that such disclosure would or could reveal commercial, scientific or technical information and would significantly harm the Licensee’s
competitive position and/or interfere with the Licensee’s negotiations with prospective sublicensees. Notwithstanding anything contained in Sections 10.0 and 11.1, the Parties acknowledge and agree that each of the Licensor and the
Licensee may identify the title of this Agreement, the parties to this Agreement and the names of the inventors of the Technology and any Improvements, and that the Licensor may also disclose to the inventors of the Technology and to IND and PNG the
amount of all payments made to the Licensor by the Licensee under this Agreement, the manner or method by which such payments were calculated and all Payment Reports delivered to the Licensor by the Licensee in connection with such payments. 

10.10 Notwithstanding any other provision of this Agreement, the Licensee shall be entitled to disclose the Licensor’s Confidential
Information and the terms of this Agreement (including a copy of all or any part hereof) to any Sublicensee or prospective sublicensee, or any Third Party to whom such disclosure is necessary or useful to exercise the Licensee’s rights under
this Agreement, provided that such person has signed a non-disclosure or confidentiality agreement with respect to such information. 

  
 20 

 10.11 Notwithstanding the termination or expiration of this Agreement, the rights and obligations
provided for in Section 10.0 will survive and continue to bind and enure to the benefit of the Parties and their respective successors and permitted assigns. 
  

	11.0	 PRODUCTION AND MARKETING 

11.1 Notwithstanding Section 10.11, except as expressly set out herein, the Licensee will not use the Licensor Trade-marks or make reference to the Licensor or its name, or the names of UPNG or IND Agency, in any advertising or publicity, without the prior written consent of the Licensor. The Licensee may identify the
title of this Agreement, the parties to this Agreement and the names of the inventors of the Technology and any Improvements. Without limitation, the Licensee will not, unless otherwise required by law, issue a press release regarding this Agreement
without first obtaining the Licensor’s written approval, such approval not to be unreasonably withheld. If the Licensor has not provided or refused its consent in writing within three business days of a request pursuant to this Section, the
Licensor shall be deemed to have consented. If the Licensee is required by law to act in contravention of this Section 11.1, the Licensee will (as is reasonably possible in the circumstances) provide the Licensor with sufficient prior notice to
permit the Licensor to bring an application or other proceeding to contest the requirement. Nothing in this Section will require the Licensee to obtain permission from the Licensor to release information previously released by the Licensee in
accordance with the terms of this Section. 
 11.2 The Licensee represents and warrants to the Licensor that it intends to build, develop
and/or acquire the infrastructure, expertise and resources: 
  

	 	(a)	 to develop and commercialize the Technology and any Improvements; 

 

	 	(b)	 to track and monitor on an ongoing basis performance under the terms of each sublicense entered into by the Licensee; 

 

	 	(c)	 to monitor in major markets patent infringement regarding any patent included in the Technology and any Improvements licensed under this Agreement;
and 

  

	 	(d)	 to initiate and maintain an appropriate program limiting the distribution of the Confidential Information, the Technology and any Improvements as
provided for in this Agreement and to obtain the appropriate non-disclosure agreements from all persons who may have access to the Technology and any Improvements. 

11.3 The Licensee will: 
  

	 	(a)	 allocate reasonable time to the development and commercialization of the Technology and any Improvements ; 

 

	 	(b)	 use reasonable efforts to promote, market and sell the Products and exploit the Technology and any Improvements 

 

	 	(c)	 until the Licensee has received at least $10 million (Canadian funds) as contemplated by Section 4.2(b), provide copies of all minutes of all
directors meetings of the Licensee in a timely manner and in no case later than 30 days after the holding of any directors meetings. 

  
 21 

 11.4 If the Licensor is of the view that the Licensee is in material breach of Section 11.3,
the Licensor may give notice thereof to the Licensee and, within 15 days of receiving such notice, the Licensee shall provide notice to the Licensor of its election to: 
  

	 	(a)	 proceed with remedying the breach in accordance with Section 18.5; 

 

	 	(b)	 dispute the breach (in this Section 11.0, a “Dispute”) and refer the Dispute to mediation in accordance with
Section 11.5; or 

  

	 	(c)	 accept the breach. 

If the Licensee fails to make an election in accordance with this Section 11.4, then the Licensee will be deemed to have accepted the
breach and the Licensor may terminate this Agreement. 
 11.5 If the Licensee elects to refer a Dispute to mediation, the Licensor
will appoint a mediator (in this Section 11.0, the “Mediator”) within 15 days of the Licensee’s election. On appointment of the Mediator, the following rules and procedures will govern the conduct of the Parties and
the Mediator before and during the mediation of the Dispute: 
  

	 	(a)	 prior to receiving any information relating to the Dispute, the Mediator will execute a non-disclosure
agreement acceptable to the Licensee and the Licensor, acting reasonably; 

  

	 	(b)	 within 30 days of the appointment of the Mediator, each Party will provide to the Mediator and the other Parties a written summary of its
position with respect to the Dispute and copies of all documents on which it intends to rely; 

  

	 	(c)	 after each of the Parties has provided its summary and documents under Section 11.5(b), but not more than 60 days from the appointment of
the Mediator, the Parties will meet in the presence of the Mediator with a view to resolving the Dispute. The role of the Mediator will be to assist in negotiating a resolution of a Dispute and will not make a binding decision without the
Parties’ prior written agreement; 

  

	 	(d)	 the mediation of a Dispute may be terminated by either Party, by giving notice to the other Party: 

 

	 	(i)	 if the other Party fails to comply with its obligations under this Section 11.5; or 

 

	 	(ii)	 if the Parties cannot agree on a resolution of the Dispute within 60 days from the appointment of the Mediator; 

 

	 	(e)	 any information or documents disclosed by either Party under this Section 11.5 must be kept confidential and must not be used except to
attempt to resolve the Dispute; and 

  

	 	(f)	 each Party must bear its own costs of complying with Section 11.5 and the Parties must bear equally the costs of any Mediator appointed
hereunder. 

  
 22 

 11.6 If the Parties cannot agree on the resolution of the Dispute within 60 days from the
appointment of the Mediator, or if the mediation of the Dispute has been terminated under Section 11.5(d), then the Licensee will (counting from the later of the end of such 60-day period or the date of
the termination of mediation) have a further 90 days to remedy the breach in accordance with Section 18.5 or dispute the existence of the breach. Nothing in this Section will limit the right of either Party to file suit in the court of its
choice in accordance with Article 15.0. 
  

	12.0	 ACCOUNTING RECORDS AND REPORTS 

12.1 The Licensee will maintain at its principal place of business, or such other place as may be convenient, separate accounts and records of
all Net Revenue, Gross Revenue and Sublicensing Revenue, sublicenses and business conducted by the Licensee in connection with the Technology or any Improvements. These accounts and records will be prepared in sufficient detail to enable proper
returns to be made as required by this Agreement, and the Licensee will use reasonable efforts to cause its Sublicensees to keep similar accounts and records. 

12.2 The Licensee will complete and deliver to the Licensor: 
  

	 	(a)	 within 45 days of each and every Royalty Due Date, a completed Payment Report in the form attached as Schedule “B” (or
in such amended form as agreed by the Licensor and the Licensee from time to time), together with the royalty payable under this Agreement. A separate Payment Report shall be prepared and delivered for each sublicense, including an accounting
statement setting out in detail how the amount of Sublicensing Revenue was determined and identifying each Sublicensee and the location of the business of each Sublicensee. The first Payment Report will be submitted within 45 days after the
first Royalty Due Date after the Licensee’s receipt of the first Gross Revenue or Sublicensing Revenue, and thereafter a Payment Report shall be delivered within 45 days after each subsequent Royalty Due Date regardless of whether any
Gross Revenue or Sublicensing Revenue was received in the preceding period; and 

  

	 	(b)	 on or before March 31 of each year during the Term, starting on March 31, 2012, an annual report in the form attached as
Schedule “C” (or in such amended form as agreed by the Licensor and the Licensee from time to time). 

12.3 The calculation of royalties will be carried out in accordance with generally accepted Canadian accounting principles, or the standards
and principles adopted by the U.S. Financial Accounting Standards Board, as determined by the Licensee, applied on a consistent basis. 

12.4 The Licensee will retain the accounts and records referred to in Section 12.1 for at least six years from when they were made
and will permit any duly authorized representative of the Licensor to inspect, at the Licensor’s expense, the accounts and records during the Licensee’s normal business hours. The Licensee will provide to the representative all reasonable
evidence necessary to verify the accounts and records and will allow copies to be made of the accounts, records and agreements. If an inspection of the Licensee’s records by the Licensor shows an under-reporting or underpayment by the Licensee
of any amount required to be paid to the Licensor under this Agreement by more than 5% for any 12-month period, then the Licensee will reimburse the Licensor for the cost of the inspection as well as pay to
the Licensor any amount found due (including any interest) within 30 days of notice by the Licensor to the Licensee. The Licensor may not give notice to the Licensee of an inspection more than once in each any two year period, unless the
Licensee has been found to be in breach of its obligations to pay royalties within such two year period. 

  
 23 

 12.5 All information provided to the Licensor or its representatives under Section 12.0 will
be deemed to be Confidential Information of the Licensee and will be subject to the provisions of Section 10.0. The Licensor may use such information solely for enforcing its rights hereunder and complying with its reporting obligations to New
Licensee Shareholders under an obligation of confidence. 
  

	13.0	 INSURANCE 

13.1 During the term of this Agreement and for three years after its expiry or termination, the Licensee will procure and maintain such
insurance (including public liability and commercial general liability insurance), if any, as would be acquired by a reasonable and prudent businessperson carrying on a similar line of business. 

13.2 Notwithstanding Section 13.1, the Licensee will procure, not less than 30 days before the commencement of clinical trials or
the first sale of a Product, clinical trial insurance and/or product liability insurance, respectively, and provide to the Licensor a copy of a certificate evidencing such insurance policy. Each of these policies of insurance will: 

 

	 	(a)	 be placed with a reputable and financially secure insurance carrier; 

 

	 	(b)	 include each of BCCA, UBC and the Provincial Health Services Authority and their respective Board of Governors, Board of Directors, faculty,
officers, employees, students and agents as additional insureds; 

  

	 	(c)	 provide coverage regarding all clinical trial activities of, or Products sold by, the Licensee under this Agreement, as applicable;

  

	 	(d)	 include a severability of interest and cross-liability clause; and 

 

	 	(e)	 provide that the policy cannot be cancelled or materially altered except on at least 30 days’ prior notice to the Licensor (to the extent
available from a commercially reasonable insurance provider). 

 13.3 The Licensor may from time to time require
reasonable amendments to the terms or the amount of coverage contained in the insurance policies of the Licensee referred to in Sections 13.1 and 13.2, and the Licensee will use commercially reasonable efforts to accommodate such amendments.

 13.4 The Licensee will also require each Sublicensee to, not less than 30 days before the commencement of clinical trials or the
first sale of a Product pursuant to this License by such Sublicensee: 
  

	 	(a)	 procure and maintain such clinical trial insurance and/or product liability insurance, respectively, if any, as would be acquired by a reasonable
and prudent businessperson of similar financial standing carrying on a similar line of business; or 

  

	 	(b)	 demonstrate that such sublicensee has a program of self insurance no less adequate than that which a reasonable and prudent businessperson carrying
on a similar line of business would require. If at the relevant time referred to in this Section 13.4, such sublicensee has a market capitalization of greater than $1 billion, then such program shall be deemed to be that required by this
Section 13.4(b). 

  
 24 

 13.5 The Licensee will use commercially reasonable efforts to ensure that any and all policies of
clinical trial and product liability insurance referred to in Section 13.4 include BCCA, UBC and the Provincial Heath Services Authority and their respective Board of Governors, Board of Directors, faculty, officers, employees, students and
agents as additional insureds, or alternatively, include a waiver of subrogation against BCCA, UBC and the Provincial Heath Services Authority. 
  

	14.0	 ASSIGNMENT 

14.1 Neither the Licensee nor the Licensor shall assign, transfer, mortgage, pledge, financially encumber, grant a security interest, permit a
lien to be created, charge or otherwise dispose of any or all of the rights granted to it under this Agreement without the prior written consent of the other Party, such consent not to be unreasonably withheld. 

14.2 Notwithstanding Section 14.1, the Licensor shall be entitled to assign its right to receive royalties and milestone payments
under this Agreement to a company of which it is the sole shareholder, or a society which it has incorporated or which has purposes which are consistent with the objectives of the Licensor (the “Royalty Stream Recipient”), provided
that no such assignment will release the Licensor from any of its obligations or liabilities hereunder and further provided that the Royalty Stream Recipient shall have no right whatsoever to enforce any the terms or provisions of this Agreement
against the Licensee or any Sublicensee. 
 14.3 Notwithstanding Section 14.1, upon and after the notice and payment referred to
in Section 7.9: the Licensee shall be entitled to assign this Agreement or make its interest in this Agreement, the Technology or any Improvement subject to a security interest, lien, charge or encumbrance in favour of one or more financial
institutions providing financing to the Licensee pursuant to the terms of a security or other agreement related to such financing, provided that no such assignment will release the Licensor from any of its obligations or liabilities hereunder,
including the payment obligations set out herein; and none of the foregoing will be grounds for termination in accordance with Section 18.2(c). 
  

	15.0	 GOVERNING LAW 

15.1 This Agreement is governed by, and will be construed in accordance with, the laws of British Columbia and the laws of Canada in force in
that province, without regard to its conflict of law rules. All Parties agree that by executing this Agreement they have attorned to the jurisdiction of the Supreme Court of British Columbia. The Parties agree that the British Columbia Supreme Court
has exclusive jurisdiction over this Agreement. This Section shall not apply to any sublicense agreement. 
  

	16.0	 NOTICES 

16.1 All reports and notices or other documents that a Party is required or may wish to deliver to any other Party will be: 

 

	 	(a)	 in writing; and 

  
  25 

	 	(b)	 delivered either by personal delivery or by registered or certified mail at the address for the receiving Party set out in Section 16.2 or as
varied by any notice. 

 Any notice personally delivered is deemed to have been received at the time of delivery. Any
notice mailed in accordance with this Section 16.1 is deemed to have been received at the end of the fifth day after it is posted. 

16.2 The address for delivery of notices and instructions for making payments to the Licensor are set out in
Schedule “D” hereto. The address for delivery of notices to the Licensee is set out below: 
 ESSA
Pharma Inc. 
 999 West Broadway, Suite 700 

V5Z 1K5 

Attn: Bob Rieder 
  

	17.0	 TERM 

17.1 The term of this Agreement (the “Term”) will commence on the Amendment Date and end on: 

 

	 	(a)	 the day that is exactly 20 years later; or 

  

	 	(b)	 the expiry of the last patent licensed under this Agreement, 

whichever is last to occur, unless terminated earlier under Section 11.0 or 18.0. 

 

	18.0	 TERMINATION OF AGREEMENT 

18.1 The Licensor may terminate this Agreement on written notice to the Licensee if: 

 

	 	(a)	 the Licensee is adjudged or declared bankrupt, or any order is made for the winding up, liquidation or other termination of the existence of the
Licensee (in each case, from which no appeal may be taken); 

  
 26 

	 	(b)	 the Licensee makes a voluntary assignment for the benefit of its creditors or a voluntary proposal or similar action under the Bankruptcy and
Insolvency Act (Canada), the Companies Creditors Arrangement Act (Canada) or any similar legislation; or 

  

	 	(c)	 the Licensee makes an involuntary assignment for the benefit of its creditors or a proposal or similar action under the Bankruptcy and
Insolvency Act (Canada), the Companies Creditors Arrangement Act (Canada) or any similar legislation and same is not dismissed within 90 days. 

18.2 The Licensor may, at its option, immediately terminate this Agreement by giving notice in writing to that effect to the Licensee if one
or more of the following occurs: 
  

	 	(a)	 prior to the notice and payment referred to in Section 7.9, any execution in excess of $20,000 or other process of any court becomes
enforceable against the Licensee, or if any such process is levied on the Licensee’s rights under this Agreement or upon any money due to the Licensor, or if a receiver or receiver manager is appointed in respect of all or substantially all of
the Licensee’s assets or undertaking, and in each case is not released, satisfied or discharged within 30 days after such notice; 

  

	 	(b)	 any resolution is passed by the Licensee or order made at the request of the Licensee or other steps voluntarily taken by the Licensee for the
winding up, liquidation or other termination of the existence of the Licensee; 

  

	 	(c)	 prior to the notice and payment referred to in Section 7.9, the Technology or any Improvement becomes subject to any security interest, lien,
charge or encumbrance in favour of any Third Party claiming through the Licensee, and in each case is not released, satisfied or discharged within 90 days after such notice. 

18.3 The Licensor may, at its option, terminate this Agreement by giving notice in writing to that effect to the Licensee if the Licensee has:

  

	 	(a)	 the Licensee ceases to carrying on business and fails to recommence carrying on business within 30 days after written notice thereof is given
by the Licensor to the Licensee; 

  

	 	(b)	 breached Section 12.2(a) by failing to deliver to the Licensor a completed Payment Report in accordance with the requirements of such Section
and such breach is not remedied within 30 days after written notice thereof is given by the Licensor to the Licensee; 

  

	 	(c)	 breached Section 12.2(b) by failing to deliver to the Licensor a completed annual report in accordance with the requirements of such Section
and such breach is not remedied within 90 days after written notice thereof is given by the Licensor to the Licensee; 

  

	 	(d)	 the failure of the Licensee and its Sublicensees to spend a total of at least $5,000,000 (Canadian funds), in cash or in kind, in connection
with the commercialization of the Technology within a 60-month period after the Start Date and such failure is not remedied within 90 days after written notice thereof is given by the Licensor to the
Licensee; or 

  

	 	(e)	 breached Section 9.1 and such breach is not remedied within 30 days after written notice thereof is given by the Licensor to the
Licensee. 

 18.4 The Licensee may, at its option, terminate this Agreement at any time on providing 120 days’
notice to the Licensor. 
 18.5 Either Party may, at its option, terminate this Agreement by giving notice in writing to that effect to the
other Party if the other Party has materially breached this Agreement (other than in respect of the obligations of the Licensee contained in Section 11.2, for which the exclusive remedies of the Licensor are set out in Section 11.0) and
such breach is not remedied within 90 days (or 30 days in case of a breach of Section 4.5 and/or Section 5.3) after written notice thereof is given by the non-breaching Party to the Party
in breach. For greater certainty, and without limiting any other material breaches, a breach of Licensee of Section 13.0 shall be deemed to be a material breach of this Agreement. 

  
  27 

 18.6 If this Agreement is terminated pursuant to Section 11.0, 18.1, 18.2, 18.3, 18.4 or
18.5, the Licensee will, within 30 days after the Effective Termination Date, pay all outstanding royalties and milestone payments accrued and owing to the Licensor under Sections 5.0 and 6.0 prior to the date of termination, and the
Licensor may proceed to enforce payment of all outstanding royalties or other monies owing to the Licensor and to exercise any or all of the rights and remedies available under this Agreement or otherwise available by law or in equity, successively
or concurrently, at the option of the Licensor. 
 18.7 As soon as reasonably possible after the Effective Termination Date, and in any
event within six months of such date, the Licensee will deliver to the Licensor all Technology and any Improvements in its possession or control and, except as expressly set out under Section 18.8, thereafter will have no further right of any
nature at all in the Technology or any Improvements. If the Licensee has not delivered up the Technology and any Improvements within the period specified for same, then the Licensee will pay all charges or expenses incurred by the Licensor in the
enforcement of its rights or remedies against the Licensee under this Section 18.7, including without limitation the Licensor’s reasonable legal fees and disbursements. 

18.8 Subject to Section 18.10, the Licensee and all Sublicensees will, as soon as reasonably possible after the Effective Termination
Date, and in any event within six months of such date: (i) cease to use the Technology and any Improvements in any manner at all, and (ii) cease to manufacture or sell the Products (provided that Licensee and all Sublicensees shall cease
to submit new orders to manufacture Products within 5 days of the Effective Termination Date). The Licensee shall deliver to Licensor within 30 days of the Effective Termination Date a written accounting and plan specifying, in such terms as
Licensor may in its reasonable discretion require, the inventory of Products on the Effective Termination Date, and the Licensee’s plan for the disposition of same. Following the delivery of such accounting and plan, the Licensee and its
Sublicensees shall then have a reasonable time to liquidate such inventory of Products, provided that such period shall not exceed six months from the Effective Termination Date. Notwithstanding anything contained in, or any exercise of rights by
the Licensor under, Section 18.7, the Licensee will continue to make royalty payments to the Licensor in the manner specified in Sections 5.0 and 6.0 with respect to all Products that are sold in accordance with this Section 18.8.
Notwithstanding the foregoing, if the Licensor enters into a license of the Technology and Licensor Improvements with a Sublicensee or sub-sublicensee pursuant to Section 18.10, Licensor may direct Licensee to transfer and deliver any remaining
inventory of Products to such Sublicensee or sub-sublicensee, as the case may be, provided that the Sublicensee or sub-sublicensee pays Licensee the Direct Costs of such remaining inventory of Products. 

18.9 Notwithstanding the termination or expiration of this Agreement, Section 12.0 will remain in full force and effect until
six years after: 
  

	 	(a)	 all payments of royalty required to be made by the Licensee to the Licensor under this Agreement have been made by the Licensee to the Licensor;
and 

  

	 	(b)	 any other claim or claims of any nature or kind at all of the Licensor against the Licensee has been settled. 

  
  28 

 18.10 In the event this Agreement is terminated pursuant to Section 11.0, 18.1, 18.2, 18.3,
18.4 or 18.5, and if the Licensee has granted a sublicense under this Agreement or if a Sublicensee has granted a sub-sublicense under this Agreement, provided that: 
  

	 	(a)	 such sublicense or sub-sublicense is consistent with the terms of this Agreement; 

 

	 	(b)	 such sublicense or sub-sublicense is in good standing at the time that this Agreement is terminated; and 

 

	 	(c)	 the termination of this Agreement has not been disputed by the Licensee nor held invalid by a court of competent jurisdiction in a final and
non-appealable decision; 

 then the Licensor will grant a license of the Technology and any Licensor Improvements to such
Sublicensee or sub-sublicensee on substantially the same terms as are contained in the relevant sublicense or sub-sublicense, as the case may be, provided that Section 15.1 (excluding the last sentence thereof) shall apply to such license. For
greater clarity, in granting such license, the Licensor will not modify or amend any of the financial terms contained in the relevant sublicense or sub-sublicense. On request by any Sublicensee or potential Sublicensee, Licensor shall provide such
Sublicensee with a letter confirming the rights of such Sublicensee under this Section 18.10. 
  

	19.0	 MISCELLANEOUS COVENANTS OF THE LICENSEE 

19.1 The Licensee represents and warrants to the Licensor that the Licensee is a company duly organized, existing and in good standing under
the laws of the Province of British Columbia and has the power, authority and capacity to enter into this Agreement and to carry out the transactions contemplated by this Agreement, all of which have been duly and validly authorized by all requisite
corporate proceedings. 
 19.2 The Licensee will comply with all laws, regulations and ordinances, whether federal, state, provincial,
county, municipal or otherwise, with respect to the Technology, any Improvements and this Agreement. 
 19.3 The Licensee will pay all
reasonable legal expenses and costs incurred by the Licensor regarding any consents and approvals required from the Licensor with respect to any sublicenses granted by the Licensee including without limitation expenses and costs regarding the
Licensor’s review of any sublicenses to be granted by the Licensee. The Licensee will pay all reasonable legal expenses and costs incurred by the Licensor in negotiating and drafting the amendment and restatement of this Agreement. 

19.4 The Licensee will pay all taxes and any related interest or penalty designated in any manner at all and imposed as a result of the
existence or operation of this Agreement, including without limitation tax which the Licensee is required to withhold or deduct from payments to the Licensor. The Licensee will provide to the Licensor evidence as may be required by Canadian
authorities to establish that the tax has been paid. The royalties specified in this Agreement are exclusive of taxes. If the Licensor is required to collect a tax to be paid by the Licensee or any of its Sublicensees, the Licensee will pay the tax
to the Licensor on demand. 
 19.5 The obligation of the Licensee to make all payments under this Agreement is absolute and unconditional
and is not, except as expressly set out in this Agreement, affected by any circumstance, including without limitation any set-off, compensation, counterclaim, recoupment, defence or other right which the
Licensee may have against the Licensor, or anyone else for any reason at all. 

  
  29 

 19.6 The Licensee will pay interest on all amounts due and owing to the Licensor under this
Agreement but not paid by the Licensee on the due date, at the rate of 12.68% per annum, calculated annually not in advance. The interest accrues on the balance of unpaid amounts from time to time outstanding, from the date on which
portions of the amounts become due and owing until payment in full. 
  

	20.0	 GENERAL 

20.1 The Licensee will permit the Licensor, during normal business hours, to enter any premises of the Licensee for the purpose of ascertaining
whether or not this Agreement has been, is being, or will be complied with by the Licensee. 
 20.2 Nothing contained in this Agreement is
to be deemed or construed to create between the Parties a partnership or joint venture. No party has the authority to act on behalf of any other party, or to commit any other party in any manner at all or cause any other party’s name to be used
in any way not specifically authorized by this Agreement. 
 20.3 Subject to the limitations in this Agreement, this Agreement operates for
the benefit of and is binding on the Parties and their respective successors and permitted assigns. 
 20.4 No condoning, excusing or
overlooking by any party of any default, breach or non-observance by any other party at any time or times regarding any terms of this Agreement operates as a waiver of that party’s rights under this Agreement. A waiver of any term or right
under this Agreement will be in writing signed by the party entitled to the benefit of that term or right, and is effective only to the extent set out in the written waiver. 

20.5 No exercise of a specific right or remedy by any party precludes it from or prejudices it in exercising another right or pursuing another
remedy or maintaining an action to which it may otherwise be entitled either at law or in equity. 
 20.6 All terms which require
performance by the Parties after the expiry or termination of this Agreement will remain in force despite this Agreement’s expiry or termination for any reason. 

20.7 Part or all of any Section that is indefinite, invalid, illegal or otherwise voidable or unenforceable may be severed and the balance of
this Agreement will continue in full force and effect. 
 20.8 The Licensee acknowledges that the law firm of Richards Buell Sutton has
acted solely for the Licensor in connection with this Agreement and that all other parties have been advised to seek independent legal advice. 

20.9 This Agreement sets out the entire understanding between the Parties and no changes are binding unless signed in writing by the Parties
to this Agreement. 
 20.10 Unless the contrary intention appears, the singular includes the plural and vice versa and words importing a
gender include other genders. 
 20.11 The parties confirm that the Prior Agreement is superseded by this Agreement. For clarity, the
parties however acknowledge and agree that the Prior Agreement remains in effect in accordance with its terms with respect to the period between the Start Date and the Amendment Date, and that the amendments contained in this Agreement (except as
otherwise set out herein) are intended to take effect as of the Amendment Date. 

  
  30 

 IN WITNESS WHEREOF the Parties have executed this Agreement on the
     day of             , 2014, but effective as of the Amendment Date. 
  

	
	 SIGNED FOR AND ON BEHALF of

THE BRITISH COLUMBIA CANCER

AGENCY BRANCH
 by its
authorized signatories:

	
	  

	
	 /s/ Sarah Jane Lee

	 Sarah Jane Lee

	 Director, Technology Development Office

	
	 /s/ Sam Abraham

	 Sam Abraham

	 Vice President, Strategic Relations

	
	 SIGNED FOR AND ON BEHALF of

THE UNIVERSITY OF BRITISH COLUMBIA

by its authorized signatory:

	
	 /s/ Mario Kassapi

	 Mario Kasapi

	 Associate Director, UBC UILO

  

  
  31 

	
	 SIGNED FOR AND ON BEHALF of

ESSA PHARMA INC.
 by its
authorized signatories:

	
	 /s/ Bob Rieder

	 Authorized Signatory

	
	 Bob Rieder, CEO, ESSA Pharma Inc.

	 Please Print Name and Title of Signatory

	
	 /s/ Marianne Sadar

	 Authorized Signatory

	
	 Dr. Marianne Sadar, Director, ESSA Pharam Inc.

	 Please Print Name and Title of Signatory

  
  32 

 SCHEDULE “A” 

DESCRIPTION OF “TECHNOLOGY” 

BADGE PATENTS 
  

																			
	Title	 	Inventors	 	BCCA #	  	UBC #	  	Seed #	  	Cooley #	  	Patent #	  	Assignee	  	File Date	  	Status
	DIGLYCIDIC ETHER DERIVATIVE THERAPEUTICS AND METHODS FOR THEIR USE	 	Marianne Sadar; NR Mawji; Jun (Jean) Wang; Raymond Andersen; David Williams; Mike LeBlanc; Lu-Ping Yan	 	INV-30220	  	08-151	  	405	  	ESSA-001	  	PCT/CA2009/000902	  	BCCA/UBC	  	7/2/2009	  	Converted
	 	 	  	  	  	  	  
 US 12/999,037
	  	  	  	Pending
	 	 	  	  	  	  	  
 US 13/866,933
	  	  	  	Granted
	 	 	  	  	  	  	  
 AU 2009266379
	  	  	  	Pending
	 	 	  	  	  	  	  
 BR PI0913673-8
	  	  	  	Pending
	 	 	  	  	  	  	  
 CA 2728219
	  	  	  	Pending
	 	 	  	  	  	  	  
 CL 1624-2010
	  	  	  	Pending
	 	 	  	  	  	  	  
 CN 200980125734.X
	  	  	  	Pending
	 	 	  	  	  	  	  
 CO 11011677
	  	  	  	Pending
	 	 	  	  	  	  	  
 EP 09771876.1
	  	  	  	Pending
	 	 	  	  	  	  	  
 HK 11104547.7
	  	  	  	Pending

  
 A-1 

																			
	 	 	 	 	 	 	 	 	 	 	 	 	  
 ID W-00201100409
	 	 	 	 	 	Pending
	 	 	 	 	 	 	  
 IL 210120
	 	 	 	Pending
	 	 	 	 	 	 	  

IN 824/DELNP/2011
	 	 	 	Pending
	 	 	 	 	 	 	  
 JP 2011-515039
	 	 	 	Pending
	 	 	 	 	 	 	  

KP 10-2011-7002474
	 	 	 	Pending
	 	 	 	 	 	 	  
 MX/a/2010/014372
	 	 	 	Granted
	 	 	 	 	 	 	  
 NZ 589759
	 	 	 	Granted
	 	 	 	 	 	 	  
 RU 2011103538
	 	 	 	Pending
	 	 	 	 	 	 	  
 TR 10/11157
	 	 	 	Pending
	 	 	 	 	 	 	  
 ZA 2011/0507
	 	 	 	Granted
	BISPHENOL COMPOUNDS AND METHODS FOR THEIR USE	 	Marianne Sadar; NR Mawji; Jun (Jean) Wang; Carmen Banuelos; Raymond Andersen; Javier Garcia Fernandez	 	INV-15-007	 	13-106	 	402	 	ESSA-002	 	WO2012/139039	 	BCCA/UBC	 	4/6/2012	 	Converted
	 	 	 	 	 	 	  
 US 14/110,615
	 	 	 	  

Pending

	 	 	 	 	 	 	  
 EP 12768410.8
	 	 	 	  

Pending

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	ESTER DERIVATIVES OF ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE	 	Marianne Sadar; NR Mawji; Jun (Jean) Wang; Carmen Banuelos; Raymond Andersen; Javier Garcia Fernandez	 	INV-15-011	 	08-151	 	418	 	ESSA-003	 	61/822186	 	BCCA/UBC	 	5/10/2013	 	Pending

  
 A-2 

																			
	 	 	 	 	 	 	 	 	 	 
	ACHIRAL GROUP CONTAINING BISPHENOL DERIVATIVE THERAPEUTICS AND METHODS FOR THEIR USE	 	Marianne Sadar; NR Mawji; Carmen Banuelos; Raymond Andersen; Javier Garcia Fernandez	 	INV-10-012	    	11-041	    	407	    	ESSA-006	    	61/282,238	    	BCCA/UBC	    	1/6/2010	    	Lapsed
	  

BISPHENOL DERIVATIVES AND THEIR USE AS ANDROGEN RECEPTOR ACTIVITY MODULATORS
	 	 	    	    	    	    	  
 US 13/520729
	    	    	1/6/2011	    	Pending
	 	 	    	    	    	    	  
 CA 2786319
	    	    	    	Pending
	 	 	    	    	    	    	  
 EP 11731645.5
	    	    	    	Pending
	 	 	    	    	    	    	  
 JP 2012-547415
	    	    	    	Pending
	 	 	 	 	 	 	 	 	 	 
	BISPHENOL COMPOUNDS AND METHODS FOR THEIR USE	 	Marianne Sadar; NR Mawji; Carmen Banuelos; Raymond Andersen; Javier Garcia Fernandez	 	INV-10-013	    	11-042	    	408	    	ESSA-007	    	61/282,234	    	BCCA/UBC	    	1/6/2011	    	Lapsed
	 	 	 	 	 	 	 	 	 	 
	BISPHENOL DERIVATIVE THERAPEUTICS AND METHODS FOR THEIR USE	 	 	 	 	    	 	    	 	    	 	    	US 13/520731	    	 	    	 	    	Pending
	 	 	 	 	 	 	 	 	 	 
	FLUORINATED BISPHENOL ETHER COMPOUNDS AND METHODS FOR THEIR USE	 	Marianne Sadar; NR Mawji; Jun (Jean) Wang; Raymond Andersen; Javier Garcia Fernandez; Carmen Adriana Banuelos	 	INV-15-006	    	13-070	    	409	    	ESSA-008	    	13/588922; US2012/051481	    	BCCA/UBC	    	8/17/2012	    	Pending
	 	 	    	    	    	    	  
 EP 12762710.7
	    	    	    	Pending

  
 A-3 

																			
	 	 	 	 	 	 	 	 	 	 
	AZIRIDINE BISPHENOL ETHERS AND RELATED COMPOUNDS AND METHODS FOR THEIR USE	 	Marianne Sadar; Raymond Andersen	 	INV-15-008	    	13-108	    	412	    	ESSA-010	    	13/863,849; US 20130336962	    	BCCA/UBC	    	4/16/2013	    	Pending
	 	 	 	 	 	 	 	 	 	 
	BISPHENOL ETHER COMPOUNDS WITH NOVEL BRIDGING GROUPS AND METHODS FOR THEIR USE	 	Marianne Sadar; Raymond Andersen; Javier Garcia Fernandez; Banuelos, Carmen Adriana; Mawji, Nasrin	 	INV-15-009	    	08-151	    	414	    	ESSA-011	    	61/842657	    	BCCA/UBC	    	7/3/2013	    	Pending
	 	 	 	 	 	 	 	 	 	 
	FLUORO-CHLORO BISPHENOL ETHER COMPOUNDS AND METHODS FOR THEIR USE	 	Marianne Sadar; Raymond Andersen; Javier Garcia Fernandez	 	INV-15-010	    	08-151	    	416	    	ESSA-013	    	61/890670	    	BCCA/UBC	    	10/14/2013	    	Pending
	 	 	 	 	 	 	 	 	 	 
	18F COMPOUNDS FOR CANCER IMAGING AND METHOD FOR THEIR USE	 	Marianne Sadar; Raymond Andersen; Javier Garcia Fernandez; Donald T. Yapp; Kuo-Shyan Lin; Francois Benard; Hsing Chen (Amy) Tien	 	INV-13-006	    	08-151	    	417	    	ESSA-014	    	61/890679	    	BCCA/UBC	    	10/14/2013	    	Pending

  
 A-4 

																			
	 	 	 	 	 	 	 	 	 	 
	1231 COMPOUNDS FOR CANCER IMAGING AND METHODS FOR THEIR USE	 	Marianne Sadar; NR Mawji; Jun (Jean) Wang; Carmen Banuelos; Yusuke Imamura; Raymond Andersen; Javier Garcia Fernandez; Jian Kunzhong; Tien, Hsing Chen (Amy)	 	INV-15-012	    	08-151	    	419	    	ESSA-015	    	61/875556	    	BCCA/UBC	    	9/9/2013	    	Pending

  
 A-5 

 OTHER PATENTS 
  

																			
	 SMALL
MOLECULE INHIBITORS
  
 OF N-TERMIUS ACTIVATION OF

 
 THE ANDROGEN RECEPTOR
	 	 Marianne Sadar; NR

Mawji; Jun (Jean)
 Wang; Raymond

Andersen; David
 Williams; Mike LeBlanc;

Lu-Ping Yan
	 	INV-08-026	    	09-137	    	406	    	N/A	    	PCT/CA2009/001173	    	BCCA/UBC	    	8/24/2009	    	Converted
	 	 	    	    	    	    	  
 US 12/999035
	    	    	    	Pending
	 	 	    	    	    	    	  
 AU 2009284668
	    	    	    	Pending
	 	 	    	    	    	    	  
 CA 2728103
	    	    	    	Pending
	 	 	    	    	    	    	  
 CL 341-2011
	    	    	    	Pending
	 	 	    	    	    	    	  
 CN 200980132751.6
	    	    	    	Pending
	 	 	    	    	    	    	  
 EP 09807798.5
	    	    	    	Pending
	 	 	    	    	    	    	  
 HK 11107462.1
	    	    	    	Pending
	 	 	    	    	    	    	  

IN 1796/CHENP/2011
	    	    	    	Pending
	 	 	    	    	    	    	  
 MX/a/2011/001890
	    	    	    	Pending
	 	 	    	    	    	    	  
 NZ 605160
	    	    	    	Pending
	 	 	    	    	    	    	  
 RU 2011110743
	    	    	    	Pending

  
 A-6 

 SCHEDULE “B” 

PAYMENT REPORT FOR THE PERIOD DD/MM/YY TO DD/MM/YY 

Instructions for Completing this Report 

Please fill out each section in full, identifying in the Royalty Summary Table the unit sales and geographical sales areas. If the license with
BCCA/UBC involves several product lines, please prepare a separate Summary Table for each product line. For licenses involving sublicensing revenue, please prepare an additional report for each sublicense. 

PLEASE NOTE: An interest rate of 12.68% per annum, calculated annually not in advance will be assessed against all payments in
arrears. 
  

											
	 Licensee
				 Agreement #
				 BCCA ID #
		
	 (or sublicensee)
		  
				  
				  

						
									 UBC File #
		  

 BCCA/UBC Technology 

Report Type (check one and complete as appropriate) 
  

									
	 Single Product Line
		  ̈
		 Product Line Trade Name
		  

			
	 Multiple Products
		  ̈
		
Page      Of          Product Line Trade Name      
                                         
                                         
                        

					
	 Sublicense Report
		  ̈
		 Page      Of     
				

 Payments this Quarter (please complete separate tables for multiple product lines) Royalties on Product Sales 

 

																			
	 Country
	  	Units
Sold	  	Unit Price
(domestic
currency)	  	Gross
sales	  	Less
Allow-
ances*	  	Net
Sales	  	Royalty
Rate	  	Conversion
Rate (to
Canadian $)	  	Period Royalty Amount
(Canadian $)
	  	  	  	  	  	  	  	  	This yr	  	Last yr
										
	 Canada
	  		  		  		  		  		  		  		  		  	
	 US
	  		  		  		  		  		  		  		  		  	
	 Europe
	  		  		  		  		  		  		  		  		  	
	 (specify countries)
	  		  		  		  		  		  		  		  		  	
										
	 Other
	  		  		  		  		  		  		  		  		  	
		  		  		  		  		  		  		  		  	  
	  	  

										
	 Total Product Royalties
																		
		  		  		  		  		  		  		  		  	  
	  	  

 Additional Payments (complete all that apply) 

 

											
	 Minimum Royalty Fee
		      				Amount				
		  		  		  		  	  
	  	  

	 Milestone Payment
		      				Amount				
		  		  		  		  	  
	  	  

	 Annual License Maintenance Fee
		      				Amount				
		  		  		  		  	  
	  	  

			
	 	  	This Year	  	Last Year
	 Total Payments for Period
	  		  		  		  		  	
		  		  		  		  	  
	  	  

  

	*	 Please indicate the reasons for returns or other allowances, if significant. Please note any unusual occurrences that affected royalty amounts
during the period. 

  

											
	 Prepared by
		  
		 Date
		 Dd/mm/yy
		 Phone
		  

 I
                                         (print
name),                                         
(title) hereby certify the foregoing information as true and correct. 
  

			
	  

	             Signature
		 Date Signed

  
 B-1 

 SCHEDULE “C” 

BCCA / UBC LICENSE AGREEMENT ANNUAL REPORT 

The information to be completed below shall constitute the annual report required pursuant to the BCCA/UBC License Agreement. Any information
or documents provided by the Licensee in this report shall not be interpreted as affecting the express rights and obligations of the Licensee contained in the License Agreement. This report is in addition to the Payment Report to accompany each
royalty payment. 
  

							
	 Date of Report:
		  
		 Person Preparing This Report:
		  

				
	 Name of Licensee:
		  
		 BCCA/UBC File Number:
		  

				
	 Jurisdiction of Corporation:
		  
		 Head Office Address:
		  

		
	 Contact Person for Company
		  

		
	 Licensed Technology:
		  

				
	 Telephone Number:
		  
		 E-mail Address:
		  

  

	 	1.	 Please provide a brief report on the status of development of the Technology, progress on creating a commercial Product or subsequent marketing of
the Product as appropriate. 

			
			  

			  

  

	 	2.	 Has the Licensee filed any patent applications for modifications or improvements relating to the original Technology? Please provide details, and
attach copies of all relevant documents. 

			
			  

			  

  

	 	3.	 Has the Licensee become aware of any potential third party infringing on the Patents or related intellectual property? If so please provide details
and outline what the Licensee is doing about this. 

			
			  

			  

  

	 	4.	 Has the Licensee met any milestone or performance objectives in the past year as set forth in the License Agreement? Please outline the past
year’s accomplishments. 

			
			  

			  

  

	 	5.	 Does the Licensee expect to meet any milestone or performance objective in the coming year as set forth in the License Agreement? If so please
provide details. 

			
			  

			  

  

	 	6.	 If applicable, has the Licensee granted sublicenses to third parties and if so have copies of the sublicense agreement been provided to the
Technology Manager at BCCA? If not, please enclose a copy of each sublicense agreement. 

			
			  

			  

  

	 	7.	 Has the Licensee made any sales in the last 12 months?    Yes      No     

 If so please submit a completed Royalty Payment Report. 

 

	 	a)	 Date of sales of Products utilizing the Technology; 

  
 C-1 

  

	 	b)	 Date of any clinical trials. 

			
			  

			  

  

	 	8.	 Does your company have public liability insurance? If so, please attach a copy of the insurance policy naming the Licensor as insured as required
by the License Agreement. 

			
			  

			  

  

	 	9.	 Please provide the Licensee’s estimate or projection of gross sales revenue for products based on the Technology for the next 12 months
by the Licensee and any sub-licensee. 

			
			  

			  

  

	 	10.	 Is there any other information relating to this License that you think we should be aware of? Please summarize them below or contact us directly.

			
			  

			  

  

											
	 Prepared by
		  
		 Date
		 Dd/mm/yy
		 Phone
		  

 I
                                         (print
name), of
                                         (title)
hereby certify the foregoing information as true and correct. 
  

					
	  

	 Signature
				Date Signed                            
	
	 Once completed, please submit this report to:

			
			 Director
		
			 Technology Development Office
		
			 British Columbia Cancer Agency
		
			 675 West 10th Ave
		
			 Vancouver, BC
		
			 V5Z 1L3
		
			
	 And to:
				
			
			 Managing Director
		
			 University – Industry Liaison Office
		
			 #103 – 6190 Agronomy Road
		
			 Vancouver, BC
		
			 V6T 1Z3
		

  
 C-2 

 SCHEDULE “D” 

ADDRESS FOR NOTICES AND PAYMENT INSTRUCTIONS 

1. The address for delivery of notices to BCCA is: 
  

			
	 Director

Technology Development Office

British Columbia Cancer Agency Branch

675 West 10th Ave

Vancouver, British Columbia
 V5Z
1L3

	 Telephone:
		 (604) 675-8198

	 Fax:
		 (604) 675-8189

 2. Payment of all amounts due to the Licensor under the terms of this License may be made as follows: 

 

	 	a)	 by cheque made payable to “BC Cancer Agency” delivered to BCCA at the above address; or 

 

	 	b)	 by wire transfer please contact BCCA for the deposit information. 

3. The address for delivery of notices to UBC is: 
  

			
	 The Director

University – Industry Liaison Office

University of British Columbia

#103 – 6190 Agronomy Road

Vancouver, British Columbia
 V6T
1Z3

	 Telephone:
		 (604) 822-8580

	 Fax:
		 (604) 822-8589

  
  D-1 

 SCHEDULE “E” 

CONFIDENTIAL INFORMATION 
  

	1.	 The Option Agreement dated November 10, 2010 between the Licensor and the Licensee (including the schedules thereto). 

 

	2.	 Any chemical structural information beyond Badge/ EPI-001 and sintokamides. 

 

	3.	 Any information relating to the primary N-terminus assay technology. 

 

	4.	 The specific text of all provisionals filed and pending patents listed in Schedule “A” to the License Agreement.

  

	5.	 Any information that has not already been publicly disclosed relating to the mechanism of action for interaction of compounds comprising the
technology with the N-terminus domain of the androgen receptor. 

  
  E-1 

 SCHEDULE “F” 

RESTRICTIONS ON TRANSFER AND DRAG-ALONG/TAG-ALONG RIGHTS 

ARTICLE 26 
 PROHIBITIONS

  

	26.1	 Definitions 

In this Article 26: 
  

	 	(a)	 “designated security” means: 

  

	 	(i)	 a voting security of the Company; 

  

	 	(ii)	 a security of the Company that is not a debt security and that carries a residual right to participate in the earnings of the Company or, on the
liquidation or winding-up of the Company, in its assets; or 

  

	 	(iii)	 a security of the Company convertible, directly or indirectly, into a security described in Article 26.1(a)(i) or (ii); 

 

	 	(b)	 “security” has the meaning assigned in the Securities Act (British Columbia); and 

 

	 	(c)	 “voting security” means a security of the Company that: 

 

	 	(i)	 is not a debt security; and 

  

	 	(ii)	 carries a voting right either under all circumstances or under some circumstances that have occurred and are continuing. 

 

	26.2	 Application 

Article 26.3 does not apply to the Company if and for so long as it is a public company or a pre-existing reporting company which has the Statutory Reporting Company Provisions as part of its Articles or to which the Statutory Reporting Company Provisions apply. 

 

	26.3	 Consent Required for Transfer of Shares or Designated Securities 

No share or designated security may be sold, transferred or otherwise disposed of without the consent of the directors and the
directors are not required to give any reason for refusing to consent to any such sale, transfer or other disposition. 

  
 F-1 

 ARTICLE 27 

DRAG-ALONG RIGHTS 
  

	27.1	 Notwithstanding any other provision of these Articles, if: 

 

	 	(a)	 one or more shareholders holding not less than 50.1% of the total number of shares of the Company then issued and outstanding (in this
Article 27, the “Accepting Shareholders”) have agreed to transfer all of their shares to a person or persons acting at arm’s length to the Accepting Shareholders (in this Article 27, a “Purchaser”);
and 

  

	 	(b)	 the Purchaser offers to purchase from each of the other shareholders (in this Article 27, the “Remaining Shareholders”) all
of the shares of the Company held by the Remaining Shareholders (in this Article 27, the “Remaining Shares”) for the same consideration and on the same terms and conditions as those agreed to by the Accepting Shareholders, and
all such terms and conditions are set out in writing in a notice delivered to the Remaining Shareholders (in this Article 27, the “Drag-Along Offer”), 

then the Remaining Shareholders shall be required to sell and transfer the Remaining Shares to the Purchaser on the terms and conditions set
out in the Drag-Along Offer. 
 27.1 If any of the Remaining Shareholders (in this Article 27, the “Delinquent
Holders”) fails to transfer its Remaining Shares to the Purchaser on the terms and conditions set out in the Drag-Along Offer, the Purchaser shall have the right to deposit the applicable consideration for such Remaining Shares in a special
account at any financial institution or in a trust account of the Company’s lawyers in Canada, to be paid, without interest, to such Delinquent Holder upon presentation and surrender to such financial institution or solicitors, as applicable,
of the share certificates representing such Delinquent Holder’s Remaining Shares, duly endorsed for transfer to the Purchaser. Upon such deposit being made, the Remaining Shares in respect of which the deposit was made shall be automatically
(without any further action of any kind on the part of the Delinquent Holder or the Purchaser) be deemed to be transferred to and purchased by the Purchaser and shall be transferred on the registers of the Company to the Purchaser and the rights of
the Delinquent Holder in respect of such Remaining Shares after such deposit shall hereby be limited to receiving, without interest, the amount so deposited against presentation and surrender of the certificates representing such Remaining Shares,
duly endorsed for transfer to the Purchaser. 
 27.2 The Company, or any officer thereof, shall be and hereby is irrevocably constituted and
appointed as the true, lawful and irrevocable attorney of each Delinquent Holder, with full power of substitution, to execute all documents and take any and all actions as may be necessary or desirable to perform any and all obligations of the
Delinquent Holder arising pursuant to this Article 27, and in executing such documents and taking such actions, to use the name of the Delinquent Holder whenever and wherever it may be considered necessary or expedient. 

27.3 Articles 27.1, 27.2 and 27.3 will not apply if and for so long as the Company is a public company. 

  
 F-2 

 ARTICLE 28 

TAG-ALONG RIGHTS 
 28.1 If
any shareholder or shareholders (this Article 28, the “Accepting Shareholders”) receive(s) an offer to purchase shares representing more than 50.1% of all of the shares of the Company then issued and outstanding (in this
Article 28, an “Offer”), which they are prepared to accept, from a person or persons acting at arm’s length to the Accepting Shareholders (in this Article 28, the “Purchaser”), then, prior to the
acceptance of the Offer, the Accepting Shareholders shall notify all of the other shareholders of the Company (in this Article 28, the “Remaining Shareholders”) of the Offer, and the terms and conditions thereof, and each of
the Remaining Shareholders shall have the right, at its option, to require that a proportionate number of its shares be purchased by the Purchaser on terms and conditions at least as favorable to such Remaining Shareholder as the terms and
conditions set out in the Offer received by the Accepting Shareholders. If the Purchaser does not agree to purchase all of the shares which the Accepting Shareholders and Remaining Shareholders wish to sell pursuant to this Article 28.1, the
number of shares which the Accepting Shareholders and Remaining Shareholders shall be permitted to sell to the Purchaser shall be proportionately reduced so that each shareholder may sell to the Purchaser the same percentage of its total outstanding
shares. The Remaining Shareholders may only exercise the rights provided for in this Article 28.1 by giving written notice thereof to the Accepting Shareholders and the Purchaser within fourteen (14) days after the date on which the
Remaining Shareholders are notified of the Offer by the Accepting Shareholders pursuant to this Article 28.1. 
  

	28.2	 Article 28.1 will not apply if and for so long as the Company is a public company. 

  
 F-3 

 SCHEDULE “G” 

NEW LICENSEE SHAREHOLDERS 
  

					
	 Name of Shareholder
	  	Number of Shares	 
		
	 *****
	  	 	*****	  
		
	 *****
	  	 	*****	  
		
	 *****
	  	 	*****	  
		
	 *****
	  	 	*****	  
		
	 *****
	  	 	*****	  
		
	 *****
	  	 	*****	  
		
	 *****
	  	 	*****	  
		
	 *****
	  	 	*****	  
		
	 *****
	  	 	*****	  
		
	 *****
	  	 	*****	  
		
	 *****
	  	 	*****	  
		  	  
	  
	 
		
	 TOTAL
		 	*****	  
		  	  
	  
	 

  
 G-1 

 SCHEDULE “H” 

MATERIAL TRANSFER AGREEMENT BETWEEN 

UBC AND UNIVERSITY OF WASHINGTON DATED NOVEMBER 16, 2010 

UBC File: MO 11-058 

MATERIAL TRANSFER AGREEMENT 
 BETWEEN:

 THE UNIVERSITY OF BRITISH COLUMBIA, a corporation continued under the University Act of British Columbia and
having offices at 103-6190 Agronomy Road, Vancouver, British Columbia, Canada V6T 1Z3, Attention: University-Industry Liaison Office, Telephone: 604-822-8580, Facsimile: 604-822-8589, on behalf of Dr. Raymond Andersen and Dr. Marianne
Sadar (“Provider Scientists”), E-mails: randersn@interchange.ubc.ca; msadar@bccancer.bc.ca 

(together, The University of British Columbia and Provider Scientist will be known as the “Provider”) 

AND: 
 UNIVERSITY OF
WASHINGTON (“Recipient Institution”), an agency of the State of Washington, operating through its Center for Commercialization and having offices at 4311 11th Ave NE, Seattle WA,
98105, USA, Telephone: 206-543-3970, Facsimile: 206-685-4767, on behalf of Dr. Stephen R. Plymate (“Recipient Scientist”), Telephone: 206-897-5275; e-mail: splymate@u.washington.edu  

(together, Recipient Institution and the Recipient Scientist will be known as the “Recipient”) 

WHEREAS: 
 As of April 1, 2005, The University of
British Columbia includes both Vancouver and Okanagan campuses; 
 Provider wishes to provide Recipient, and Recipient wishes to obtain from
Provider, certain proprietary information and biological materials on terms and conditions set out In this Agreement. 
 THE PARTIES AGREE AS FOLLOWS:

  

	1.	 DEFINITIONS. 

  

	 	1.1	 In this Agreement, the following words have the following definitions: 

  
 H-1 

	 	(a)	 “Commercial Purposes” means the sale, lease, license or other exploitation of the Material, Information or Modifications to a
person for profit, including, but not limited to, use of the Material, Information or Modifications by Recipient or any individual or organization to perform contract research, to screen compound libraries, to produce or manufacture products for
general sale, or to conduct research activities that result in any sale, lease, license or other exploitation of the Material, Information or Modifications to any individual or organization for profit. For greater certainty, academic research
sponsored by government or industry does not fall within the definition of “commercial purposes” unless the sponsor retains rights, title or interests in and to the Material, Information or Modifications; or unless the research activities
result in any sale, lease, license or other exploitation of the Material, Information or Modifications to any individual or organization for profit. 

  

	 	(b)	 “Information” means any and all information, know-how, techniques or practices that Provider discloses to Recipient in writing and
identified as CONFIDENTIAL at the time of disclosure relating to the Material or its use and includes all research, data, specifications, plans, drawings, prototypes, recordings, instructions, manuals, papers or other materials so disclosed, but
excludes any Information that: 

  

	 	(i)	 was already in the possession of Recipient and evidenced by written documents existing prior to the date of disclosure of the Information by
Provider to Recipient; 

  

	 	(ii)	 is publicly known at the time of the disclosure or later becomes publicly known other than through a breach of this Agreement by Recipient;

  

	 	(iii)	 is required to be disclosed under applicable laws, regulations or orders of any governmental authority; 

 

	 	(iv)	 is furnished by Provider to others without restrictions on its use or disclosure; 

 

	 	(v)	 is subsequently disclosed to the Recipient by a third party who Recipient has no reason to believe is under confidentiality obligations to
Provider; or 

  

	 	(vi)	 is independently developed by Recipient without use of the Information. 

Oral or visual disclosure of any Information will be reduced to writing within 30 days. 

  
 H-2 

	 	(c)	 “Inventions” means any discoveries, improvements, processes or inventions made by Recipient through use of the Material,
Modifications or Information. 

  

	 	(d)	 “Material” means the Original Material, any Progeny or Unmodified Derivatives. 

 

	 	(e)	 “Modifications” means substances created by Recipient, which contain or incorporate any form of the Material (including Original
Material, Progeny or Unmodified Derivatives). 

  

	 	(f)	 “Original Material” means the original material being transferred to Recipient as described in Schedule “A” of this
Agreement. 

  

	 	(g)	 “Progeny” means unmodified descendant from the Material (for example, virus from virus, cell from cell, or mouse from mouse).

  

	 	(h)	 “Research Project” means the research described in Schedule “A” of this Agreement. 

 

	 	(i)	 “Unmodified Derivatives” means substances created by Recipient, which constitute an unmodified functional subunit or product
expressed by the Original Material (for example, subclones of unmodified cell lines, purified or fractionated subsets of the original material, proteins expressed by DNA/RNA supplied by Provider, or monoclonal antibodies secreted by a hybridoma cell
line). 

  

	2.	 LICENSE OF MATERIAL & INFORMATION. 

  

	 	2.1	 Subject to the terms and conditions of this Agreement, Provider hereby grants to Recipient a non-transferable, non-exclusive license to use the
Material and Information in the Research Project for academic research purposes only, for a period commencing on the date authorized Provider signs this Agreement and ending 1 year thereafter unless terminated earlier in accordance with this
Agreement. 

  

	3.	 RESTRICTIONS ON USE. 

  

	 	3.1	 Recipient will not: 

  

	 	(a)	 make Modifications of the Material without the express written consent of the Provider, with the exception of the Research Project described in
Schedule “A”; 

  

	 	(b)	 use the Material, Modifications or Information for Commercial Purposes; 

  
 H-3 

	 	(c)	 use the Material or Modification in human subjects, whether in clinical trials or otherwise and whether for therapeutic, preventive, diagnostic or
other purposes; 

  

	 	(d)	 use the Material, Modifications or Information in research projects that grant sublicense, ownership or other proprietary rights in the Material,
Modifications or Information to a third party; or 

  

	 	(e)	 provide or make available to anyone outside of Recipient Scientist’s direct supervision, or to any third party for any purpose whatsoever the
Material, Information or Modifications without the prior written consent of Provider whose consent may be withheld at its sole discretion. 

  

	4.	 4.0 TRANSMITTAL FEE 

  

	 	4.1	 To reimburse Provider for preparation and distribution costs: 

Amount: $0.00 

Recipient’s FedEx Account No.: 2777-0216-9 
  

	5.	 OWNERSHIP, PROGRESS REPORTS & INVENTIONS 

 

	 	5.1	 Provider retains all rights, title and interest in and to the Material, Information, Modifications and Inventions. Material and Information may be
subject to patent protection. 

  

	 	5.2	 Recipient will provide Provider with a written report on the progress of the Research Project every three months. 

 

	 	5.3	 Recipient will promptly notify Provider in writing within 30 days of any Inventions. Nothing in this Agreement grants any rights under any patents
or in any know-how of Provider nor any rights to use the Materials, Information, Modifications, or Inventions for profit-making or Commercial Purposes such as, but not limited to production, sale, screening or drug design. 

 

	 	5.4	 Nothing in this Agreement grants any rights under any patents or in any know-how of Provider nor any rights to use the Materials or Information for
profit-making or Commercial Purposes such as, but not limited to production, sale, screening or drug design. 

  

	6.	 DISCLAIMER OF WARRANTIES 

  

	 	6.1	 The Material and Information are being provided by Provider to Recipient on an “AS IS” basis and the Material is understood to be
experimental in nature. Any use of the Material or Information by Recipient will be at the sole risk and liability of Recipient, whether or not Provider has consented or acquiesced to such use. PROVIDER MAKES NO REPRESENTATION OR WARRANTY, WHETHER
EXPRESSED OR IMPLIED, WITH RESPECT TO THE MATERIAL AND INFORMATION, INCLUDING ANY REPRESENTATION OR WARRANTY AS TO THE DURABILITY, STORAGE, DISPOSAL, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR TO THE NON-INFRINGEMENT OF THE MATERIAL AND
INFORMATION ON THE PROPRIETARY RIGHTS OF A THIRD PARTY. ALSO, PROVIDER WILL NOT BE LIABLE FOR ANY INDIRECT, SPECIAL, INCIDENTAL OR CONSEQUENTIAL DAMAGE OR LOSS ARISING OUT OF OR RELATED TO THE FOREGOING EVEN IF PROVIDER HAS BEEN ADVISED OF THE
POSSIBILITY OF SUCH DAMAGE OR LOSS. 

  
 H-4 

	7.	 REGULATION 

  

	 	7.1	 Both parties will abide by their respective ethical institutional review board (“IRB”) and all applicable laws and regulations
with regards to the use and transfer of the Material. 

  

	8.	 LIABILITY 

  

	 	8.1	 Recipient assumes all liability for damages, which may arise from its use, storage or disposition of the Material. Provider will not be liable to
Recipient for any loss, claim or demand made by Recipient, or made against Recipient by any other party, due to arising from the use of the Material by Recipient. 

 

	9.	 CONFIDENTIALITY 

  

	 	9.1	 Subject to Article 10 (Publication), during the term of this Agreement and for a period of 3 years after the termination of this Agreement,
Recipient will use reasonable efforts to maintain the confidentiality of the Material and Information (whether or not owned or developed by Provider or disclosed to Provider by a third party whose material or information Provider is obligated to
treat as confidential or proprietary) and to prevent any unauthorized access, reproduction, disclosure and/or use of the Material and Information. 

  

	10.	 PUBLICATION 

  

	 	10.1	 If Recipient wishes to present or publish results of research conducted using the Material or Information, Recipient will submit a copy of the
proposed presentation or publication to Provider at least 30 days in advance of the presentation or publication submission date to allow Provider time to review and identify any disclosure of its confidential or proprietary information. If Provider
responds within the 30 day period and identifies its Information, Recipient shall remove such information before publication or presentation. If Provider responds to Recipient within the 30 day period and identifies patentable subject matter for
which Provider desires to have patent applications filed, Recipient shall delay publication for a maximum of 90 days from date of original disclosure to allow Provider an opportunity to file the required patent applications. The parties agree that
any publication made pursuant to this Agreement shall be made in accordance with the custom of scientific research and shall acknowledge the contribution of the parties’ scientists, as appropriate. 

  
 H-5 

	11.	 TERMINATION 

  

	 	11.1	 This Agreement may be terminated immediately upon the occurrence of any one of the following events: 

 

	 	(a)	 Recipient notifies Provider in writing that the Research Project has been completed or terminated; 

 

	 	(b)	 Recipient becomes bankrupt or insolvent or a receiver is appointed to take possession of Recipient’s business or property or Recipient has
assigned its interest to creditors; 

  

	 	(c)	 Recipient is more than 30 days in arrears of any monies that are due to Provider under this Agreement; 

 

	 	(d)	 Recipient commits a breach of Article 3 (Restriction on Use), 9 (Confidentiality) or 10 (Publication); 

 

	 	(e)	 Recipient terminates the non-exclusive license granted to Provider under Article 5; or 

 

	 	(f)	 giving of at least 30 days written notice by one party to the other of its intention to terminate this Agreement in the absence of a breach of any
of the provisions of this Agreement. 

  

	 	11.2	 Articles 3, 5, 6, 8, 9, 10 and 12 will survive the expiration or earlier termination of this Agreement. 

 

	12.	 RETURN, DESTRUCTION or CONTINUED USE OF MATERIAL & INFORMATION 

 

	 	12.1	 On the expiration or earlier termination of this Agreement, Recipient will, on the written direction of Provider, return or destroy the Material
and Information. However, at the request of Recipient, Provider may extend the term of this Agreement with respect to provisions governing Modifications so that Recipient can continue to use the Material contained or incorporated in the
Modifications. Upon request, Recipient will send Provider samples of Modifications, for academic research only. 

  

	13.	 NOTICES 

  

	 	13.1	 All payments, reports and notices or other communication required or desired to be given or delivered under this Agreement will be given in writing
and delivered by person, by registered mail, or by fax, addressed to the party at its address first set out above or such other address as the party otherwise advise in writing. Any notice personally delivered or sent by fax will be deemed to have
been given or received at the time of delivery or transmission. Any notice mailed will be deemed to have been received on the expiration of 5 days after it is posted, provided that if, at the time of mailing or between the time of mailing and actual
receipt, there is a postal strike, slow down or labour dispute which might affect the delivery of the notice, then the notice will only be effective if actually delivered or faxed. 

  
 H-6 

	14.	 ASSIGNMENT 

  

	 	14.1	 Recipient will not assign this Agreement, in whole or in part, without the prior written consent of Provider, whose consent may not be unreasonably
withheld. 

  

	15.	 GOVERNING LAW 

  

	 	15.1	 This Agreement will be governed by and construed under the laws of British Columbia and the applicable laws of Canada without reference to its
conflict of law rules. Nothing in the foregoing sentence will prevent Provider from applying to any court of competent jurisdiction for injunctive relief for any actual or threatened breach of confidentiality obligations by Recipient.

  

	16.	 GENERAL 

  

	 	16.1	 If any provision of this Agreement is deemed to be invalid or unenforceable, such provision or provisions will be deemed modified to the extent
necessary to render the same valid or enforceable, or if such modification is not possible, the remaining terms and provisions of this Agreement will be construed and enforced as if the invalid or unenforceable provision or provisions did not exist.

  

	 	16.2	 The headings of the sections of this Agreement are inserted for convenience only and do not in any way limit or amplify the provisions of this
Agreement. 

  

	 	16.3	 No provision of this Agreement will be deemed waived or any breach excused, unless such waiver or consent excusing the breach is in writing signed
by the party giving the waiver or consent. A waiver of a provision of this Agreement will not be construed to be a waiver of a subsequent breach of the same provision. 

 

	 	16.4	 This Agreement contains the entire agreement and understanding of the parties with respect to the subject matter of this Agreement and supersedes
all prior proposals, negotiations, agreements, understandings, representations and warranties of any form or nature, whether oral or written, and whether express or implied, which may have been entered into between the parties relating to its
subject matter. 

  

	 	16.5	 Each party will execute and deliver such further agreements and other documents and do such further acts and things as the other parties reasonably
request to evidence, carry out or give full force and effect to the intent of this Agreement. 

  
 H-7 

	 	16.6	 This Agreement may be executed in counterpart by the Parties, either through original copies or by facsimile. An executed copy of this Agreement
delivered by facsimile will constitute valid execution and delivery of this Agreement. 

 In signing this
Agreement, the signatories confirm that they have the authority of their respective organizations to enter into the obligations of the Agreement. 

[signature page follows] 

  
 H-8 

 SIGNED BY THE PARTIES AS AN AGREEMENT and effective as of the date of the last signature. 

 

													
	THE UNIVERSTIY OF BRITISH COLUMBIA		UNIVERSTIY OF WASHINGTON
					
	Signature:		/s/ Mario A. Kasapi				Signature:		/s/ Ariadne A. Santander
	Title:		Associate Director				Title:		Agreement Office
					
			University – Industry Liaison Office						Center for Commercialization University of Washington
					
	Date:		11/16/2010				Date:		11/8/2010

 The scientists of the respective organizations hereby acknowledge that they have read and will comply with the
terms of this Agreement. 
  

													
	PROVIDER’s SCIENTISTS		RECIPIENT’s SCIENTI
					
	Signature:		/s/ Dr. Raymond Andersen				Signature:		/s/ Dr. Stephen R. Plymate
	Name:		Dr. Raymond Andersen				Name:		Dr. Stephen R. Plymate
					
	Date:		11/18/2010				Date:		11/10/2010
		
	PROVIDER’s SCIENTISTS		
						
	Signature:		/s/ Dr. Marianne Seder								
	Name:		Dr. Marianne Seder						
					
	Date:		11/15/2010						

  
 H-9 

 Schedule “A” 

Description of Original Material and Research Project 
  

	1.	 Original Material  

Please provide a detailed description of the Original Material, which Provider will be providing to Recipient. 

EPI-001 
 The Material is derived from Providers
proprietary technology ( UBC Technology number 08-051). The technology is under an option agreement obligation to an industry partner of the Provider. 
  

	2.	 Research Project 

Please describe the research project in detail: 

Study plan: to compare the antitumour effects of abiraterone, MDV3100, and EPI-001 in a head-to-head in vivo studies using 6 xenograft lines
that express androgen receptor and its splice variants. Animals should be castrated prior to commencement of treatments with EPI-001. Treatments will continue for a period of 54 days. In the first xenograft line to be tested with EPI-001, LuCap
86.2, the 16 animals will be castrated then 7 days later the animals will be dosed with 100 mg/kg body weight in the morning and then again in the evening for a total daily dose of 200 mg/kg body weight daily by gavage for 54 days. There will also
be a small i.v. arm. This experiment will follow that reported in Cancer Cell. Briefly, 7 days after castration, 50 mg/kg body weight will be administered by i.v. every other day over a period of at least 2 weeks (longer if possible). The remaining
5 xenograft lines will only be treated by gavage for 54 days following the same protocol as provided above. 
  

	3.	 Shipping Address 

Attention: Dr. S. R. Plymate, MD 
 HMC R and T 

300 9th Ave 
 Room 418 

Seattle, WA 98104 
 USA 

Phone 206-897-5275 

  
 H-10EX-4.3

 Exhibit 4.3 

AGENCY AGREEMENT 

October 22, 2014 
 ESSA
Pharma Inc. 
 999 West Broadway, Suite 720 

Vancouver, British Columbia V5Z 1K5 

Attention: Bob Rieder, Chief Executive Officer 

Dear Sir: 
 Haywood Securities Inc. (the
“Agent”) understands that ESSA Pharma Inc. (the “Corporation”) proposes to issue and sell a minimum of 250,000 and a maximum of up to 3,814,600 special warrants of the Corporation (“Special
Warrants”) at a purchase price of Cdn$2.00 per Special Warrant (the “Offering Price”) for aggregate gross proceeds of up to Cdn$7,629,200. Each Special Warrant shall entitle the holder thereof to receive one preferred share
in the capital of the Corporation (a “Preferred Share”), subject to adjustment in certain circumstances, for no additional consideration upon the exercise of the Special Warrant. Each Special Warrant shall be exercisable by the
holder thereof at any time after the Closing Date and all unexercised Special Warrants will be automatically exercised by the Special Warrant Trustee (as defined herein) on behalf of the holder, without any further action on the part of the holder,
in accordance with the terms of the Special Warrant Indenture (as defined herein). 
 The Preferred Shares underlying the Special Warrants
shall have the attributes as set out in the Subscription Agreement (as defined herein). 
 The Preferred Shares shall be automatically
convertible into common shares in the capital of the Corporation (“Common Shares”) upon a Liquidity Event (as defined herein) and are also convertible at any time by and at the sole discretion of the holder of Preferred Shares. 

The Special Warrants may be offered to purchasers resident in each of the provinces of Canada, the United States and such other jurisdictions
as the Agent, with the consent of the Corporation, may designate prior to the Closing Date (the “Selling Jurisdictions”), on a private placement basis. The Agent is entitled to appoint a soliciting dealer group consisting of other
registered dealers acceptable to the Corporation for the purposes of arranging for purchasers of the Special Warrants. 
 The Agent further
understands that the Corporation expects to complete a non-brokered private placement offering of Special Warrants on the same terms as, and concurrent with the Initial Closing (the “Non-Brokered Private Placement”) which shall not
form part of the Offering. 
 DEFINITIONS 

In this Agreement, 

“1933 Act” means the United States Securities Act of 1933, as amended; 

“affiliate”, and “associate” shall have the respective meanings ascribed thereto in the Securities
Act (British Columbia); 
 “Agency Fee” has the meaning ascribed thereto in Section 6 of this Agreement; 

 “Agent” has the meaning ascribed thereto in the first paragraph of this
Agreement; 
 “Agent’s Expenses” has the meaning ascribed thereto in Section 12 of this Agreement; 

“Agreement” means this agreement between the Corporation and the Agent dated as of the date hereof; 

“Applicable Securities Laws” means, collectively, the applicable securities laws of each of the Selling Jurisdictions and the
states thereof, and, in each case, the respective regulations, rules and orders made and forms prescribed thereunder together with all applicable published policy statements, blanket orders and rulings of the securities regulators in the Selling
Jurisdictions; 
 “to the best of the Corporation’s knowledge” or “to the Corporation’s
knowledge” or “known to the Corporation” or similar language describing facts known to the Corporation or its agents and associates, means matters relating to the Corporation that are known, after due inquiry, to any of the
Corporation’s current president, principal executive officer or principal financial officer; 
 “Broker Shares” means
(i) the Preferred Shares issuable upon exercise of any Broker Warrants exercised prior to a Liquidity Event and (ii) the Common Shares issuable upon exercise of any Broker Warrants exercised after a Liquidity Event, in either case in
accordance with their terms; 
 “Broker Warrants” has the meaning given to it in Section 6; 

“Business Day” means a day on which the major banks are open in Vancouver, British Columbia and which is not a Saturday, a
Sunday or a statutory or civic holiday in Vancouver, British Columbia; 
 “Canadian Securities Regulators” means the
securities commissions or other securities regulatory authorities in the Qualifying Jurisdictions, as the case may be; 

“CIPO” means the Canadian Intellectual Property Office; 

“Closing” means the Initial Closing or any Subsequent Closing, as the case may be; 

“Closing Date” means the Initial Closing Date or any Subsequent Closing Date, as the case may be; 

“Closing Time” means the Initial Closing Time or any Subsequent Closing Time, as the case may be; 

“Common Shares” has the meaning ascribed thereto in the second paragraph of this Agreement; 

“Corporate Finance Fee” has the meaning ascribed thereto in Section 6 of this Agreement; 

“Corporation” means ESSA Pharma Inc., a corporation organized under the laws of British Columbia; 

“Corporation IP” means the Intellectual Property that has been developed by or for, or is being developed by or for, the
Corporation, or that is being used by the Corporation, other than Licensed IP; 
 “Corporation’s Auditors” means such
firm of accountants as the Corporation may have appointed or may from time to time appoint as auditors of the Corporation; 
 “CPRIT
Agreement” means the definitive agreement entered into with the Cancer Prevention & Research Institute of Texas providing for, among other things, the Corporation being entitled to receive matching funds of up to a maximum of
US$12,000,000 on and subject to the terms and conditions therein; 

  
 - 2 - 

 “Due Diligence Session” has the meaning ascribed thereto in subsection 4(yy) of
this Agreement; 
 “Enforceability Qualifications” means (a) bankruptcy, insolvency, reorganization, moratorium and
other laws relating to or affecting the rights of creditors generally, (b) the application of equitable principles when equitable remedies are sought, including the remedies of specific performance and injunctive relief, and (c) applicable
laws limiting rights to indemnity, contribution, waiver, and the ability to sever unenforceable terms; 
 “Environmental
Laws” has the meaning ascribed thereto in subsection 4(v) of this Agreement; 
 “FDA” means the U.S. Food and Drug
Administration of the U.S. Department of Health & Human Services; 
 “Final Prospectus” means the final long form
prospectus of the Corporation prepared in connection with the qualification of the Preferred Shares issuable pursuant to the exercise or deemed exercise of the Special Warrants and the Broker Warrants issuable pursuant to the exercise or deemed
exercise of the Special Broker Warrants for distribution in the Qualifying Jurisdictions; 
 “Financial Statements” means
the audited financial statements of the Corporation as of September 30, 2013 and December 31, 2012 and for the period from January 6, 2009 (inception) to December 31, 2011; 

“Indemnified Party” has the meaning ascribed thereto in Section 10 of this Agreement; 

“Initial Closing” means the first closing of the issue and sale by the Corporation of the Special Warrants; 

“Initial Closing Date” means October 22, 2014 or such other date or dates as the Corporation and the Agent may agree
upon in writing; 
 “Initial Closing Time” means 10:00 a.m. (Vancouver time) on the Initial Closing Date or such other time
on the Initial Closing Date as the Corporation and the Agent may agree; 
 “Initial Public Offering” or
“IPO” means an initial public offering and listing of the Common Shares on a Recognized Exchange; 
 “Intellectual
Property” means intellectual property rights, including: (i) all patents, patent rights, inventions, industrial designs and licenses; (ii) trademarks, service marks, trade dress, trade names, corporate names, logos, slogans and
Internet domain names, together with all goodwill associated with each of the foregoing; (iii) copyrights and copyrightable works in whatever form or medium; (iv) registrations, applications and renewals for any of the foregoing;
(v) proprietary computer software (including but not limited to data, data bases and documentation); and (vi) trade secrets, confidential information and know-how; 

“Internal Reorganization” means one or a series of corporate reorganizations of the Corporation whereby a holding company
structure is formed and all or a portion of the Corporation’s shareholders exchange their Common Shares for securities in such holding company and which does not result in the Corporation becoming a “reporting issuer” under Applicable
Securities Laws or the Common Shares being listed on a Recognized Exchange; 
 “Leased Premises” has the meaning ascribed
thereto in subsection 4(p) of this Agreement; 
 “Liabilities” has the meaning ascribed thereto in Section 10 of this
Agreement; 

  
 - 3 - 

 “Licensed IP” means the Intellectual Property owned by any person other than the
Corporation and which the Corporation uses; 
 “Liquidity Event” means, with respect to the Corporation, the completion of:
(i) an IPO; (ii) an RTO; or (iii) the sale of all or substantially all of the issued and outstanding shares in the capital of the Corporation for cash proceeds or for securities provided that such securities are listed and posted for
trading on a Recognized Exchange; or the amalgamation merger, arrangement or any other corporate transaction involving the Corporation with or into another entity pursuant to which the common shares of the resulting issuer from such transaction are
listed on a Recognized Exchange, excluding, however, an Internal Reorganization; 
 “Material Adverse Effect” means any
change, effect, event, occurrence or change in a state of facts that is, or would reasonably be expected to be, individually or in the aggregate, material and adverse to the business, operations, financial condition, results, assets, properties,
rights, liabilities or prospects of the Corporation taken as a whole; 
 “material change” means a material change for the
purposes of Applicable Securities Laws or any of them or where undefined under Applicable Securities Laws of a jurisdiction means a change in the business, operations or capital of the Corporation that would reasonably be expected to have a
significant effect on the market price or value of the Corporation’s securities and includes a decision to implement such a change made by the Corporation’s board of directors or by senior management of the Corporation who believe that
confirmation of the decision by the board of directors is probable; 
 “material fact” means a material fact for the
purposes of Applicable Securities Laws or any of them or where undefined under Applicable Securities Laws of a jurisdiction means a fact that significantly affects, or would reasonably be expected to have a significant effect on, the market price or
value of the Corporation’s securities; 
 “misrepresentation” means a misrepresentation for the purposes of Applicable
Securities Laws or any of them or where undefined under Applicable Securities Laws of a jurisdiction means (i) an untrue statement of a material fact, or (ii) an omission to state a material fact that is required to be stated or that is
necessary to make a statement not misleading in the light of the circumstances in which it was made; 
 “Money Laundering
Laws” has the meaning ascribed thereto in subsection 4(ddd) of this Agreement; 
 “Notice” has the meaning
ascribed thereto in Section 17 of this Agreement; 
 “Offering” means the issue and sale of the Special Warrants as
contemplated in this Agreement; 
 “Offering Price” has the meaning ascribed thereto in the first paragraph of this
Agreement; 
 “Outstanding Common Shares” means the issued and outstanding Common Shares of the Corporation; 

“Preferred Shares” has the meaning ascribed thereto in the first paragraph of this Agreement; 

“Preliminary Prospectus” means the preliminary long form prospectus of the Corporation prepared in connection with the
qualification of the Preferred Shares issuable pursuant to the exercise or deemed exercise of the Special Warrants and the Broker Warrants issuable pursuant to the exercise or deemed exercise of the Special Broker Warrants for distribution in the
Qualifying Jurisdictions; 
 “Proceedings” has the meaning ascribed thereto in Section 10 of this Agreement; 

  
 - 4 - 

 “Qualifying Jurisdictions” means collectively, all of the Provinces of Canada,
other than Québec, where Subscribers are resident on the Closing Date, as specified in the Subscription Agreements; 

“Recognized Exchange” means the Toronto Stock Exchange, TSX Venture Exchange, NASDAQ Stock Market or the New York Stock
Exchange, any equity market based in North America having listing standards similar to those of the TSX Venture Exchange, as determined by the Board of Directors of the Corporation, acting reasonably, or any other equity market as may be approved by
holders of Preferred Shares representing at least 66 2⁄3% of the issued and outstanding Preferred Shares; 

“Registered Corporation IP” means all Corporation IP that is the subject of registration with a national intellectual
property office (including, without limitation, the CIPO and the USPTO) for Intellectual Property or applications for such registration with a national intellectual property office; 

“Regulation S” means Regulation S adopted under the 1933 Act; 

“Regulatory Authority” means the statutory or governmental bodies authorized under Applicable Laws to protect and promote
public health through regulation and supervision of therapeutic drug candidates intended for use in humans, including, without limitation, the FDA and Health Canada; 

“RTO” means a reverse takeover of a corporation listed on, or that obtains, a listing of its principal voting securities on a
Recognized Exchange; 
 “Securities” means and includes, individually and collectively, the Special Warrants, Preferred
Shares, the Common Shares, the Special Broker Warrants, the Broker Warrants and the Broker Shares; 
 “Securities
Commissions” means the securities commissions or similar regulatory authorities in the Selling Jurisdictions; 
 “Selling
Jurisdictions” has the meaning ascribed thereto on the first page of this Agreement; 
 “Special Broker Warrants”
has the meaning ascribed thereto in Section 6 of this Agreement; 
 “Special Broker Warrant Certificate” means the
form of certificate representing the Special Broker Warrants, which contains the terms and conditions of the Special Broker Warrants along with the form of certificate representing the Broker Warrants, which contains the terms and conditions of the
Broker Warrants, attached thereto; 
 “Special Warrant Agent” means the registrar and transfer agent of the Special
Warrants, Computershare Trust Company of Canada, having an office at 3rd Floor, 510 Burrard Street, Vancouver, British Columbia V6C 3B9; 

“Special Warrant Indenture” means the special warrant indenture between the Corporation and the Special Warrant Agent, dated
as of the Closing Date, governing the terms of the Special Warrants. 
 “Special Warrants” has the meaning ascribed thereto
in the first paragraph of this Agreement; 
 “Subscriber” means any person who executes a Subscription Agreement that is
accepted by the Corporation; 

  
 - 5 - 

 “Subscription Agreements” means the agreements in the forms mutually acceptable
to the Corporation and the Agent to be entered into between the Subscribers and the Corporation with respect to the Offering; 

“Subsequent Closing” has the meaning ascribed thereto in Section 7 of this Agreement; 

“Subsequent Closing Date” means such date as may be agreed upon between the Corporation and the Agent for any Subsequent
Closing, but in any event shall not be later than December 31, 2014; 
 “Subsequent Closing Time” means 10:00 a.m.
(Vancouver time) on any Subsequent Closing Date or such other time on such Subsequent Closing Date as the Corporation and the Agent may agree; 

“Supplementary Material” means, collectively, any amendment to the Preliminary Prospectus, the Final Prospectus, any amended
or supplemental prospectus or ancillary material required to be filed by or on behalf of the Corporation under Applicable Securities Laws relating to the distribution of the subject securities described therein; 

“Taxes” has the meaning ascribed thereto in subsection 4(f) of this Agreement; 

“Term Sheet” means the term sheet relating to the Offering agreed to between the Corporation and the Agent; 

“Transaction Documents” has the meaning ascribed thereto in subsection 4(a) of this Agreement; 

“Transfer Agent” means Blake, Cassels & Graydon LLP as registrar and transfer agent for the securities of the
Corporation; 
 “United States” means the United States of America, its territories and possessions, any state of the
United States, and the District of Columbia; 
 “U.S. Affiliate” has the meaning ascribed thereto in Section 2 of this
Agreement; 
 “U.S. Person” means a U.S. Person as that term is defined in Regulation S; and 

“USPTO” means the United States Patent and Trademark Office. 

Unless otherwise expressly provided in this Agreement, words importing only the singular number include the plural and vice versa and words
importing gender includes all genders. References to “Sections”, “subsections” or “clauses” are to the appropriate section, subsection or clause of this Agreement. 

The following are the schedules attached to this Agreement, which schedules are deemed to be a part hereof and are hereby incorporated by
reference herein: 
  

					
	 Schedule “A”
		-		 Terms and Conditions for United States Offers and Sales

	 Schedule “B”
		-		 Securities Convertible into or Exchangeable for Shares in the Capital of the Corporation

  
 - 6 - 

 TERMS AND CONDITIONS 

 

	1.	 Appointment of Agent 

Based upon the foregoing and subject to the terms and conditions set out below, the Corporation hereby appoints the Agent and the Agent hereby
accepts such appointment, to effect the sale of the Special Warrants at the Offering Price, on a commercially reasonable best efforts basis to persons resident in the Selling Jurisdictions and such other jurisdictions as may be agreed upon by the
Corporation. The Agent agrees to use its best efforts to sell the Special Warrants, but it is hereby understood and agreed that the Agent shall act as agent only and is under no obligation to purchase any of the Special Warrants, although the Agent
may subscribe for Special Warrants, subject to applicable laws. 
  

	2.	 U.S. Sales 

The parties acknowledge that the Special Warrants and the other Securities have not been and will not be registered under the 1933 Act and may
not be offered or sold in the United States except pursuant to exemptions from the registration requirements of the 1933 Act and the applicable laws of any applicable state of the United States. Accordingly, the Corporation and the Agent agree that
any offers or sales in the United States shall be conducted only in the manner specified in Schedule “A” hereof. All actions to be undertaken by an Agent in the United States in connection with the matters contemplated herein shall
be undertaken through an Agent’s duly registered broker-dealer affiliate in the United States or such other duly registered broker-dealer in the United States engaged in connection with such offer or sale (the “U.S.
Affiliate”). 
  

	3.	 Certain Representations, Warranties, Covenants and Obligations of the Agent 

 

	(1)	 The Agent, on its own behalf and on behalf of a U.S. Affiliate, if any, hereby covenants to the Corporation as follows: 

 

	 	(a)	 it will offer the Special Warrants for sale on behalf of the Corporation only to Subscribers who will purchase such Special Warrants under the
private placement exemptions or such other exemptions available under Applicable Securities Laws and it will not offer the Special Warrants for sale in those jurisdictions where it is not permitted to do so under Applicable Securities Laws;

  

	 	(b)	 it will conduct activities in connection with the proposed offering and sale of the Special Warrants in compliance with all Applicable Securities
Laws in the Selling Jurisdictions applicable to the Agent and, without limitation, agrees that it will not make available to prospective purchasers of the Special Warrants any document or material (other than the Term Sheet and the Subscription
Agreement), nor will it solicit or procure subscriptions for Special Warrants so as to require the registration thereof or the filing of a prospectus with respect thereto under the laws of any jurisdiction; 

 

	 	(c)	 any offers and sales of Special Warrants and the other Securities in the United States or to, or for the account or benefit of, a U.S. Person shall
be made in accordance with the terms and conditions set out in Schedule “A” to this Agreement, which schedule is incorporated by reference and forms part of this Agreement. The Corporation and the Agent shall, and the Agent
shall cause the U.S. Affiliate to comply with the terms and conditions set out therein; 

  
 - 7 - 

	 	(d)	 it will not engage in any form of general solicitation or general advertising in connection with the offer and sale of the Special Warrants,
including but not limited to, causing the sale of the Special Warrants to be advertised in any newspaper, magazine, printed public media, printed media or similar medium of general and regular paid circulation, broadcast over radio, television or
telecommunications, including electronic display, or conduct any seminar or meeting relating to the offer and sale of the Special Warrants whose attendees have been invited by general solicitation or advertising; 

 

	 	(e)	 it will obtain from each Subscriber an executed Subscription Agreement and all applicable undertakings, questionnaires and other forms required
under Applicable Securities Laws and supplied to the Agent for completion in connection with the distribution of the Special Warrants and deliver such Subscription Agreements and other forms to the Corporation; 

 

	 	(f)	 it will not solicit subscriptions for Special Warrants or other Securities except in accordance with the terms and conditions of this Agreement;

  

	 	(g)	 it will not, in connection with the Offering, make any representation or warranty with respect to the Special Warrants, other Securities or the
Corporation other than as set forth in this Agreement or the Subscription Agreement; 

  

	 	(h)	 subject to the terms and conditions of this Agreement and the Subscription Agreements, it will release to the Corporation at the Closing Time the
subscription funds received from the sale of the Special Warrants; 

  

	 	(i)	 it will provide to the Corporation all necessary information in respect of the Agent, the U.S. Affiliate and the Subscribers to allow the
Corporation to file, with the Securities Commissions, if required, reports of the sale of the Special Warrants and the other Securities in accordance with Applicable Securities Laws within ten days of the Closing; and 

 

	 	(j)	 subject to its reasonable satisfaction with sections 5(a) and (j), provide promptly upon request of the Corporation, pursuant to section
3.4(ii)(B)(II) of Policy 2.2 of the Corporate Finance Manual of the TSX-V, confirmation to the TSX-V that the Agent has completed appropriate due diligence in connection with the Offering and the Final Prospectus that is generally in compliance with
the relevant standards and guidelines applicable in Policy 2.2, or such similar confirmation as may be required to be given to a Recognized Exchange in connection with the Corporation’s efforts to obtain the conditional approval for a listing
on another Recognized Exchange, as may be required by the policies of such Recognized Exchange. 

  

	(2)	 The Agent represents and warrants to the Corporation that: 

 

	 	(a)	 it is duly qualified in accordance with Applicable Securities Laws to solicit and procure subscriptions for the Special Warrants in the Selling
Jurisdictions in which it is qualified to do so in connection with the Offering; and 

  

	 	(b)	 it is an “accredited investor” as such term is defined under National Instrument 45-106 by virtue of being a person registered under
Applicable Securities Laws and is acquiring the Special Broker Warrants as principal for its own account and not for the benefit of any other person. 

  
 - 8 - 

	4.	 Representations and Warranties of the Corporation 

The Corporation represents and warrants to the Agent and the Subscribers, and acknowledges that the Agent and the Subscribers
are relying upon such representations and warranties in connection with the purchase and sale of the Special Warrants, as of a Closing Date as follows: 
  

	 	(a)	 the Corporation is a corporation duly organized and validly existing under the laws of the jurisdiction in which it was incorporated, has all
requisite corporate power and authority and is duly qualified and holds all necessary material permits, licences and authorizations necessary or required to carry on its business as now conducted and to own, lease or operate its properties and
assets and no steps or proceedings have been taken by any person, voluntary or otherwise, requiring or authorizing its dissolution or winding up, and the Corporation has all requisite power and authority to enter into each of this Agreement, the
Subscription Agreements and the Special Broker Warrant Certificate, (collectively, the “Transaction Documents”) and to carry out its obligations hereunder and thereunder; 

 

	 	(b)	 each of the execution and delivery of the Transaction Documents, the performance by the Corporation of its obligations hereunder and thereunder,
the issue and sale of the Special Warrants, the performance by the Corporation of its obligations thereunder and the consummation of the transactions contemplated by the Transaction Documents, do not and will not conflict with or result in a breach
or violation of any of the terms or provisions of, or constitute a material default under (whether after notice or lapse of time or both) (A) any statute, rule or regulation applicable to the Corporation including, without limitation,
Applicable Securities Laws; (B) the constating documents, by-laws or resolutions of the Corporation which are in effect at the date hereof; (C) any mortgage, note, indenture, contract, agreement, joint venture, partnership, instrument,
lease or other document to which the Corporation is a party or by which it is bound; or (D) any judgment, decree or order binding the Corporation or the property or assets of the Corporation; 

 

	 	(c)	 The Corporation does not beneficially own, or exercise control or direction over, 10% or more of the outstanding voting securities of any company;

  

	 	(d)	 the Corporation has not approved, is not contemplating, has not entered into any agreement in respect of, or does not have any knowledge of:
(A) the purchase of any property material to the Corporation or assets or any interest therein or the sale, transfer or other disposition of any property material to the Corporation or assets or any interest therein currently owned, directly or
indirectly, by the Corporation whether by asset sale, transfer or sale of shares or otherwise; or (B) the change of control (by sale or transfer of shares or sale of all or substantially all of the property and assets of the Corporation) of the
Corporation; 

  

	 	(e)	 the Financial Statements have been prepared in accordance with accounting principles generally accepted in Canada and consistently applied
throughout the period referred to herein, contain no misrepresentation and present fully, fairly and correctly, in all material respects, the financial condition of the Corporation as at the dates thereof and the results of the operations and the
changes in the financial position of the Corporation for the periods then ended and contain and reflect adequate provisions or allowance for all reasonably anticipated liabilities, expenses and losses of the Corporation and there has been no change
in accounting policies or practices of the Corporation since September 30, 2013; 

  
 - 9 - 

	 	(f)	 all taxes (including income tax, capital tax, payroll taxes, employer health tax, workers’ compensation payments, property taxes, custom and
land transfer taxes), duties, royalties, levies, imposts, assessments, deductions, charges or withholdings and all liabilities with respect thereto including any penalty and interest payable with respect thereto (collectively,
“Taxes”) due and payable by the Corporation have been paid, except where the failure to pay such taxes would not have a Material Adverse Effect on the Corporation. All tax returns, declarations, remittances and filings required to
be filed by the Corporation have been filed with all appropriate governmental authorities and all such returns, declarations, remittances and filings are complete and accurate and no material fact or facts have been omitted therefrom which would
make any of them misleading, except where such failure would not have a Material Adverse Effect on the Corporation. To the best of the Corporation’s knowledge, no examination of any tax return of the Corporation is currently in progress and
there are no issues or disputes outstanding with any governmental authority respecting any taxes that have been paid, or may be payable, by the Corporation, in any case, except where such examinations, issues or disputes would not constitute an
adverse material fact in respect of the Corporation or have a Material Adverse Effect on the Corporation; 

  

	 	(g)	 no holder of outstanding shares in the capital of the Corporation will be entitled to any pre-emptive or any similar rights to subscribe for any
Common Shares or other securities of the Corporation and, other than as set out in Schedule B attached hereto, no rights, warrants or options to acquire, or instruments convertible into or exchangeable for, any shares in the capital of the
Corporation are outstanding; 

  

	 	(h)	 no legal or governmental proceedings or inquiries are pending to which the Corporation is a party or to which its property is subject that would
result in the revocation or modification of any material contract, order, certificate, right, authority, permit or license necessary to conduct the business now owned or operated by the Corporation which, if the subject of an unfavourable decision,
ruling or finding would have a Material Adverse Effect on the Corporation and, to the knowledge of the Corporation, no such legal or governmental proceedings or inquiries have been threatened against or are contemplated with respect to the
Corporation or with respect to its properties; 

  

	 	(i)	 the Corporation is not in default in the performance or observance of any material obligation, agreement, covenant or condition contained in any
contract, indenture, trust deed, mortgage, loan agreement, note, lease or other agreement or instrument to which it is a party or by which it or its property may be bound; 

 

	 	(j)	 the Corporation owns or has the right to use under license, sub-license or otherwise all material Intellectual Property used by the Corporation in
its business; 

  

	 	(k)	 any and all of the agreements and other documents and instruments pursuant to which the Corporation holds the property and assets thereof
(including any interest in, or right to earn an interest in, any property) are valid and subsisting agreements, documents or instruments in full force and effect, enforceable in accordance with terms thereof. The Corporation is not in default of any
of the material provisions of any such agreements, documents or instruments nor has any such default been alleged and such properties and assets are in good standing under the applicable statutes and regulations of the

  
 - 10 - 

	 	 
jurisdictions in which they are situated, all leases, licences and claims pursuant to which the Corporation derive the interests thereof in such property and assets are in good standing and there
has been no material default under any such lease, licence or claim. The properties (or any interest in, or right to earn an interest in, any property) of the Corporation are not subject to any right of first refusal or purchase or acquisition
right; 

  

	 	(l)	 the Transaction Documents have been or will be duly authorized and executed and delivered by the Corporation and constitute or will constitute
valid and binding obligations of the Corporation enforceable against the Corporation in accordance with their respective terms, except as enforcement thereof may be limited by the Enforceability Qualifications; 

 

	 	(m)	 at the Closing Time all necessary corporate action will have been taken by the Corporation to validly issue the Special Warrants pursuant to the
terms of the Special Warrant Indenture, to validly create and issue the Special Broker Warrants and to allot and reserve the Broker Warrants, Preferred Shares issuable upon exercise of the Special Warrants and Broker Shares, which upon issuance in
accordance with the terms of such securities shall be validly issued as fully paid and non-assessable securities in the capital of the Corporation; 

  

	 	(n)	 the authorized capital of the Corporation consists of an unlimited amount of Common Shares and an unlimited amount of Preferred Shares of which, as
at the close of business on the Business Day immediately preceding the date hereof, 15,687,534 Common Shares and 1,702,900 Preferred Shares were issued and outstanding as fully paid and non-assessable shares of the capital of the Corporation. There
is sufficient authorized capital for the issuance of all Common Shares issuable on conversion of all Securities contemplated hereby and all outstanding convertible securities of the Corporation. 

 

	 	(o)	 the Corporation has not made any loans to or guaranteed the obligations of any person; 

 

	 	(p)	 with respect to each premises of the Corporation which is material to the Corporation and which the Corporation occupies as tenant (the
“Leased Premises”), the Corporation occupies the Leased Premises and has the exclusive right to occupy and use the Leased Premises and each of the leases pursuant to which the Corporation occupies the Leased Premises is in good
standing and in full force and effect; 

  

	 	(q)	 the Corporation is in compliance with all applicable laws respecting employment and employment practices, terms and conditions of employment, pay
equity and wages, except where non-compliance with such laws could not reasonably be expected to have a Material Adverse Effect on the Corporation, and the Corporation has not and is not engaged in any unfair labour practice; 

 

	 	(r)	 none of the directors, officers or employees of the Corporation or any associate or affiliate of any of the foregoing had or has any material
interest, direct or indirect, in any transaction or any proposed transaction with the Corporation which, as the case may be, materially affects, is material to or will materially affect the Corporation; 

 

	 	(s)	 there have not been and there are not currently any material disagreements with any employee or employees of the Corporation which are adversely
affecting or could adversely affect the business of the Corporation; 

  
 - 11 - 

	 	(t)	 the assets of the Corporation and its business and operations are insured against loss or damage with responsible insurers on a basis consistent
with insurance obtained by reasonably prudent participants in comparable businesses, and such coverage is in full force and effect, and the Corporation has not failed to promptly give any notice of any material claim thereunder;

  

	 	(u)	 the minute books and records of the Corporation made available to counsel for the Agent in connection with its due diligence investigation of the
Corporation for the periods from the Corporation’s date of incorporation to the date hereof are all of the minute books and records of the Corporation and contain copies of all proceedings (or certified copies thereof or drafts thereof pending
approval) of the shareholders, the directors and all committees of directors of the Corporation to the date of review of such corporate records and minute books and there have been no other meetings, resolutions or proceedings of the shareholders,
directors or any committees of the directors of the Corporation to the date hereof not reflected in such minute books and other records, other than those which have been disclosed in writing to the Agent; 

 

	 	(v)	 in connection with the ownership, use, maintenance or operation of its property and assets, including the Leased Premises, the Corporation has not
been in violation of any applicable federal, provincial, municipal or local laws, by-laws, regulations, orders, policies, permits, licences, certificates or approvals having the force of law, domestic or foreign, relating to environmental, health or
safety matters (collectively the “Environmental Laws”) which violation would have a Material Adverse Effect on the Corporation; 

  

	 	(w)	 without limiting the generality of subsection (v) immediately above, the Corporation does not have any knowledge of, and has not received any
notice of, any material claim, judicial or administrative proceeding, pending or threatened against, or which may affect the Corporation or any of the property, assets or operations thereof, relating to, or alleging any violation of any
Environmental Laws; to the Corporation’s knowledge, there are no facts which could give rise to any such claim or judicial or administrative proceeding; to the best of the Corporation’s knowledge, neither the Corporation nor any of the
property, assets or operations thereof is the subject of any investigation, evaluation, audit or review by any Governmental Authority (which term means and includes any national, federal government, province, state, municipality or other political
subdivision of any of the foregoing, any entity exercising executive, legislative, judicial, regulatory or administrative functions of or pertaining to government and any corporation or other entity owned or controlled (through stock or capital
ownership or otherwise) by any of the foregoing) to determine whether any violation of any Environmental Laws has occurred or is occurring or whether any remedial action is needed in connection with a release of any contaminant into the environment,
except for compliance investigations conducted in the normal course by any governmental authority, in each case which could reasonably be expected to have a Material Adverse Effect on the Corporation; 

 

	 	(x)	 there are no orders, rulings or directives issued, pending or, to the best of the Corporation’s knowledge, threatened against the Corporation
under or pursuant to any Environmental Laws requiring any work, repairs, construction or capital expenditures with respect to the property or assets of the Corporation (including the Leased Premises) which would have a Material Adverse Effect on the
Corporation; 

  
 - 12 - 

	 	(y)	 other than the Agent, there is no person acting or purporting to act at the request or on behalf of the Corporation that is entitled to any
brokerage or finder’s fee in connection with the transactions contemplated by this Agreement; 

  

	 	(z)	 the Transfer Agent has been duly appointed as registrar and transfer agent for the securities of the Corporation; 

 

	 	(aa)	 the Corporation is the sole legal and beneficial owner of, has good and marketable title to, and owns all right, title and interest in all
Corporation IP free and clear of all encumbrances, charges, covenants, conditions, options to purchase and restrictions or other adverse claims or interest of any kind or nature, and the Corporation has no knowledge of any claim of adverse ownership
in respect thereof. No consent of any person is necessary to make, use, reproduce, license, sell, modify, update, enhance or otherwise exploit any Corporation IP and none of the Corporation IP comprises an improvement to Licensed IP that would give
any person any rights to the Corporation IP, including, without limitation, rights to license the Corporation IP. The Corporation has a valid and enforceable right to the Licensed IP used or held for use in the business of the Corporation;

  

	 	(bb)	 the Corporation has not received any notice or claim (whether written, oral or otherwise) challenging the Corporation’s ownership or right to
use any of the Corporation IP or suggesting that any other person has any claim of legal or beneficial ownership or other claim or interest with respect thereto, nor, to the knowledge of the Corporation, is there a reasonable basis for any claim
that any person other than the Corporation has any claim of legal or beneficial ownership or other claim or interest in any of the Corporation IP; 

  

	 	(cc)	 all applications for registration of any Registered Corporation IP are in good standing, are recorded in the name of the Corporation and have been
filed in a timely manner in the appropriate offices to preserve the rights thereto and, in the case of a provisional application, the Corporation confirms that all right, title and interest in and to the invention(s) disclosed in such application
have been or as of the Closing Date will be assigned in writing (without any express right to revoke such assignment) to the Corporation. To the knowledge of the Corporation, there has been no public disclosure, sale or offer for sale of any
Corporation IP anywhere in the world that may prevent the valid issue of all available Intellectual Property rights in such Corporation IP. All material prior art or other information has been disclosed to the appropriate offices as required in
accordance with Applicable IP Laws in the jurisdictions where the applications are pending; 

  

	 	(dd)	 all registrations of Registered Corporation IP are in good standing and are recorded in the name of the Corporation in the appropriate offices to
preserve the rights thereto. All such registrations have been filed, prosecuted and obtained in accordance with all Applicable IP Laws and are currently in effect and in compliance with all Applicable IP Laws. To the knowledge of the Corporation, no
registration of Registered Corporation IP has expired, become abandoned, been cancelled or expunged, or has lapsed for failure to be renewed or maintained; 

  

	 	(ee)	 the conduct of the business of the Corporation (including, without limitation, the use or other exploitation of the Corporation IP by the
Corporation or other licensees) has not infringed, violated, misappropriated or otherwise conflicted with any Intellectual Property right of any person; 

  
 - 13 - 

	 	(ff)	 the Corporation is not a party to any action or proceeding, nor, to the knowledge of the Corporation, is or has any action or proceeding been
threatened that alleges that any current or proposed conduct of its business (including, without limitation, the use or other exploitation of any Corporation IP by the Corporation or any customers, distributors or other licensees) has or will
infringe, violate or misappropriate or otherwise conflict with any Intellectual Property right of any person; 

  

	 	(gg)	 to the knowledge of the Corporation, no person has interfered with, infringed upon, misappropriated, illegally exported, or violated any rights
with respect to the Corporation IP; 

  

	 	(hh)	 the Corporation has entered into valid and enforceable written agreements pursuant to which the Corporation has been granted all licenses and
permissions to use, reproduce, sub license, sell, modify, update, enhance or otherwise exploit the Licensed IP to the extent required to operate all aspects of the business of the Corporation currently conducted (including, if required, the right to
incorporate such Licensed IP into the Corporation IP). All license agreements in respect of the Licensed IP are in full force and effect, and neither the Corporation nor, to the knowledge of the Corporation, any other person is in default of its
obligations thereunder; 

  

	 	(ii)	 to the extent that any of the Corporation IP is licensed or disclosed to any person or any person has access to such Corporation IP (including,
without limitation, any employee, officer, shareholder or consultant of the Corporation), the Corporation has entered into a valid and enforceable written agreement which contains terms and conditions prohibiting the unauthorized use, reproduction,
disclosure, reverse engineering or transfer of such Corporation IP by such person. All such agreements are in full force and effect, and neither the Corporation nor, to the knowledge of the Corporation, any other person is in default of its
obligations thereunder; 

  

	 	(jj)	 the Corporation has taken all actions that are contractually obligated to be taken and all actions that are customary and reasonable to protect the
confidentiality of the Corporation IP; 

  

	 	(kk)	 the Corporation is not, and will not be, necessary for the Corporation to utilize any Intellectual Property owned by or in possession of any of the
employees (or people the Corporation currently intends to hire) made prior to their employment with the Corporation in violation of the rights of such employee or any of his or her prior employers; 

 

	 	(ll)	 the Corporation has not received any advice or any opinion that any of the Corporation IP is invalid or unregistrable or unenforceable, in whole or
in part; 

  

	 	(mm)	 the Corporation has not received any grant relating to research and development which is subject to repayment in whole or in part or to conversion
to debt upon sale of any securities of the Corporation or which may affect the right of ownership of the Corporation in the Corporation IP; 

  

	 	(nn)	 the Corporation has and enforces a policy requiring each employee and consultant to execute a non-disclosure agreement substantially in the forms
provided to the Agent and Agent’s counsel, and all current employees and consultants of the Corporation have executed such agreement and, to the knowledge of the Corporation, all past employees and consultants of the Corporation have executed
such agreement; 

  
 - 14 - 

	 	(oo)	 all of the present and past employees of the Corporation, and all of the present and past consultants, contractors and agents of the Corporation
performing services relating to the development, modification or support of the Corporation IP, have entered into a written agreement assigning to the Corporation all right, title and interest in and to all such Intellectual Property;

  

	 	(pp)	 any and all fees or payments required to keep the Corporation IP and the Licensed IP in force or in effect have been paid, except those which the
Corporation has determined the failure to pay would not have a Material Adverse Effect; 

  

	 	(qq)	 to the knowledge of the Corporation, there is no claim of infringement or breach by the Corporation of any industrial or Intellectual Property
rights of any other person, nor has the Corporation received any notice or threat from any such third party, nor does the Corporation have knowledge that the use of the business names, trademarks, service marks and other industrial or Intellectual
Property of the Corporation infringes upon or breaches any industrial or Intellectual Property rights of any other person; 

  

	 	(rr)	 there are no Intellectual Property disputes, negotiations, agreements or communications between the Corporation and any other persons relating to
or potentially relating to the business of the Corporation; 

  

	 	(ss)	 the Corporation has conducted and is conducting its business in compliance in all material respects with all Applicable Laws of each jurisdiction
in which it carries on business and has not received a notice of non-compliance, nor knows of, nor has reasonable grounds to know of, any facts that could give rise to a notice of non-compliance with any such laws, regulations or permits which would
have a Material Adverse Effect; 

  

	 	(tt)	 the Corporation does not have knowledge of any reason as a result of which it is not entitled to make use of and commercially exploit the
Corporation IP. With respect to each license or agreement by which the Corporation has obtained the rights to exploit, in any way, the Licensed IP rights of any other person or by which the Corporation has granted to any third party the right to so
exploit such Licensed IP: 

  

	 	(i)	 such license or agreement is in full force and effect and is legal, valid, binding and enforceable in accordance with its terms, except to the
extent that enforceability may be limited by: (A) applicable bankruptcy, insolvency, reorganization, moratorium, and other laws of general application affecting enforcement of creditors’ rights generally; or (B) laws relating to the
availability of specific performance, injunctive relief, or other equitable remedies, and represents the entire agreement between the parties thereto with respect to the subject matter thereof, and no event of default has occurred and is continuing
under any such license or agreement; 

  

	 	(ii)	 (A) the Corporation has not received any notice of termination or cancellation under such license or agreement, and no party thereto has any right
of termination or cancellation thereunder except in accordance with its terms; (B) the Corporation has not received any notice of a breach or default under such 

  
 - 15 - 

	 	 
license or agreement which breach or default has not been cured; and (C) the Corporation has not granted to any other person any rights adverse to, or in conflict with, such license or
agreement; and 

  

	 	(iii)	 the Corporation does not have knowledge of any other party to such license or agreement that is in breach or default thereof, and does not have
knowledge of any event that has occurred that, with notice or lapse of time would constitute such a breach or default or permit termination, modification or acceleration under such license or agreement. No litigation, legal or governmental
proceedings or inquiries are pending to which the Corporation is a party or to which its property is subject that would result in the revocation or modification of any material certificate, authority, permit or license necessary to conduct the
business now owned or operated by the Corporation which, if the subject of an unfavourable decision, ruling or finding would have a Material Adverse Effect on the Corporation and no such litigation, legal or governmental proceedings or inquiries
have been threatened against or, to the Corporation’s knowledge, are contemplated with respect to the Corporation or with respect to its business, assets and/or properties; 

 

	 	(uu)	 for so long as the Special Broker Warrants and Broker Warrants remain outstanding, the Corporation shall use its best efforts to comply with its
obligations under Applicable Securities Laws, to the extent applicable to it; 

  

	 	(vv)	 the definitive form of certificate representing the Special Warrants complies with the requirements of the Business Corporations Act
(British Columbia) and does not conflict with the constating documents of the Corporation; 

  

	 	(ww)	 the Corporation has not declared or paid any dividends or declared or made any other payments or distributions on or in respect of any of its
Common Shares and has not, directly or indirectly, redeemed, purchased or otherwise acquired any of its Common Shares or agreed to do so or otherwise effected any return of capital with respect to such shares; 

 

	 	(xx)	 the Corporation has, and to the best of the Corporation’s knowledge, the directors and officers of the Corporation have, answered every
question or inquiry of the Agent and the Agent’s counsel in connection with the Agent’s due diligence investigations fully and truthfully; 

  

	 	(yy)	 from the effective date of the Corporation’s engagement of the Agent and until the Closing Time, the Corporation has allowed, and shall
continue to allow, the Agent the opportunity to conduct all required due diligence and to obtain, acting reasonably, satisfactory results therefrom and in particular, the Corporation shall allow the Agent and Agent’s counsel to conduct all due
diligence which the Agent may reasonably require and, in this regard, the Corporation shall make available its senior management and relevant employees and shall use its reasonable commercial efforts to make available its auditors to answer any
questions which the Agent may have and to participate in one or more due diligence sessions to be held prior to a Closing Date (all of such sessions referred to as the “Due Diligence Session”); 

 

	 	(zz)	 the Corporation has provided the Agent with all information reasonably requested by the Agent in connection with the Offering. There is no material
fact known to the 

  
 - 16 - 

	 	 
Corporation that has not been disclosed herein, or to the Agent on behalf of the Subscribers in connection with the transactions contemplated hereby and which would result in a Material Adverse
Effect on the Corporation. The Corporation has not withheld from the Agent any material fact relating to the Corporation or to the Offering; 

  

	 	(aaa)	 to the best of the Corporation’s knowledge it is not aware of any legislation, or proposed legislation (published by a legislative body),
which it anticipates will materially and adversely affect the business, affairs, operations, assets, liabilities (contingent or otherwise) or prospects of the Corporation; 

 

	 	(bbb)	 the Corporation has not, and to the knowledge of the Corporation, no director, officer, agent, employee or other person associated with or acting
on behalf of the Corporation has: (i) used any corporate funds for any unlawful contribution, gift, entertainment or other unlawful expense relating to political activity; (ii) made any direct or indirect unlawful payment to any foreign or
domestic government official or employee from corporate funds; (iii) violated or is in violation of any provision of the Corruption of Foreign Officials Act (Canada) or similar legislation; or (iv) made any bribe, rebate, payoff,
influence payment, kickback or other unlawful payment; 

  

	 	(ccc)	 all clinical, pre-clinical and other studies and tests conducted by or on behalf of or sponsored by the Corporation (collectively
“Clinical Trials”) have been and are being conducted in accordance with all Applicable Laws where such studies and tests are being conducted, including Applicable Laws administered by Regulatory Authorities. The Corporation
has not received any notices or written correspondence from any Regulatory Authority with respect to any Clinical Trial requiring the termination or suspension of such Clinical Trial; 

 

	 	(ddd)	 the operations of the Corporation are and have been conducted at all times in compliance with applicable financial recordkeeping and reporting
requirements of money laundering statutes, the rules and regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced by any government or governmental agency (collectively, the “Money
Laundering Laws”) and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Corporation with respect to the Money Laundering Laws is pending, or to the best of
the Corporation’s knowledge threatened; 

  

	 	(eee)	 the Corporation has not, directly or indirectly: (i) made or authorized any contribution, payment or gift of funds or property to any
official, employee or agent of any governmental agency, authority or instrumentality of any jurisdiction; or (ii) made any contribution to any candidate for public office, in either case where either the payment or the purpose of such
contribution, payment or gift was, is or would be prohibited under the Canada Corruption of Foreign Public Officials Act (Canada) or the Proceeds of Crime (Money Laundering) and Terrorist Financing Act (Canada) or the rules and
regulations promulgated thereunder or under any other legislation of any relevant jurisdiction covering a similar subject matter applicable to the Corporation and its operations, and will not use any portion of the gross proceeds, in contravention
of such legislation; 

  

	 	(fff)	 the Corporation or, to the best knowledge of the Corporation, any director, officer, agent, employee, affiliate or person acting on behalf of the
Corporation has not been or is not currently subject to any United States sanctions administered by the Office of Foreign Assets Control of the United States Treasury Department and the Corporation will not

  
 - 17 - 

	 	 
directly or indirectly use any proceeds of the Offering or lend, contribute or otherwise make available such proceeds to the Corporation or to any affiliated entity, joint venture partner or
other person or entity, to finance any investments in, or make any payments to, any country or person targeted by any of the sanctions of the United States; and 

 

	 	(ggg)	 the delivery of the Final Prospectus and any Supplementary Material to the Agent by the Corporation will constitute the representation and warranty
of the Corporation to the Agent that (except for any information and statements relating solely to the Agent and furnished by the Agent for use in the Final Prospectus), at the respective times of delivery: 

 

	 	(i)	 the information and statements contained in each of the Final Prospectus and any Supplementary Material: (A) are true and correct and contain
no misrepresentation; and (B) constitute full, true and plain disclosure of all material facts relating to the subject securities and the Corporation considered as a whole; and 

 

	 	(ii)	 the Final Prospectus and the Supplementary Material complies in all material respects with Applicable Securities Laws. 

 

	5.	 Covenants of the Corporation 

The Corporation covenants and agrees with the Agent as follows: 
  

	 	(a)	 from the effective date hereof to the Closing Time (or the respective time of filing of the Preliminary Prospectus and Final Prospectus and all
times subsequent to such filing during the distribution of the subject securities) the Corporation will promptly inform the Agent of the full particulars of: (i) any actual, anticipated or threatened material change, change in material fact or
the occurrence of a material fact or event, which, in any such case, is, or may be, of such nature to: (A) render any portion of the due diligence conducted by the Agent or the Agent’s counsel, including the results of the Due Diligence
Session, untrue, false or misleading in any material respect; (B) result in a misrepresentation in any of the due diligence documentation reviewed by the Agent or Agent’s counsel or during the Due Diligence Session; (C) result in the
Preliminary Prospectus or Final Prospectus containing a misrepresentation; or (D) result in the Corporation not complying with Applicable Securities Laws; 

 

	 	(b)	 if the Corporation is uncertain as to whether a material change, change in material fact, occurrence of a material fact or event of the nature
referred to in this aforementioned subparagraph has occurred, the Corporation shall promptly inform the Agent of the full particulars of the occurrence giving rise to the uncertainty and shall consult with the Agent as to whether the occurrence is
of such a nature; 

  

	 	(c)	 as soon as reasonably possible, and in any event by a Closing Date the Corporation shall take all such steps as may be required by the Agent and
the Agent’s counsel to enable the Special Warrants to be offered for sale and sold on a private placement basis to Subscribers in the Selling Jurisdictions that qualify as “accredited investors” under Applicable Securities Laws
through the Agent or any other investment dealers or brokers registered in any of the Selling Jurisdictions by way of the exemptions set forth in Applicable Securities Laws of each of the Selling Jurisdictions, provided, however, that the
Corporation shall not be required to qualify as a foreign corporation in any state, to consent to service of process in any state other than with respect to claims related to the Offering or to comply with any continuous disclosure or other similar
requirements; 

  
 - 18 - 

	 	(d)	 the Corporation will make all filings necessary with each applicable Securities Commission and pay all applicable fees in connection with the
Offering in full compliance with the manner and within the time limits prescribed by Applicable Securities Laws; 

  

	 	(e)	 the Corporation shall duly, faithfully and punctually perform all the obligations to be performed by it and comply with its covenants and
agreements hereunder and under the Transaction Documents and the CPRIT Agreement; 

  

	 	(f)	 the Corporation shall use the proceeds from the issuance and sale of the Special Warrants for pre-clinical and clinical development of the prostate
cancer program and for general corporate purposes; 

  

	 	(g)	 the Corporation shall use its best efforts to maintain its status as a “specified small business corporation” (within the meaning of the
Income Tax Act (Canada)) at all times until the completion of an IPO or RTO and shall not take any action that would cause or contribute to prevent the Corporation from maintaining such status; 

 

	 	(h)	 the Corporation shall, as soon as practicable following the Closing Date, use its commercially reasonable efforts to prepare, file and have a
receipt issued for the Preliminary Prospectus under the Applicable Securities Laws of the Qualifying Jurisdictions qualifying the distribution of: (i) the Preferred Shares issuable on the exercise or deemed exercise of the Special Warrants to
holders of the Special Warrants and (ii) the Broker Warrants to holders of the Special Broker Warrants; 

  

	 	(i)	 the Corporation shall use its commercially reasonable efforts to: (i) settle as expeditiously as possible all comments made by the Canadian
Securities Regulators on the Preliminary Prospectus, (ii) as soon as practicable thereafter prepare, file and have a receipt issued for the Final Prospectus under the Applicable Securities Laws of the Qualifying Jurisdictions and
(iii) take all other steps and proceedings that may be reasonably necessary to be taken by the Corporation in order to qualify the subject securities for distribution in each of the Qualifying Jurisdictions under Applicable Securities Laws as
soon as practicable following the Closing Date; 

  

	 	(j)	 the Corporation shall allow the Agent to: (A) review drafts of the Preliminary Prospectus, the Final Prospectus and any Supplementary Material
that the Corporation is required to file under Applicable Securities Laws in connection therewith and provide comments thereon, which comments shall be considered in good faith by the Corporation (B) conduct all due diligence and provide all
such information which the Agent may reasonably require in order to fulfill its obligations as Agent and in order to enable the Agent to execute the relevant certificate required to be executed by the Agent; 

 

	 	(k)	 the Corporation will promptly inform the Agent after receiving notice or obtaining knowledge thereof, of: 

 

	 	(i)	 the issuance by any Canadian Securities Regulator of any order suspending or preventing the use of the Preliminary Prospectus, the Final Prospectus
or any Supplementary Material or the institution, threatening or contemplation of any proceeding for any such purposes; 

  
 - 19 - 

	 	(ii)	 any order, ruling or determination having the effect of suspending the sale or ceasing the trading in any securities of the Corporation having been
issued by any Canadian Securities Regulator or the institution, threatening or contemplation of any proceeding for any such purposes; or 

  

	 	(iii)	 any requests made by any Canadian Securities Regulator for amending or supplementing the Preliminary Prospectus or the Final Prospectus or for
additional information, and will use its commercially reasonable efforts to prevent the issuance of any order referred to in (i) above, and if any such order is issued, to obtain the withdrawal thereof as quickly as possible;

  

	 	(l)	 the Corporation will deliver to the Agent, without charge, contemporaneously with, or prior to the filing of, the Final Prospectus, unless
otherwise indicated: 

  

	 	(i)	 a copy of any document filed with, or delivered to, the Canadian Securities Regulators by the Corporation under Applicable Securities Laws with the
Final Prospectus; 

  

	 	(ii)	 a certificate dated the date of the Final Prospectus, addressed to the Agent and signed by the Chief Executive Officer or Chief Financial Officer
of the Corporation, certifying for and on behalf of the Corporation, and not in their personal capacity, after having made due inquiries, with respect to the following matters: 

 

	 	(A)	 the Corporation having complied with all of the covenants and satisfied all of the terms and conditions of this Agreement on its part to be
complied with and satisfied at or prior to the date of the Final Prospectus; 

  

	 	(B)	 no order, ruling or determination having the effect of ceasing or suspending trading in any securities of the Corporation having been issued and no
proceeding for such purpose being pending or, to the knowledge of such officer, threatened; 

  

	 	(C)	 the representations and warranties of the Corporation contained in this Agreement and in any certificates of the Corporation delivered pursuant to
or in connection with this Agreement being true and correct as at the date of the Final Prospectus, with the same force and effect as if made on and as at the date of the Final Prospectus, after giving effect to the transactions contemplated by this
Agreement; and 

  

	 	(D)	 since the Closing Time, there having been no material adverse change, financial or otherwise, in the assets, liabilities (contingent or otherwise),
capital, business or results of operations of the Corporation; 

  

	 	(m)	 the Corporation shall cause to be delivered to the Agent concurrently with the filing of the Final Prospectus or any amendment thereto (i) a
comfort letter from the Corporation’s Auditors dated the date of the Final Prospectus addressed to the Agent, in form and substance satisfactory to the Agent and directors of the Corporation, acting reasonably,

  
 - 20 - 

	 	 
relating to the financial and accounting information relating to the Corporation contained in the Final Prospectus, which letter shall be based on a review by the Corporation’s
Auditor’s within a cut-off dated of not more than [two] Business Days prior to the date of the letter, which letter shall be in addition to the auditor’s consent and comfort letter addressed to the Canadian Securities Regulators;

  

	 	(n)	 the Corporation shall use its commercially reasonable best efforts to obtain the conditional approval of a Recognized Exchange for the listing of
its Common Shares by no later than the earlier of: (A) six months from the date the Corporation becomes a “reporting issuer” under Applicable Securities Laws and (B) June 5, 2015; and 

 

	 	(o)	 the Corporation will refuse to register any transfer of Securities not made in accordance with the provisions of Regulation S, pursuant to
registration under the 1933 Act, or pursuant to an available exemption from such registration. 

  

	6.	 Agent’s Compensation 

In return for the Agent’s services hereunder, the Corporation agrees to pay to the Agent a fee equal to 7.0% of the gross proceeds
of the Offering (excluding subscriptions from the directors and officers of the Corporation (or any of their associates)) payable in cash on any Closing Date (the “Agency Fee”). As additional consideration for the Agent’s
services performed under this Agreement, the Corporation shall issue to the Agent on such Closing Date special broker warrants (the “Special Broker Warrants”) exercisable to acquire for no additional consideration broker warrants
(the “Broker Warrants”) exercisable to purchase, on or before the date which is 12 months after the Closing Date, that number of Broker Shares of the Corporation equal to 7.0% of the aggregate of the number of Special Warrants sold
pursuant to the Offering (excluding Special Warrants purchased by the directors and officers of the Corporation (or any of their associates)) at the Offering Price. 

In addition to the above, in connection with the Agent’s review and execution of the Preliminary Prospectus and the Final
Prospectus, the Corporation will pay to the Agent a corporate finance advisory cash fee (the “Corporate Finance Fee”) equal to $30,000 and 5,000 Special Broker Warrants entitling the Agent to acquire for no additional consideration
an equivalent number of Broker Warrants entitling the Agent to purchase, on or before the date which is 12 months after the Closing Date, an equivalent number of Broker Shares at the Offering Price. 

The Agent acknowledges that the Special Warrants issued pursuant to the Non-Brokered Private Placement shall not form part of the Offering and
the Agent shall not be entitled to compensation therefor. 
  

	7.	 Closing 

 The
purchase and sale of the Special Warrants shall be completed at the Initial Closing Time by the electronic exchange of documents and funds or at such other place or places as the Agent and the Corporation may agree. At the Initial Closing Time, the
Corporation shall duly and validly deliver to Baker & McKenzie LLP definitive Special Warrant certificates registered in such names as shall be designated by the Agent not less than one Business Day prior to the Initial Closing Time against
payment by the Agent to the Corporation of the aggregate proceeds from the sale of the Special Warrants, by certified cheque or wire transfer, net of the Agency Fee, the Corporate Finance Fee and the Agent’s Expenses in accordance with
Section 12, against the delivery of cross-receipts therefor. In addition, the Corporation shall at the Initial Closing Time, issue to the Agent the Special Broker Warrants by execution and delivery to the Agent of a Special Broker Warrant
Certificate representing the Special Broker Warrants issuable to the Agent in connection with the Offering. 

  
 - 21 - 

 If the number of Special Warrants issued and sold at the Initial Closing is less than
3,814,600 the Agent may from time to time hold additional closings on or prior to December 31, 2014 for the issuance and sale of additional Special Warrants until such time as 3,814,600 Special Warrants in aggregate have been issued and sold
pursuant to this Agreement. Any such additional closing shall be referred to as a “Subsequent Closing” and shall be on the same terms and be conducted in the same manner as the Initial Closing. At any Subsequent Closing, the
Corporation shall, at its expense, deliver all of the certificates, opinions and other documents to be delivered by the Corporation on the Initial Closing Date, each updated to the date of any such Subsequent Closing. 

 

	8.	 Closing Conditions 

The Agent’s obligation to complete the Closing at the Closing Time, shall be subject to the accuracy of the representations and warranties
of the Corporation contained in this Agreement as of the date of this Agreement and as of the Closing Date and performance by the Corporation of its obligations under this Agreement in all material respects and the following conditions: 

 

	 	(a)	 The Agent shall have received at the Closing Time, a legal opinion dated such Closing Date, in form and substance satisfactory to counsel to the
Agent, addressed to the Agent and counsel to the Agent from counsel to the Corporation, Blake, Cassels & Graydon LLP with respect to certain customary matters related to the Corporation and the Offering, which counsel in turn may rely upon
the opinions of local counsel where they deem such reliance proper as to the laws other than those of Canada, British Columbia, Alberta and Ontario, and, as to matters of fact, on certificates of public officials and officers of the Corporation;

  

	 	(b)	 The Agent shall have received at the Closing Time, a legal opinion dated the Closing Date, in form and substance satisfactory to counsel to the
Agent, addressed to the Agent from counsel to the Corporation, Blake, Cassels & Graydon LLP providing that in the opinion of counsel to the Corporation, subject to the limitations and conditions contained therein, the investment in the
Special Warrants by registered retirement savings plans, registered retirement income funds and tax-free savings accounts will be a “qualified investment” (within the meaning of the Income Tax Act (Canada)) for such registered
plans; 

  

	 	(c)	 The Agent shall have received at the Closing Time certificates dated the Closing Date addressed to the Agent and counsel to the Agent and signed by
appropriate officers of the Corporation, with respect to the constating documents of the Corporation, all resolutions of the board of directors of the Corporation relating to this Agreement, the incumbency and specimen signatures of signing officers
of the Corporation and with respect to such other matters as the Agent may reasonably request; 

  

	 	(d)	 The Agent shall have received at the Closing Time, a certificate dated the Closing Date addressed to the Agent and counsel to the Agent and signed
on behalf of the Corporation by the Chief Executive Officer and the Chief Financial Officer of the Corporation or other officers of the Corporation acceptable to the Agent, certifying for and on behalf of the Corporation after having made due
enquiry, that: 

  

	 	(i)	 there are no contingent liabilities affecting the Corporation which are material to the Corporation; 

  
 - 22 - 

	 	(ii)	 the Corporation has complied with and satisfied in all material respects the covenants, terms and conditions of this Agreement on its part to be
complied with and satisfied up to the Closing Time; 

  

	 	(iii)	 the representations and warranties of the Corporation contained in this Agreement are true and correct in all material respects as of the Closing
Time with the same force and effect as if made at and as of the Closing Time after giving effect to the transactions contemplated by this Agreement; and 

  

	 	(iv)	 such other matters as the Agent may reasonably request; 

  

	 	(e)	 The Special Warrant Indenture shall have been entered into by the Corporation and the Special Warrant Agent in such form and containing such terms
as are acceptable to the Corporation and the Agent acting reasonably; and 

  

	 	(f)	 If any of the Special Warrants are purchased by U.S. Persons, the Agent shall have received at the Closing Time a legal opinion, in form and
substance satisfactory to the Agent, acting reasonably, addressed to the Agent from U.S. counsel, and based upon such assumptions as are reasonable to the effect that registration under the 1933 Act is not required in connection with the offer or
sale of the Special Warrants and the Securities comprising or underlying the Special Warrants in the United States. 

  

	9.	 Rights of Termination 

This Agreement may be terminated in the sole discretion of the Agent by written notice to the Corporation given prior to any Closing Time in
the event that: 
  

	 	(a)	 the Corporation is in material breach of any term, condition, covenant or agreement contained in this Agreement or any representation or warranty
given by the Corporation in this Agreement is determined to have been untrue, false or misleading in any material way as of the date upon which such was given; or 

 

	 	(b)	 prior to any Closing Time: 

  

	 	(i)	 there shall have occurred any adverse material change or there shall be discovered any previously undisclosed adverse material fact in relation to
the Corporation; or 

  

	 	(ii)	 there shall have occurred any change in Applicable Securities Laws or any inquiry, investigation or other proceeding is made or any order is issued
under or pursuant to any statute of Canada or any province thereof or any regulatory authority in relation to the Corporation or any of its securities (except for any inquiry, investigation or other proceeding based upon activities of the Agent and
not upon activities of the Corporation); 

 which, in the reasonable opinion of the Agent, prevents or
restricts trading in or the distribution of the Preferred Shares or the Broker Shares; or 
  

	 	(iii)	 there should develop, occur or come into effect or existence any event, action, state, condition or major financial occurrence or catastrophe of
national or international consequence or any law or regulation or a change thereof which, in 

  
 - 23 - 

	 	 
the reasonable opinion of an Agent, materially adversely affects or involves, or will materially adversely affect or involve, the financial markets or the business, operations or affairs of the
Corporation, taken as a whole; or 

  

	 	(iv)	 the due diligence investigations of the Agent identify a material adverse fact with respect to the Corporation or the Preferred Shares which
existed as of the date hereof but which had not been disclosed to the Agent. 

 The rights of termination contained in
this Section 9 are in addition to any other rights or remedies the Agent may have in respect of any default, act or failure to act or non-compliance by the Corporation in respect of any of the matters contemplated by this Agreement or
otherwise. In the event of any such termination, there shall be no further liability on the part of the Agent to the Corporation or on the part of the Corporation to the Agent except in respect of any liability which may have arisen prior to or
arise after such termination under any of Sections 10 and 12. 
  

	10.	 Indemnity 

  

	 	(a)	 The Corporation shall indemnify and save harmless the Agent, its affiliates, directors, partners, officers, employees, advisors, agents, each other
person, if any, controlling the Agent or any of its subsidiaries, and each shareholder of such Agent and any selling group member (collectively the “Indemnified Parties”) from and against any and all (including shareholder actions,
derivative or otherwise) claims, actions, suits, investigations and proceedings (collectively “Proceedings”) and all losses (other than loss of profits), expenses, fees, damages, obligations, payments and liabilities whatsoever
(collectively “Liabilities”) (including without limitation all amounts paid to settle any action or to satisfy any judgment or award and all legal fees and disbursements actually incurred) which now or any time hereafter are
suffered or incurred by reason of any event, act or omission in any way connected, directly or indirectly, with: 

  

	 	(i)	 any information or statement contained in: 

  

	 	(A)	 the Subscription Agreements or any information or statement relating solely to the Corporation and furnished to the Agent by the Corporation
expressly for inclusion in the Subscription Agreements, or 

  

	 	(B)	 either the Preliminary Prospectus or the Final Prospectus or any Supplementary Material (except for any information or statement relating solely to
the Agent and furnished by the Agent for use in such documents), 

 which is untrue or any omission to
provide any information or state any fact in the documents referred to above the omission of which makes any such information or statement untrue or misleading in light of the circumstances in which it was made; 

 

	 	(ii)	 any misrepresentation made by the Corporation in the Subscription Agreements, during the Due Diligence Session or otherwise (except a
misrepresentation which is based upon information relating to the Agent and furnished to the Corporation by the Agent in writing expressly for inclusion in the Subscription Agreements); 

 

	 	(iii)	 any prohibition or restriction affecting the offer and sale of the Special Warrants imposed by any competent authority if such prohibition or
restriction is based on any misrepresentation of a kind for which the Agent are entitled to indemnity under subsection 10(a)(ii); 

  
 - 24 - 

	 	(iv)	 any order made or any inquiry, investigation (whether formal or informal) or other proceeding commenced or threatened by any one or more competent
authorities (not based upon the activities or the alleged activities of the Agent or its banking or selling group members, if any) relating to or materially affecting the sale of the Special Warrants in the Selling Jurisdictions; or

  

	 	(v)	 any breach of, default under or non-compliance by the Corporation with any material representation, warranty, term or condition of this Agreement,
the Subscription Agreements or any requirement of Applicable Securities Laws; 

 provided that no such
indemnity shall apply in the event and to the extent that a court of competent jurisdiction in a final judgment from which no appeal can be made or a regulatory authority in a final ruling from which no appeal can be made shall determine that such
Proceedings or Liabilities resulted solely from the gross negligence, wilful misconduct or other fraudulent act of the Indemnified Party claiming indemnity or in the event of a material breach by the Agent of Section 3 of this Agreement. 

 

	 	(b)	 The Corporation hereby waives its right to recover contribution from the Agent with respect to any liability of the Corporation by reason of or
arising out of any misrepresentation provided by the Corporation to the Agent during the course of the Agent’s due diligence or otherwise provided, however, such waiver shall not apply in respect of liability caused or incurred by reason of or
arising out of (i) any misrepresentation which is based upon information relating solely to the Agent furnished to the Corporation by the Agent in writing for inclusion in any document or other use in connection with the transactions
contemplated by this Agreement; or (ii) any misrepresentation made by the Agent or a member of the selling group or by an Affiliate or Associate of either of them (A) relating to the Corporation or matters concerning the Corporation, its
management, business, financial condition, capital structure, performance, outlook or prospects, which is inconsistent with information on the same subject or subjects that (a) was furnished by the Corporation to the Agent for use in connection
with the transactions contemplated by this Agreement, and (b) did not constitute or contain any material misrepresentation or omission; or (B) relating to the Offering, the Securities or other matters contained in the Transaction
Documents, which is inconsistent with the Transaction Documents; or (iv) any material breach by the Agent of Section 3 of this Agreement. 

  

	 	(c)	 If any Proceeding is brought or instituted in respect of any Indemnified Party which may result in a claim for indemnification under this
Agreement, such Indemnified Party shall promptly after receiving notice thereof notify the Corporation of the notice of claim, in writing, and the Corporation shall be entitled (but not required) to assume conduct of the defence thereof and retain
counsel on behalf of the Indemnified Party who is reasonably satisfactory to the Indemnified Party, to represent the Indemnified Party in such Proceeding and the Corporation shall pay the reasonable fees and disbursements of such counsel and all
other expenses of the Indemnified Party relating to such Proceeding as incurred. Failure to so notify the Corporation shall not relieve the Corporation from liability except and only to the extent that the failure materially prejudices the
Corporation. If the Corporation assumes conduct of the defence for an Indemnified Party, the Indemnified Party shall, except when a conflict of interest as described in 

  
 - 25 - 

	 	 
subsection 10(d)(i) exists and counsel to the Indemnified Party advises the Indemnified Party that such action would be prejudicial to the interests of the Indemnified Party, fully cooperate in
the defence including without limitation the provision of documents, appropriate officers and employees to give witness statements, attend examinations for discovery, make affidavits, meet with counsel, testify and divulge all information reasonably
required to defend or prosecute the Proceedings. 

  

	 	(d)	 In any such Proceeding the Indemnified Party shall have the right to employ separate counsel and to participate in the defence thereof if:

  

	 	(i)	 employment of such counsel has been authorized in writing by the Corporation; 

 

	 	(ii)	 the Indemnified Party has been advised in writing by counsel that there may be a reasonable legal defence available to the Indemnified Party that
is different from or in addition to those available to the Corporation or that a conflict of interest exists which makes representation by counsel chosen by the Corporation not advisable; or 

 

	 	(iii)	 the Corporation has not assumed the defence of the Proceeding and employed counsel therefor reasonably satisfactory to the Indemnified Party within
a reasonable period of time after receiving notice thereof; 

 in which event the reasonable fees and
disbursements of such counsel (on a solicitor and his client basis) shall be paid by the Corporation. It being understood, however, that the Corporation shall not, in connection with any one such action or separate but substantially similar or
related actions in the same jurisdiction arising out of the same general allegations or circumstances, be liable for the reasonable fees and expenses of more than one separate counsel (in addition to any local counsel) for all such Indemnified
Parties. 
  

	 	(e)	 No admission of liability and no settlement of any Proceeding shall be made without the consent of the Indemnified Parties affected, such consent
not to be unreasonably withheld. No admission of liability shall be made by an Indemnified Party without the consent of the Corporation, such consent not to be unreasonably withheld, and the Corporation shall not be liable for any settlement of any
Proceeding made without its consent, such consent not to be unreasonably withheld. 

  

	 	(f)	 In order to provide for just and equitable contribution in circumstances in which the indemnification provided for in this agreement is due in
accordance with its terms but is (in whole or in part), for any reason, held by a court to be unavailable from the Corporation on ground of policy or otherwise, each of the Corporation and the party or parties seeking indemnification shall
contribute to the aggregate Liabilities (or Proceedings in respect thereof) to which they may be subject or which they may suffer or incur: 

  

	 	(i)	 in such proportion as is appropriate to reflect the relative benefit received by the Corporation on the one hand and by the Agent on the other hand
from the offering of the Special Warrants; or 

  

	 	(ii)	 if the allocation provided by clause (i) above is not permitted by applicable law, in such proportion as is appropriate to reflect not only
the relative benefits referred to in clause (i) above but also to reflect the relative fault of the party or 

  
 - 26 - 

	 	 
parties seeking indemnity, on the one hand, and the parties from whom indemnity is sought, on the other hand, in connection with the statement, omission, misrepresentation or alleged
misrepresentation, order, inquiry, investigation or other matter or thing which resulted in such liabilities, claims, demands, losses, costs, damages or expenses, as well as any other relevant equitable considerations. 

The relative benefits received by the Corporation, on the one hand, and the Agent, on the other hand, shall be deemed to be in
the same proportion that the total proceeds of the Offering received by the Corporation (net of fees but before deducting expenses) bear to the fees received by the Agent. The relative fault of the Corporation, on the one hand, and of the Agent, on
the other hand, shall be determined by reference, among other things, to whether the misrepresentation or alleged misrepresentation, order, inquiry, investigation or other matter giving rise to liability relates to information supplied or which
ought to have been supplied by, or steps or actions taken or done on behalf of or which ought to have been taken or done on behalf of the Corporation or the Agent and the parties’ relevant intent, knowledge, access to information and
opportunity to correct or prevent such misrepresentation or alleged misrepresentation, order, inquiry, investigation or other matter giving rise to liability. 

The amount paid or payable by the Corporation as a result of any Proceedings or Liabilities shall, without limitation, include
any legal or other expenses reasonably incurred by the Indemnified Person in connection with investigating or defending such liabilities, claims, demands, losses, costs, damages and expenses (or claims, actions, suits or proceedings in respect
thereof), whether or not resulting in any action, suit, proceeding or claim. 
 The Corporation agrees that it would not be
just and equitable if contributions pursuant to this Agreement were determined by pro rata allocation or by any other method of allocation which does not take into account the equitable considerations referred to in the immediately preceding
paragraphs. 
  

	 	(g)	 The rights to indemnity and right of contribution provided in the foregoing sections shall be in addition to and not in derogation of any other
right to contribution which the Indemnified Parties may have by statute or otherwise at law or in equity. 

  

	 	(h)	 It is the intention of the Corporation to constitute the Agent as trustee for the Indemnified Parties for the purposes of sections 10(a) to 10(g)
inclusive and the Agent shall be entitled, as trustee, to enforce such covenants on behalf of any other Indemnified Parties. 

  

	 	(i)	 If any Proceeding is brought in connection with the transactions contemplated by this Agreement and an Indemnified Party is required to testify in
connection therewith or is required to respond to procedures designed to discover information relating thereto, the Corporation shall pay to the relevant Agent reasonable fees at the normal per diem rate for its directors, officers, partners,
employees, agents and advisors involved in preparation for and attendance at such Proceeding or in so responding and any other reasonable costs and out-of-pocket expenses incurred by such Agent in connection therewith will be paid by the Corporation
as they are incurred; provided and to the extent that such Proceeding is not caused solely by or the result of the gross negligence or wilful misconduct of an Indemnified Party or a material breach by the Agent of Section 3 of this Agreement.

  

	 	(j)	 The obligations under the indemnity and right of contribution provided herein shall apply whether or not the transactions contemplated by this
Agreement are completed and shall survive the completion of the transactions contemplated under this Agreement and the termination of this Agreement. 

  
 - 27 - 

	11.	 Severability 

If any provision of this Agreement is determined to be void or unenforceable in whole or in part, it shall be deemed not to affect or impair
the validity of any other provision of this Agreement and such void or unenforceable provision shall be severable from this Agreement. 
  

	12.	 Expenses 

Whether or not the transactions contemplated by this Agreement are completed, the Corporation shall pay all expenses and fees in connection
with the Offering, including, without limitation, all expenses of or incidental to the issue, sale or distribution of the Special Warrants; the fees and expenses of the Corporation’s counsel; and all costs incurred in connection with the
preparation of documents relating to the Offering. The Corporation shall also pay, whether or not the transactions contemplated by this Agreement are completed, all expenses and fees incurred by the Agent, which shall include the reasonable fees of
the Agent’s counsel Baker & McKenzie LLP, up to a maximum of Cdn$65,000 plus disbursements and taxes, and all reasonable out-of-pocket expenses of the Agent (collectively, the “Agent’s Expenses”). All fees and
expenses incurred by the Agent or on its behalf shall be deducted from the aggregate gross proceeds of the Offering in accordance with Section 7. In the event the closing of the Offering contemplated by this Agreement does not occur, all fees
and expenses incurred by the Agent shall be payable by the Corporation immediately upon receiving an invoice therefor from the Agent. 
  

	13.	 Survival of Representations and Warranties 

The representations, warranties, covenants, obligations and agreements of the Corporation contained in this Agreement and in any certificate
delivered pursuant to this Agreement or in connection with the purchase and sale of the Special Warrants shall survive the purchase of the Special Warrants and shall continue in full force and effect for a period of three years following the Closing
Date regardless of any subsequent disposition of the Special Warrants by the Subscribers or the termination of the Agent’s obligations and shall not be limited or prejudiced by any investigation made by or on behalf of the Agent in connection
with the sale of the Special Warrants. 
  

	14.	 Time of the Essence 

Time shall be of the essence of this Agreement. 
  

	15.	 Governing Law 

This Agreement shall be governed by and construed in accordance with the laws of British Columbia and the laws of Canada applicable in British
Columbia and the parties hereto irrevocably attorn to the jurisdiction of the courts of such province. 
  

	16.	 Funds 

Unless otherwise specified, all funds referred to in this Agreement shall be in Canadian dollars. 

  
 - 28 - 

	17.	 Notice 

Unless otherwise expressly provided in this Agreement, any notice or other communication to be given under this Agreement (a
“Notice”) shall be in writing addressed as follows: 
  

			
	 If to the Corporation, addressed and sent to:

	
	 ESSA Pharma Inc.

	 999 West Broadway, Suite 720

	 Vancouver, BC V5Z 1K5

		
	 Attention:
		 Bob Rieder, Chief Executive Officer

	 Fax:
		 888-308-8974

	
	 with a copy (which shall not constitute notice) to:

	
	 Blake, Cassels & Graydon LLP

	 599 Burrard Street, Suite 2600

	 Vancouver, BC V7X 1L3

		
	 Attention:
		 Joseph Garcia

	 Fax:
		 604-631-3307

	
	 If to the Agent, addressed and sent to:

	
	 Haywood Securities Inc.

	 200 Burrard Street, Suite 700

	 Vancouver, BC V6C 3L6

		
	 Attention:
		 Kevin Campbell

	 Fax:
		 (604) 697-7495

	 Email:
		 kcampbell@haywood.com

	
	 with a copy (which shall not constitute notice) to:

	
	 Baker & McKenzie LLP

	 Brookfield Place

	 181 Bay Street, Suite 2100

	 Toronto, Ontario

	 M5J 2T3

		
	 Attention:
		 Sonia Yung

	 Fax:
		 416-863-6275

 or to such other address as any of the persons may designate by Notice given to the others. 

Each Notice shall be personally delivered to the addressee or sent by fax to the addressee and (i) a Notice which is personally delivered
shall, if delivered on a Business Day, be deemed to be given and received on that day and, in any other case, be deemed to be given and received on the first Business Day following the day on which it is delivered; and (ii) a Notice which is
sent by fax shall be deemed to be given and received on the first Business Day following the day on which it is sent. 

  
 - 29 - 

	18.	 Entire Agreement 

The provisions herein contained constitute the entire agreement between the parties relating to the Offering and supersede all previous
communications, representations, understandings and agreements between the parties with respect to the subject matter hereof whether verbal or written. 
  

	19.	 Press Releases 

Any press release connected with the offering issued by the Corporation shall be issued only after consultation with the Agent. If the Offering
is successfully completed, the Agent shall be permitted only after consultation with the Corporation, to publish, at the Agent’s expense, and in compliance with Applicable Securities Laws such advertisements or announcements relating to the
services provided hereunder in such newspaper or other publications as they may consider appropriate. 
  

	20.	 Counterparts 

This Agreement may be executed by any one or more of the parties to this Agreement in any number of counterparts, each of which shall be deemed
to be an original, but all such counterparts shall together constitute one and the same instrument. 
  

	21.	 Language 

The parties hereto confirm their express wish that this agreement and all documents and agreements directly or indirectly relating thereto be
drawn up in the English language. 
 Les parties reconnaissent leur volonté express que la présente convention ainsi que tous
les documents et contrats s’y rattachant directement ou indirectement soient rédigés en anglais. 
  

	22.	 Facsimile 

The Corporation and the Agent shall be entitled to rely on delivery by facsimile or other electronic means of an executed copy of this
Agreement and acceptance by the Corporation and the Agent of that delivery shall be legally effective to create a valid and binding agreement between the Corporation and the Agent in accordance with the terms of this Agreement. 

  
 - 30 - 

 If the foregoing is in accordance with your understanding and is agreed to by you, please signify
your acceptance by executing this letter where indicated below and returning the same to the Agent upon which this letter as so accepted shall constitute an agreement among us. 

 

			
	 Yours very truly,

	
	 HAYWOOD SECURITIES INC.

		
	 Per:
		 [Redacted]

	 Name:
		 Kevin Campbell

	 Title:
		 Managing Director, Investment Banking

	
	 Authorized Signing Officer

 The foregoing offer is accepted and agreed to as of the date first above written. 

 

			
	 ESSA PHARMA INC.

		
	 By:
		 /s/ Bob Rieder

			 Bob Rieder

			 Chief Executive Officer

  
 - 31 - 

 SCHEDULE “A” 

TERMS AND CONDITIONS FOR UNITED STATES OFFERS AND SALES 

As used in this Schedule “A” and related appendices, capitalized terms used herein and not defined herein
shall have the meanings ascribed thereto in the Agency Agreement to which this Schedule “A” is annexed and the following terms shall have the meanings indicated: 

 

	 	(a)	 “Accredited Investor” means a person or entity that is an “accredited investor” as defined in Rule 501(a) of Regulation
D under the U.S. Securities Act of 1933; 

  

	 	(b)	 “Directed Selling Efforts” means directed selling efforts as that term is defined in Regulation S. Without limiting the foregoing,
but for greater clarity in this Schedule, it means, subject to the exclusions from the definition of directed selling efforts contained in Regulation S, any activity undertaken for the purpose of, or that could reasonably be expected to have the
effect of, conditioning the market in the United States for the Special Warrants and includes the placement of any advertisement in a publication with a general circulation in the United States that refers to the offering of the Special Warrants;

  

	 	(c)	 “Foreign Issuer” means “foreign issuer” as that terms is defined in Rule 902(e) of Regulation S; 

 

	 	(d)	 “General Solicitation” and “General Advertising” means “general solicitation” and “general
advertising”, respectively, as used under Rule 502(c) under the U.S. Securities Act, including advertisements, articles, notices or other communications published in any newspaper, magazine or similar media or broadcast over radio or
television, or any seminar or meeting whose attendees had been invited by general solicitation or general advertising; 

  

	 	(e)	 “Regulation D” means Regulation D adopted by the SEC under the U.S. Securities Act; 

 

	 	(f)	 “Regulation S” means Regulation S adopted by the SEC under the U.S. Securities Act; 

 

	 	(g)	 “SEC” means the United States Securities and Exchange Commission; 

 

	 	(h)	 “Substantial U.S. Market Interest” means “substantial U.S. market interest” as that term is defined in
Regulation S; 

  

	 	(i)	 “United States” means the United States of America, its territories and possessions, any state of the United States, and the
District of Columbia; 

  

	 	(j)	 “U.S. Affiliate” of the Agent means the U.S. registered broker-dealer affiliate of the Agent; 

 

	 	(k)	 “U.S. Exchange Act” means the United States Securities Exchange Act of 1934, as amended; 

 

	 	(l)	 “U.S. Person” means a U.S. person as that term is defined in Regulation S; and 

 

	 	(m)	 “U.S. Securities Act” means the United States Securities Act of 1933, as amended. 

 Representations, Warranties and Covenants of the Agent 

Each of the Agent and the U.S. Affiliate acknowledges that the Special Warrants have not been and will not be registered under
the U.S. Securities Act and may be offered and sold only in transactions exempt from or not subject to the registration requirements of the U.S. Securities Act and applicable state securities laws. Accordingly, each of the Agent and the U.S.
Affiliate represents, warrants and covenants to the Corporation that: 
  

	1.	 It has not offered and sold, and will not offer and sell, any Special Warrants except (a) in an offshore transaction in accordance with Rule
903 of Regulation S or (b) in the United States as provided in Sections 2 through 10 below. Accordingly, neither the Agent nor any of its affiliates nor any persons acting on its behalf, has made or will make (except as permitted in Sections 2
through 10 below), (i) any offer to sell or any solicitation of an offer to buy, any Special Warrants to any person in the United States or a U.S. Person, (ii) any sale to any purchaser unless, at the time the buy order was or will have
been originated, the purchaser was outside the United States, or the Agent, affiliate or person acting on its behalf reasonably believed that such purchaser was outside the United States, or (iii) any Directed Selling Efforts in the United
States with respect to the Special Warrants. 

  

	2.	 It has not entered and will not enter into any contractual arrangement with respect to the distribution of the Special Warrants, except with its
U.S. Affiliate, any selling group members or with the prior written consent of the Corporation. It shall require each selling group member to agree, for the benefit of the Corporation, to comply with, and shall use its best efforts to ensure that
each selling group member complies with, the provisions of this Schedule “A” applicable to the Agent as if such provisions applied to such selling group member. 

 

	3.	 All offers and sales of Special Warrants in the United States shall be made by an Agent through a U.S. Affiliate, which on the dates of such offers
and sales was and will be duly registered as a broker-dealer under the U.S. Exchange Act and under all applicable state securities laws (except where exempted from the respective state’s broker-dealer registration requirements) and a member of,
and in good standing with, the Financial Industry Regulatory Authority, Inc. (“FINRA”), in accordance with all applicable United States state and federal securities (including broker-dealer) laws. The U.S. Affiliate will make all
offers and sales of Special Warrants in compliance with all applicable United States federal and state broker-dealer requirements. 

  

	4.	 It and its affiliates have not, either directly or through a person acting on its or their behalf, solicited and will not solicit offers for, and
have not offered to sell and will not offer to sell, any of the Special Warrants in the United States by any form of General Solicitation or General Advertising or in any manner involving a public offering within the meaning of Section 4(2) of
the U.S. Securities Act or Regulation D. 

  

	5.	 Any offer, sale or solicitation of an offer to buy Special Warrants that has been made or will be made in the United States was or will be made
only to Accredited Investors in transactions that are exempt from registration under the U.S. Securities Act and applicable state securities laws. 

  

	6.	 It had reasonable grounds to believe and did believe that each such purchaser was an Accredited Investor, and at the time of completion of each
sale to or for the benefit or account of a U.S. Person or a person in the United States, the Agent, the U.S. Affiliate, their respective affiliates, and any person acting on their behalf will have reasonable grounds to believe and will believe, that
each purchaser designated by the Agent or the U.S. Affiliate to purchase Special Warrants from the Corporation is an Accredited Investor. 

  
 A-2 

	7.	 Prior to any sale of Special Warrants in the United States, it shall cause each purchaser that is a U.S. Person thereof to execute a Subscription
Agreement for Special Warrants, United States Resident Subscribers, and attached documents, including an Accredited Investor Certificate and an Accredited Investor Questionnaire (“U.S. Subscription Agreement”) in the form attached
hereto as Appendix I. 

  

	8.	 At least one Business Day prior to the Closing Date, the Corporation will be provided with a list of all purchasers of the Special Warrants in the
United States. 

  

	9.	 At Closing, the U.S. Affiliate and the Agent, will provide a certificate, substantially in the form of Appendix II, relating to the manner of the
offer and sale of the Special Warrants in the United States. 

  

	10.	 Prior to soliciting any offerees and prior to the completion of any sale of Special Warrants to U.S. Persons or persons in the United States, each
purchaser will be informed that the Special Warrants and the Securities underlying the Special Warrants have not been and will not be registered under the U.S. Securities Act and are being offered to such purchaser for investment and in reliance on
an exemption from the registration requirements of the U.S. Securities Act provided by Rule 506 of Regulation D. 

  

	11.	 None of the Agent, the U.S. Affiliate nor any person acting on its or their behalf has engaged or will engage in any violation of Regulation M
under the U.S. Exchange Act in connection with its offers or sales of the Special Warrants in the United States. 

 Representations,
Warranties and Covenants of the Corporation 
 The Corporation represents, warrants, covenants and agrees that: 

 

	1.	 The Corporation is not, and as a result of the sale of the Special Warrants contemplated hereby will not be, an “investment company” as
defined in the United States Investment Company Act of 1940, as amended. 

  

	2.	 Except with respect to offers and sales to Accredited Investors in reliance upon an exemption from registration under the U.S. Securities Act,
neither the Corporation nor any of its affiliates, nor any person acting on its or their behalf (other than the Agent, the U.S. Affiliate, or any members of the banking and selling group formed by them, as to whom the Corporation makes no
representation), has made or will make: (A) any offer to sell, or any solicitation of an offer to buy, any Special Warrants to a person in the United States; or (B) any sale of Special Warrants unless, at the time the buy order was or will
have been originated, the purchaser is (i) outside the United States, or (ii) the Corporation, its affiliates, and any person acting on their behalf reasonably believe that the purchaser is outside the United States. 

 

	3.	 Neither it nor any of its affiliates, nor any person acting on its or their behalf (other than the Agent, the U.S. Affiliate, or any members of the
banking and selling group formed by them, as to whom the Corporation makes no representation), has made or will make any Directed Selling Efforts in the United States with respect to the Special Warrants, or has taken or will take any action that
would cause the applicable exemption afforded by the U.S. Securities Act or Regulation S to be unavailable for offers and sales of the Special Warrants pursuant to this Agreement. 

  
 A-3 

	4.	 None of the Corporation, any of its affiliates or any person acting on its or their behalf, (including the Agent, its Affiliate, or any members of
the banking and selling group formed by them, as to all of whom the Corporation makes no representation) has offered or will offer to sell, or has solicited or will solicit offers to buy, any of the Special Warrants in the United States by means of
any form of General Solicitation or General Advertising or in any manner involving a public offering within the meaning of Section 4(2) of the U.S. Securities Act. 

 

	5.	 Neither the Corporation nor any of its predecessors or affiliates has been subject to any order, judgment, or decree of any court of competent
jurisdiction temporarily, preliminarily or permanently enjoining such person for failure to comply with Rule 503 of Regulation D. 

  

	6.	 None of the Corporation, its affiliates or any person acting on its behalf, (including the Agent, the U.S. Affiliate, or any members of the banking
and selling group formed by them, as to all of whom the Corporation makes no representation) has engaged or will engage in any violation of Regulation M under the U.S. Exchange Act in connection with any offer or sale of the Special Warrants.

  
 A-4 

 APPENDIX II 

TO SCHEDULE “A” 

AGENT’S CERTIFICATE 

In connection with the private placement in the United States of Special Warrants (the “Special Warrants”) of ESSA Pharma
Inc. (the “Company”), with a U.S. Accredited Investor (the “U.S. Private Placee”) pursuant to a Subscription Agreement, and pursuant to an agency agreement (the “Agency Agreement”) dated
October 22, 2014, between the Corporation and the agent named therein, the undersigned hereby certify as follows: 
  

	(i)	 On the date hereof and on the date each offer or sale of Special Warrants, [NAME OF AGENT] (the “U.S. Agent”) is and was a duly
registered broker-dealer with the United States Securities and Exchange Commission, duly registered as a broker-dealer under the laws of each state where it made offers of Special Warrants (unless exempted from the respective state’s
broker-dealer registration requirements, and a member of and is in good standing with the Financial Industry Regulatory Authority, Inc. (“FINRA”) on the date hereof; 

 

	(ii)	 All offers and sales of Special Warrants in the United States have been and will be effected by the U.S. Agent in accordance with U.S.
broker-dealer requirements. 

  

	(iii)	 Other than written materials provided by or expressly approved by the Company, no written material was used in connection with the offer and sale
of the Special Warrants in the United States; 

  

	(iv)	 We had reasonable grounds to believe and did believe that each offeree was an “accredited investor” as defined in Rule 501(a) of
Regulation D (an “Accredited Investor”) under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), and, on the date hereof, we continue to believe that each U.S. person purchasing
Special Warrants from us is an Accredited Investor; 

  

	(v)	 no form of general solicitation or general advertising (as those terms are used in Regulation D under the U.S. Securities Act) was used by us,
including advertisements, articles, notices or other communications published in any newspaper, magazine or similar media or broadcast over radio or television, or any seminar or meeting whose attendees had been invited by general solicitation or
general advertising, in connection with the offer or sale of the Special Warrants in the United States or to U.S. persons; 

  

	(vi)	 the offering of the Special Warrants in the United States has been conducted by us in accordance with the terms of the Agency Agreement; and

  

	(vii)	 prior to any sale of Special Warrants in the United States, we caused each U.S. purchaser to execute a Subscription Agreement for United States
Resident Subscribers in the form agreed to by the Company. 

 Terms used in this certificate have the meanings given to them in the Agency
Agreement unless otherwise defined herein. 
 Dated this      day of
            , 2014. 

  
 A-5 

									
	 [NAME OF AGENT]
				 [NAME OF US AFFILIATE]

					
	 By:
		  
				 By:
		  

					
	 Name:
		  
				 Name:
		  

					
	 Title:
		  
				 Title:
		  

  
 A-6 

 SCHEDULE “B” 

SECURITIES CONVERTIBLE INTO OR EXCHANGEABLE FOR SHARES IN THE CAPITAL OF THE CORPORATION 

Preferred Shares and Broker Warrants: 
 On
July 29, 2014, the Corporation issued 1,702,900 Preferred Shares and 79,479 Broker Warrants pursuant to a private placement. Each Broker Warrant entitles the holder thereof to purchase one Preferred Share at $2.00 per Preferred Share. 

Warrants: 
 As of the date of this
Agreement, there are warrants outstanding to purchase 25,000 Common Shares at an exercise price of $2.00 per Common Share and expiring on April 15, 2019. 

Options: 
  

											
	Optionee	  	Amount	 	  	Exercise Price	 	  	Expiry
	 Dr. Marianne Sadar (CSO, founder)
	  	 	120,000	  	  	$	0.50/share	  	  	April 30, 2016
		  	 	300,000	  	  	$	0.80/share	  	  	January 31, 2018
	 Dr. Raymond Andersen (CTO, founder)
	  	 	120,000	  	  	$	0.50/share	  	  	April 30, 2016
		  	 	300,000	  	  	$	0.80/share	  	  	January 31, 2018
	 Dr. Jennifer Hamilton (consultant)
	  	 	35,000	  	  	$	0.50/share	  	  	July 27, 2016
		  	 	25,500	  	  	$	0.50/share	  	  	October 21, 2017
	 Dr. Roger Ulrich (consultant)
	  	 	50,000	  	  	$	0.80/share	  	  	November 20, 2017
	 Dr. James Bristol (consultant)
	  	 	50,000	  	  	$	0.80/share	  	  	November 20, 2017
	 Kim Hewitt (consultant)
	  	 	8,750	  	  	$	0.50/share	  	  	June 1, 2017
		  	 	11,250	  	  	$	0.80/share	  	  	May 20, 2019
	 Dr. Oreola Donini (former VP, R&D)
	  	 	60,000	  	  	$	0.80/share	  	  	June 1, 2017
	 Dr. Stephen Plymate
	  	 	50,000	  	  	$	0.80/share	  	  	July 1, 2018
	 Bloom Burton & Co Inc.
	  	 	529,219	  	  	$	2.00/share	  	  	February 27, 2019
	 Gary Sollis (director)
	  	 	120,000	  	  	$	0.80/share	  	  	May 20, 2019
	 Kally Singh (consultant)
	  	 	25,000	  	  	$	0.80/share	  	  	May 20, 2019
	 David Wood - Chief Financial Officer
	  	 	75,000	  	  	$	0.80/share	  	  	May 20, 2019
		  	 	200,000	  	  	$	2.00/share	  	  	July 30, 2019
	 Richard Glickman - Director and Chair
	  	 	75,000	  	  	$	0.80/share	  	  	May 20, 2019
	 Daisy Wong
	  	 	15,000	  	  	$	0.80/share	  	  	May 20, 2019
	 Frank Perabo – Chief Medical Officer
	  	 	500,000	  	  	$	2.00/share	  	  	September 8, 2019
	 Paul Cossum – (Exec VP, Research)
	  	 	400,000	  	  	$	2.00/share	  	  	April 14, 2019
	 TOTAL
	  	 	3,069,719

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00246-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00246-of-00352.parquet"}]]